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Type 1 diabetes is a chronic disease, which commonly presents itself in childhood or in 
adolescence. Type 1 diabetes is characterised by hyperglycaemia and results from 
(auto-immune) destruction of insulin-producing beta cells clustered in the islets of 
Langerhans of the pancreas, resulting in mostly absolute insulin deficiency requiring 
daily insulin treatment. Symptoms caused by hyperglycaemia include polyuria, 
polydipsia, weight loss, vision changes, and fatigue (1). The incidence of childhood 
type 1 diabetes varies worldwide from 0.1/100,000 per year in Zunyi, China to 
36.8/100,000 per year in Sardinia, Italy (2). In The Netherlands the incidence of type 
diabetes is estimated to be 13/100,000 per year in children ≤14 years of age (2). The 
incidence of type 1 diabetes seems to be increasing in all age groups, especially in 
younger children (3-6), with an overall annual increase of ~3.9% estimated from 20 
population-based registers in 17 European countries in the period 1989-2003 (5). The 
reasons for this increasing incidence are unknown, but probably involve 
environmental factors (7). Despite extensive research (8-11), type 1 diabetes cannot 
be prevented or cured with current available treatments, such as immunotherapy 
(12), stem cell therapy (10) or transplantation of islets of Langerhans (8). 
Worldwide there are ~22 million patients with type 1 diabetes and this is predicted 
to double in the next 20-30 years (1,13). In The Netherlands the current prevalence of 
type 1 diabetes is estimated to be 100,000 (14,15). The burden of diabetes for 
patients as well as for the society is mainly caused by diabetes-related short- and 
long-term complications, illustrated by a ~4-fold increase in the risk of cardiovascular 
disease in type 1 diabetes (16), and a ~7-fold and ~17-fold increase in risk for mortality 
from heart disease in men and women, respectively, who had type 1 diabetes and 
were younger than 40 years of age (17). In addition, diabetes-related microvascular 
complications (i.e. diabetic retinopathy and nephropathy) result in impaired vision 
and kidney function, which lead to higher morbidity in patients with type 1 diabetes. 
Diabetic retinopathy and diabetic nephropathy are present in ~45% and ~30%, 
respectively, of the patients with type 1 diabetes after a duration of diabetes of ~13 
years (18). Another late complication of diabetes is diabetic neuropathy, which is 
present in ~42% of the patients with type 1 diabetes after a duration of ≥15 years 
(19). Diabetic neuropathy can be divided into distal symmetric sensorimotor 
polyneuropathy, autonomic neuropathy, and focal mononeuropathy, of which distal 
symmetric sensorimotor polyneuropathy is the most common form. Furthermore, the 
need for insulin treatment also imposes on patients the risk of hypoglycaemia, which 
is an unpredictable and potentially dangerous side effect of insulin therapy. An 
observational study in six UK secondary care diabetes centres reported that the 
incidences of self-reported mild hypoglycaemic events that could be self-treated and 
severe hypoglycaemic events that needed help for recovery were 36 and 1.1 episodes 
per patient-year, respectively, in patients with type 1 diabetes and <5 years disease 
duration (20). The incidences of self-reported mild and severe hypoglycaemic events 
in patients with type 1 diabetes and >15 years disease duration were 29 and 3.2 
episodes per patient-year, respectively (20). Besides these complications and the daily 
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insulin injections, the burden of diabetes for patients is further increased by the need 
for continuous self-management to achieve self-directed behavioural changes to 
reduce their risk of short- and long-term complications. Because the prevalence of 
type 1 diabetes and the incidence op childhood type 1 diabetes are increasing, the 
health care costs related to anti-diabetic medication as well as treatment of the 
diabetes-associated complications are also increasing (21). 
Cardiovascular diseases include four main clinical categories: coronary heart 
diseases, cerebrovascular disease, peripheral artery disease, and aortic 
atherosclerosis or aneurysm. Cardiovascular diseases result from arterial stiffening 
(i.e. arteriosclerosis) and atherothrombosis. Ageing is the dominant process altering 
arterial stiffness (22). Ageing-associated loss of elasticity in the arteries results from 
intrinsic structural alterations of the arterial wall (e.g. alteration of medial elastin) 
(22,23). Arterial stiffening leads to an impaired cushioning function of the major 
arteries, which will increase pulse wave velocity and cause an early return of the 
pressure waves in late systole instead of early diastole (22,24,25). Therefore, systolic 
blood pressure will increase, which will increase the cardiac afterload and oxygen 
demand. In addition, the decrease in diastolic blood pressure will impair coronary 
filling. Atherothrombosis is a focal arterial progressive disease starting with the 
formation of fatty streaks that may develop into atherosclerotic plaques (26,27). 
Symptomatic complications occur when the lumen of the artery is occluded by the 
atherosclerotic plaque itself or by the thrombus formed when a plaque ruptures 
(27,28). 
Diabetic retinopathy can be classified into two groups: background/non-
proliferative and proliferative retinopathy (29). Non-proliferative retinopathy is 
characterised by retinal vascular microaneurysms, blot haemorrhages, and cotton 
wool spots (29). This form of retinopathy can progress into more extensive disease 
with further pericyte loss, increase in retinal vascular permeability, and abnormal 
changes in retinal blood flow and vasculature, all of which contribute to retinal 
ischaemia (30). Neovascularisation in response to severe retinal ischaemia 
characterises proliferative retinopathy (30).  
The development of diabetic nephropathy starts with hemodynamic alterations in 
the renal microcirculation, characterised by glomerular hyperperfusion and renal 
hypertrophy in the first years of the disease. Initially the glomerular filtration rate 
increases due to these changes, but will return to normal when the processes of 
glomerular basement membrane thickening, glomerular hypertrophy, and mesangial 
volume expansion set in (31). Diabetic nephropathy is characterised by albuminuria, 
which can be classified into micro- and macroalbuminuria. Microalbuminuria is 
defined as an albumin excretion of 30 to 300 mg/d in a 24-h urine collection, and 
macroalbuminuria is defined as an albumin loss of >300 mg/d in a 24-h urine 
collection (32). The early abnormalities in albumin excretion may be reversible, but 
once it progresses to overt macroalbuminuria, the changes are likely to be irreversible 
and glomerular filtration rate will steadily decrease and in 10 years ~25% of these 
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patients will reach end stage renal disease (33). However, reduced glomerular 
filtration rate can also be present in patients with persistent normoalbuminuria 
(34,35), and rapid loss of glomerular filtration rate can occur in patients with normo- 
or microalbuminuria (36,37). 
For the prevention and/or treatment of these diabetes-related complications, the 
underlying cellular and molecular mechanisms that could link hyperglycaemia to the 
development of micro- and macrovascular complications in patients with type 1 
diabetes need to be better elucidated (26). This thesis focuses on the potential roles 
of advanced glycation endproducts (AGEs) and their receptor (RAGE), high-mobility 
group box-1 (HMGB1), endothelial and renal dysfunction, chronic low-grade 
inflammation, and accelerated arterial stiffening.  
Advanced glycation endproducts (AGEs)  
Non-enzymatic glycation is a chemical post-translational modification of proteins, 
lipids and nucleic acids and is a major cause of spontaneous damage to cellular and 
extracellular components in physiological systems. Although glycation is a naturally 
occurring process, increased glycation and the resulting formation of AGEs occur 
under physiological circumstances with ageing (38) and is implicated in many diseases 
such as diabetes. The non-enzymatically reaction known as the Maillard reaction 
results in irreversible AGEs via the formation of reversible Schiff bases and Amadori 
products (38,39), as illustrated in Figure 1.1. The early steps of this glycation process 
are (glucose) concentration dependent which is, thus, enhanced in diabetes (38,39). 
The formation of AGEs is also enhanced in conditions of elevated oxidative stress and 
inflammation (39). The reversible nature of the early glycation products, Schiff bases 
and Amadori products, prevents accumulation of these products. However, these 
early glycation products can undergo a slow process of further rearrangements to 
form irreversible AGEs (Figure 1.1), which comprise a heterogeneous group with 
different characteristics (38-40).  
Serum AGEs were found to be higher in patients with type 1 diabetes compared 
with controls (41,42). Several studies so far have reported positive associations 
between various circulating AGEs and micro- (42-44) and macrovascular complications 
(45,46), or surrogates thereof (47), in patients with type 1 diabetes, but most of these 
were limited by their cross-sectional study design (42-46). The few prospective studies 
investigating AGEs, or markers thereof, in patients with type 1 diabetes have reported 
skin autofluorescence (48), as a potential marker of tissue AGEs levels, and AGE-
modified LDL in immune complexes (47) to be positively associated with cardiac 
mortality (48) and progression of carotid intima-media thickness (47), respectively. 
However, so far, no prospective studies have investigated the associations between 
plasma AGEs and incident cardiovascular complications in patients with type 1 
diabetes. 
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Figure 1.1 Formation of AGEs by the Maillard reaction. Reducing sugars, such as glucose, react non-
enzymatically with amino groups in proteins, lipids, and nucleic acids through a series of 
reactions forming Schiff bases and Amadori products to produce AGEs. Structures of the well-
characterised AGEs, CEL, CML, and pentosidine, are given. 
 
 
AGEs affect cells in three general ways: 1) cellular functions can be altered when 
intracellular proteins are modified to AGEs, 2) modification of extracellular matrix 
proteins to AGEs resulting in abnormal interactions between these proteins, and 3) 
circulating AGEs can bind to AGE receptors, which could induce receptor-mediated 
production of reactive oxygen species and activate transcription factor nuclear factor-
κB (NF-κB), thereby leading to deleterious changes in cellular processes (39) (Figure 
1.2). Several AGE receptors have been identified, including macrophage scavenger 
receptors type I and II (49), oligosaccharyltransferase-48 (50), 80K-H phosphoprotein 
(50), galectin-3 (51), CD36 (52), LOX-170 (53), and RAGE (54). So far the AGE receptor 
that has been best-characterised and most frequently studied is RAGE. 
Receptor for advanced glycation endproducts (RAGE) 
RAGE (55kD) is a multi-ligand member of the immunoglobulin superfamily of cell 
surface molecules and under physiological conditions it is mainly expressed in the 
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lungs, though its expression occurs in multiple tissues (56). The cell types that express 
RAGE include endothelial, monocytes/macrophages, T-lymphocytes, neuronal and 
glomerular epithelial cells (56,57). RAGE consists of three specific domains including 
an extracellular, transmembrane, and an intracellular cytoplasmic domain. The 
extracellular domain has a V-type immunoglobulin domain, in which the ligand 
binding site is located, and two C-type domains (C1 and C2) (58,59). However, the 
V-domain may not act independently in ligand binding, but needs to integrate with 
the C1-domain into one unit (60). In addition, RAGE does not act as a monomeric 
receptor, but rather oligomerises to acquire high affinity in binding ligands (61).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Mechanisms by which AGEs and its precursors exert unfavourable effects. Covalent 
modification of intracellular proteins by AGE precursors alters several cellular functions (1). 
Modification of extracellular matrix proteins causes abnormal interactions with other matrix 
proteins and with integrins (2). Modification of plasma proteins by AGE precursors creates 
ligands that bind to AGE receptors, inducing changes in gene expression (3). (Figure adapted 
from Brownlee et al. Nature 2001) (55). 
 
 
Various downstream cellular signalling pathways have been identified, including 
p21ras, extracellular signal-regulated kinase (ERK) 1/2, p38 and SAPK/JNK MAP 
kinases, rho GTPases, phosphoinositol-3 kinase, and the JAK/STAT pathway (40,62), 
while the proximal signalling proteins, which actually bind to the cytoplasmic domain 
of RAGE, still need to be identified (62). The diverse RAGE-induced signalling pathways 
could imply that these may be ligand-specific.  
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Binding of AGEs to RAGE activates diverse cellular processes, including tubular 
epithelial-myofibroblast transdifferentiation (63) and glomerular sclerosis (57) in 
diabetic nephropathy, increases in generation of pro-inflammatory cytokines and 
expression of adhesion molecules (64,65), migration of mononuclear phagocytes (66), 
increases in vascular hyperpermeability to macromolecules (67), and increases in 
cytosolic reactive oxygen species production and mitochondrial oxidase activity (68).  
These RAGE-associated cellular processes could contribute to endothelial and 
renal dysfunction, low-grade inflammation and arterial stiffening (57,58,64,65), all of 
which may explain, at least in part, the increased cardiovascular morbidity and 
mortality in diabetes. Recent studies (62,69,70) have suggested a potential role of 
RAGE in the development of vascular disease in diabetes mellitus. Indeed, at the 
molecular level, RAGE has been shown to be upregulated in atherosclerotic lesions in 
diabetes (69). 
In addition to the membrane-bound form, soluble forms of RAGE can be detected 
in plasma. These soluble forms result from alternative splicing (71) or from 
proteolytical cleavage of the membrane-bound RAGE (72) (Figure 1.3). The functional 
role of these soluble forms of RAGE in the circulation remains unclear, but they may 
reflect RAGE expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Different forms of RAGE. In addition to the membrane-bound form, soluble forms of RAGE 
can be detected in plasma. These soluble forms result from alternative splicing or from 
proteolytical cleavage of the membrane-bound RAGE. 
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High-mobility group box 1 (HMGB1) 
Besides AGEs, RAGE can also be activated by other ligands, which include amyloid-β-
peptide (73), amyloid A (74), members of the S100/calgranulin family (75), and 
HMGB1 (76). HMGB1 is a multifunctional nuclear DNA-binding protein that facilitates 
gene transcription  (77). Extracellular HMGB1 released from necrotic cells (78) as well 
as from immune cells upon inflammatory stimuli (79) functions as a pro-inflammatory 
cytokine (80), which elicits pro-inflammatory responses from macrophages and 
endothelial cells (81). Extracellular effects of HMGB1 are mediated by its binding to 
RAGE, but also, at least in part, by its binding to the receptors of the toll-like receptors 
family (82).  
HMGB1-induced production of adhesion molecules and inflammatory cytokines 
may contribute to the increased risk of vascular complications in diabetes, which is 
supported by the findings that HMGB1 expression is higher in the cytoplasm of renal 
tissue of diabetic rats compared with control rats (83), and that kidney HMGB1 levels 
were associated with the presence and severity of diabetic nephropathy in rats (84). 
Three cross-sectional studies have investigated the associations between HMGB1 and 
cardiovascular outcomes in humans. These have reported higher levels of HMGB1 in 
patients with stable or unstable angina pectoris (85), with type 2 diabetes and 
coronary artery disease (86), and with heart failure (87) as compared with controls. In 
addition, one of these studies has also shown that individuals with heart failure at 
study entry who died during the follow-up of two years had higher levels of HMGB1 at 
baseline compared with the survivors (87). So far, no study has investigated the 
potential association of HMGB1 with vascular complications in patients with type 1 
diabetes. 
Potential mediating mechanisms through which AGE-RAGE 
axis could lead to increased risk of vascular complications 
Endothelial dysfunction 
The endothelium is the inner layer of blood vessels and it plays an important role in 
the regulation of vascular tone and permeability as well as inflammatory processes in 
the vessel wall (88). Endothelial dysfunction is involved in the development of 
atherothrombosis and its progression (89). Risk factors for atherothrombotic disease 
may induce endothelial activation and subsequently endothelial dysfunction, 
characterised by an imbalance between vasodilators and vasoconstrictors, elevated 
expression of adhesion molecules, increased permeability, decreased anticoagulant 
activity, and altered extracellular matrix synthesis (89). Circulating adhesion molecules 
(e.g. soluble intercellular adhesion molecule, soluble vascular cell adhesion molecule, 
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and soluble E-selectine) and other endothelium-derived factors (e.g. von Willebrand 
factor) may reflect the degree of endothelial activation/dysfunction (89).  
Compared to controls, it has been reported that patients with type 1 diabetes 
have higher levels of circulating adhesion molecules (90,91), and other endothelium-
derived factors (91). In addition, it has been shown that markers of endothelial 
dysfunction are positively associated with the presence of micro- and macrovascular 
complications (92,93), progression of carotid intima-media thickness (92), and 
incident coronary artery disease (94) in patients with type 1 diabetes. However, in a 
prospective study after adjustment for conventional cardiovascular risk factors no 
association could be found between endothelial dysfunction markers and incident 
cardiovascular morbidity and mortality (95). 
Low-grade inflammation 
Atherosclerosis is thought to be an inflammatory disease and involves immune 
responses in every phase of the disease (96). Accumulation of immune cells and lipid 
droplets, and the formation of foam cells belong to the early stages in the 
development of atherosclerotic lesions (96). In general, pro-inflammatory cytokines 
produced by the immune cells will activate macrophages and endothelial cells, 
increase production of other inflammatory cytokines, elevate expression of adhesion 
molecules, prompt the tendency for thrombus formation, and inhibit collagen 
production (97).  
Markers of low-grade inflammation (e.g. c-reactive protein and interleukin-6) have 
been reported to be higher in patients with type 1 diabetes than in controls without 
type 1 diabetes (91,98,99). In addition, various markers of low-grade inflammation 
(i.e. c-reactive protein, tumour necrosis factor-α, interleukin-6, and secreted 
phospholipase A2) have been positively associated with higher prevalence of micro- 
(100,101) and macrovascular complications (102), carotid intima-media thickness 
(103), as well as incident fatal and non-fatal CVD (95) in type 1 diabetes. In contrast, it 
has also been reported that c-reactive protein was not associated with nephropathy 
and carotid intima-media thickness in a large cohort among patients with type 1 
diabetes (92). 
Accelerated arterial ageing (arterial stiffening)  
Arterial stiffness leads to an increase in systolic blood pressure, because hearts 
ejecting into a stiffer arterial bed must generate higher end-systolic pressures for the 
same net stroke volume. This leads to increased arterial pressure and volume during 
systole, causing a reduced arterial volume at the onset of diastole, which in turn 
causes an enhanced fall in diastolic blood pressure (22,104). Systolic blood pressure 
increases with age, while diastolic blood pressure decreases, in particular, from the 5
th
 
decade onwards (22). Therefore, pulse pressure (calculated by systolic minus diastolic 
blood pressure) increases with age and is a marker of arterial stiffness (22,25). 
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However, in type 1 diabetes the increases in pulse pressure with ageing occurs ~10-15 
years earlier (105), which illustrates the process of accelerated arterial ageing in these 
patients. Importantly, higher pulse pressure is associated with increased risk of 
incident CVD in type 1 diabetes (18,106).  
Renal dysfunction  
Renal dysfunction can be evaluated by a decrease in glomerular filtration rate and/or 
by the presence of albuminuria reflecting increased glomerular permeability. Patients 
with severe chronic kidney disease are more likely to die of cardiovascular disease 
than of kidney failure (107,108). The highly increased incidence of CVD was first 
demonstrated in patients who need dialysis treatment. However, the adverse 
association between renal dysfunction and CVD is not limited to the dialysis 
population, but applies across various degrees (including the mildest degrees) of 
kidney dysfunction (107). Mechanisms through which renal dysfunction could lead to 
increased risk of CVD include activation of the renin-angiotensin aldosterone system, 
oxidative stress, elevated asymmetric dimethyl arginine (ADMA), increased circulating 
pro-inflammatory cytokines, and dyslipidaemia (107).  
However, whether renal dysfunction is causally linked to cardiovascular disease 
remains to be elucidated (109). Alternatively, renal function may be a risk marker of 
cardiovascular disease, or renal dysfunction and cardiovascular disease may be caused 
by a common risk factor or pathophysiological mechanisms (e.g. endothelial 
dysfunction) (109). 
Aim of this thesis 
The increasing prevalence of type 1 diabetes and its related vascular complications 
pose a tremendous burden for patients and our society. However, the 
pathophysiological mechanisms underlying the development of these vascular 
complications still need to be better elucidated. Several potential cellular and 
molecular mechanisms have been proposed that could explain the link between 
diabetes and the development of vascular complications. These could constitute new 
targets in the prevention and/or treatment of vascular complications in these 
patients. 
We have investigated these issues (Figure 1.4.) in two cohort studies; a cross-
sectional nested case-control study (EURODIAB) (110), and a prospective study (Steno 
Diabetes Center) (111), which will be described in detail in the specific chapters. 
Briefly, the cross-sectional case-control study (n=543) is a follow-up of the EURODIAB 
IDDM complications study, of which baseline investigations were performed between 
1989 and 1991 on 3,250 patients with diabetes mellitus type 1. The patients were 
recruited from 31 centres in 16 European countries. These patients were invited for a 
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follow-up examination on average 7-9 years after the baseline examinations. Of the 
3,250 included patients, 1,880 (57.8%) returned for re-examination. At follow-up, a 
cross-sectional nested case-control study of markers of inflammation and endothelial 
dysfunction and their associations with vascular complications was performed. Cases 
were selected as those with greatest vascular complication burden as possible and 
controls were selected as those who were completely free of any complications (i.e. 
with no evidence of CVD, albuminuria, and retinopathy). In the prospective cohort 
study, 199 patients with type 1 diabetes and nephropathy and 192 with 
normoalbuminuria were recruited from the outpatient clinic at the Steno Diabetes 
Center in 1993. All patients were followed to the last visit at Steno Diabetes Center, 
until 1 September 2006 or until death (n=82) or emigration (n=3). The primary study 
outcome was a combined end-point of fatal and non-fatal CVD  and the study’s 
secondary end-point was all-cause mortality. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Potential pathophysiological mechanisms that could explain the link between diabetes and 
the development of vascular complications as hypothesised in the present thesis. 
 
 
One of the proposed pathways that could link diabetes with the increased risk for 
vascular complications involves the AGE-RAGE axis. Circulating soluble RAGE may be a 
marker that reflects the AGE-RAGE axis and we have, therefore, investigated the 
associations between soluble RAGE (Chapters 2-3) and AGEs (Chapter 4) on the one 
hand and prevalence (Chapter 2) as well as incidence (Chapters 3-4) of cardiovascular 
complications in patients with type 1 diabetes. We have also investigated the 
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associations between HMGB-1, a pro-inflammatory cytokine but also a ligand of RAGE, 
and cardiovascular complications (Chapters 5-6). 
In addition, we have examined whether endothelial and renal dysfunction, low-
grade inflammation, and arterial stiffness could explain, in part, the potential 
associations between sRAGE, AGEs as well as HMGB-1 and cardiovascular 
complications in type 1 diabetes (Chapters 2-6). 
Furthermore, patients with type 1 diabetes show signs of accelerated arterial 
ageing, which has been related to increased risk of cardiovascular disease in these 
patients. However, the role of arterial stiffness and its relation to other potential 
mechanisms (i.e. low-grade inflammation and cross-linking AGEs) that are related to 
increased risk of cardiovascular disease remain to be clarified. We have, therefore, 
investigated whether low-grade inflammation, pentosidine (a cross-linking AGE), and 
arterial stiffness were related to each other, and with incident cardiovascular disease 
in patients with type 1 diabetes (Chapter 7). 
Finally, in Chapter 8 the present findings, limitations and implications will be 
discussed. 
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Abstract 
Background and objective 
Serum soluble receptor for advanced glycation endproducts (sRAGE) may reflect the activity of the AGE-
RAGE axis, which has been proposed as a potential mechanism linking hyperglycaemia to vascular 
complications in diabetes. We have therefore investigated 1) whether sRAGE is associated with greater 
prevalence of cardiovascular disease (CVD) and microvascular complications in type 1 diabetic patients; and 
2) the extent to which any such associations are explained by markers of endothelial and renal dysfunction 
and inflammation. 
 
Methods 
The study included 477 subjects (234 women; mean age 42±10 yrs) from the EURODIAB Prospective 
Complications Study. We used linear regression analyses to investigate the differences in sRAGE levels 
between subjects with vs. without vascular complications. All analyses were adjusted for age, sex, HbA1c, 
duration of diabetes and other risk factors.  
 
Results 
Subjects with CVD (n=116) had higher levels of sRAGE than those without CVD or any microvascular 
complications (n=178): β=0.15 (95%CI: 0.04;0.27). Further adjustments for markers of endothelial [β=0.13 
(0.02;0.24)] and renal dysfunction [β=0.10 (-0.01;0.20)] and inflammation [β=0.12 (0.01;0.23)] attenuated 
these differences; altogether these variables explained about 50% of the association between sRAGE and 
prevalent CVD. Soluble RAGE levels tended to be higher in the presence and across the levels of severity of 
albuminuria (p-trend=0.087) and retinopathy (p-trend=0.057); adjustments for endothelial and renal 
dysfunction and inflammation also attenuated these differences. 
 
Conclusions 
sRAGE is associated with greater prevalence of CVD in type 1 diabetic subjects, and these associations may 
be partly explained by endothelial and renal dysfunction and low-grade inflammation. 
 
 
 sRAGE and vascular complications 
29 
2 
Introduction 
The increased cardiovascular disease risk in patients with diabetes mellitus (DM) 
cannot be fully explained by traditional cardiovascular risk factors (1-3). Therefore, 
other factors and mechanisms potentially involved need to be explored. At the 
molecular level, one pathway through which hyperglycaemia may lead to vascular 
complications is the formation of advanced glycation endproducts (AGEs). An 
important mechanism through which AGEs induce vascular disease is by binding to 
their specific receptors (4,5).  
Several different receptors for AGEs have been identified, one of which is termed 
RAGE. Different cell types including human endothelial cells express RAGE (6). In 
addition to cell-bound RAGE, soluble forms of RAGE appear in plasma (6,7), as 
different splice variants of RAGE (esRAGE) leaking the transmembrane and cytosolic 
domain (6,8), and as a proteolytically cleaved form of RAGE (sRAGE), which is most 
probably shed into the circulation by the sheddase a disintegrin and metalloprotease 
10 (9). The functional role of these soluble forms of RAGE in the circulation remains 
unclear, but they may reflect the activity of the AGE-RAGE axis. The ligation of RAGE 
activates the endothelial cell and triggers multiple signalling cascades (10,11), 
resulting in activation and translocation of nuclear transcription factors and 
transcription of the target genes, including adhesion molecules (11,12) and 
proinflammatory cytokines (13). The activation of RAGE may also lead to nephropathy 
(14). We have therefore hypothesised that the activation of the AGE-RAGE axis may 
lead to vascular complications in diabetes through increases in endothelial and renal 
dysfunction and low-grade inflammation.  
Evidence so far with regard to the association between soluble forms of RAGE and 
vascular disease is contradictory, with several studies showing positive (15-18) but 
also inverse associations (19-22). Soluble forms of RAGE levels have also been shown 
to be either increased (16,23) or decreased (19) in diabetic patients. The fact that 
these studies have investigated either esRAGE (18-20) or sRAGE (15-18,21-23) may 
explain the discrepancies. Indeed, in the only study in which both soluble forms of 
RAGE were examined, sRAGE, but not esRAGE, was associated with albuminuria in 
subjects with type 2 diabetes (18). In addition, the extent to which mechanisms such 
as endothelial and renal dysfunction and low-grade inflammation, which are 
intertwined and related to macro- and microvascular complications in diabetes 
(24-26), underlie the association between sRAGE and vascular complications (if any) 
has never been investigated.  
In view of these considerations, we have investigated, first, whether sRAGE levels 
are associated with a greater prevalence of macro- and microvascular complications in 
patients with type 1 diabetes; and second, the extent to which any such associations 
are explained (i.e. are mediated) by markers of endothelial and renal dysfunction and 
low-grade inflammation.  
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Methods 
Subjects and study design  
We used data from the EURODIAB Prospective Complications Study, which is a follow-
up of the EURODIAB IDDM complications study that has been described in detail 
elsewhere (27-29). Briefly, baseline investigations were performed between 1989 and 
1991 on 3,250 patients with diabetes mellitus type 1, defined as a clinical diagnosis 
made before the age of 36 years, and needing continuous insulin therapy within 
1 year of diagnosis. The patients, aged between 15 and 60 years, were recruited from 
31 centres in 16 European countries. Sample selection was stratified by sex, age group 
and duration of diabetes, to ensure sufficient representation in all categories. All 
patients gave informed consent and the study was approved by the local Ethics 
Committees (29). These patients were invited for a follow-up examination on average 
7-9 years after the baseline examinations. Of the 3,250 included patients, 1,880 
(57.8%) returned for re-examination. At follow-up, a cross-sectional nested case-
control study of markers of inflammation and endothelial dysfunction and their 
associations with complications was performed in a subset of patients (n=543). The 
present study includes 477 of these subjects in whom complete data on serum levels 
of sRAGE, endothelial and renal dysfunction markers, inflammatory markers and other 
covariates were available.  
Main determinant 
Plasma levels of sRAGE were measured using a commercially available enzyme-linked 
immunosorbent assay kit (Quantikine: R&D systems, Minneapolis, USA) according to 
the manufacturer’s protocol. Briefly, a monoclonal antibody generated against the 
N-terminal extracellular domain of human RAGE was used to capture sRAGE from 
plasma. Captured sRAGE was detected with a polyclonal antihuman sRAGE antibody. 
After washing, plates were incubated with streptavidin horseradish peroxidase, 
developed with appropriate substrate, and OD450 was determined using an enzyme-
linked immunosorbent assay plate reader. Measurements were performed in 
duplicate and the intra-assay and inter-assay coefficients of variation were 2.9% and 
11.5%, respectively. 
Main outcomes 
Macrovascular disease  
Cardiovascular disease was defined as a positive medical history of a cardiovascular 
event, including myocardial infarction, angina, coronary artery bypass graft and/or 
stroke, and/or ischaemic changes on a centrally Minnesota coded ECG (30).  
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Microvascular disease  
Albumin excretion rates were measured from duplicate 24-h urine collections (28) and 
micro- and macroalbuminuria were defined as an albumin excretion rate between 20 
and 200, and above 200 μg/min, respectively. We also estimated subjects’ glomerular 
filtration rate (eGFR) with the Cockcroft–Gault formula (31). Retinopathy was assessed 
from retinal photographs according to the EURODIAB protocol; non-proliferative 
retinopathy was defined as the presence of one or more microaneurysms, 
haemorrhages, and/or hard exudates. Proliferative retinopathy was defined as any 
new vessels, fibrous proliferations, pre-retinal haemorrhage, vitreous haemorrhage, 
or photocoagulation scars (32).  
Other risk factors 
Blood pressure was recorded twice with a random zero sphygmomanometer 
(Hawskley, Lancing, UK). Hypertension was defined as systolic pressure ≥140 mmHg, 
diastolic pressure ≥90 mmHg and/or use of antihypertensive drugs. Smoking habits 
were ascertained by questionnaire and subjects were categorised into categories: 
‘non-‘, ‘moderate’, and ‘heavy smokers’, according to their levels of pack years 
smoked (none, and below or above the sex-specific median, respectively). Weight and 
height were measured with indoor clothing without shoes and body mass index (BMI) 
was calculated. Blood samples were taken, fasting if possible, for measurement of 
lipids and glycaemic control. Cholesterol and triglyceride levels were measured by 
enzymatic colorimetric tests (33), and HDL cholesterol was measured directly (34). LDL 
cholesterol was calculated from Friedewald's formula (35). Glycated haemoglobin 
(HbA1c) was measured by a latex enhanced turbidimetric immunoassay (Roche 
Products, Welwyn Garden City, UK). The reference range for this assay was 4.2–6.2%.  
Potential Mediators 
Markers of endothelial dysfunction  
Soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble E-selectin (sE-
selectin) were measured in duplicate by sandwich enzyme immunoassays (R&D 
Systems, Oxon, U.K.). The mean of the duplicates is presented. The intra- and inter-
assay coefficients of variation for sVCAM-1 were 4.0% and 9.1%, respectively, and for 
sE-selectin, 2.1% and 3.1%, respectively.  
Inflammatory markers  
Plasma levels of C-reactive protein (CRP) were measured with a highly sensitive in-
house ELISA (25) and plasma levels of interleukin-6 (IL-6) and tumour necrosis factor-α 
(TNF-α) were measured using commercially available ELISA kits (R&D Systems, Oxon, 
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U.K.) (25). Intra- and inter-assay coefficients of variation were 3.9 and 8.7%, 4.5 and 
9.0%, 7.3 and 8.5%, respectively. 
Advanced glycation endproducts  
Pentosidine levels were determined in unhydrolysed urine (36). Urinary excretion of 
pentosidine was normalised for urine concentration by expressing it as nmol 
pentosidine/mmol urinary creatinine. Protein-bound N
ε
-(carboxymethyl)lysine (CML) 
and N
ε
-(carboxyethyl)lysine (CEL) were determined in plasma as previously described 
(37) with an inter-assay coefficient of variation of 6.0%. CML and CEL were normalised 
for lysine concentration.  
Statistical analyses  
All analyses were performed with the Statistical Package for Social Sciences (SPSS) 
version 15.0 for Windows (SPSS Inc, Chicago, Illinois, USA). Variables with a skewed 
distribution (i.e. triglycerides, CRP, IL-6, TNFα and pentosidine) were log transformed 
prior to further analyses. Comparisons of characteristics between subjects with vs. 
without vascular complications were performed with Student’s t- or Chi-Square tests, 
as appropriate. Cases were all those subjects with cardiovascular disease or 
retinopathy or micro- or macroalbuminuria (n=299); controls were all those who had 
no evidence of cardiovascular disease, nor retinopathy, and were normoalbuminuric 
(n=178). 
Linear regression analyses were used to examine whether sRAGE levels differed 
between subjects with vs. without CVD, and similarly, between those with and 
without microvascular complications. In the analyses comparing individuals with vs. 
without CVD, we excluded those in whom CVD was absent but who did have any of 
the other vascular complications (183 out of 299 individuals). The same control group 
(n=178) was used in the analyses comparing subjects with vs. without albuminuria and 
subjects with vs. without retinopathy. These analyses were first adjusted for age, sex, 
HbA1c and duration of DM, and then further adjusted for other cardiovascular risk 
factors (i.e. BMI, triglycerides, HDL, LDL, systolic blood pressure and smoking). Linear 
regression analyses were also used to examine the extent to which sRAGE levels were 
associated with endothelial dysfunction (comprised in an averaged Z-score of 
sVCAM-1 and sE-selectin), inflammation (comprised in an averaged Z-score of CRP, 
IL-6 and TNFα) and eGFR. Results of these analyses are expressed in standardised 
regression coefficients (95% confidence interval) to allow the comparison of the 
strength of the association between sRAGEs and each of these variables/scores. 
Finally, successive adjustments for these variables were performed in order to 
investigate the extent to which these variables explained (i.e. attenuated) the 
differences in sRAGE levels between subjects with and without complications.  
Because we measured the markers of the potential mediators only once, the 
associations observed will tend to be diluted. This is the reason why we combined the 
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markers per mechanism (i.e. inflammation and endothelial dysfunction) to yield an 
inflammatory and an endothelial dysfunction marker Z-score. We thereby assumed 
that each marker contributes equally to the activity of the mechanism to which it 
belongs.  
Results 
Table 2.1 shows the characteristics of the patients with vascular complications (cases) 
vs. those without (controls).  
 
Table 2.1 Clinical characteristics of the study population. 
 All (n=477) 
 
Vascular 
complications 
(n=299) 
No vascular 
complications 
(n=178) 
p-value 
Age (years) 41.7 (10.4) 35.9 (8.1) <0.001 
Gender (m/f, %) 54/46 46/54   0.072 
BMI (kg/m
2
) 24.9 (3.5) 23.7 (2.6) <0.001 
HbA1c (%)   9.0 (1.6)   7.8 (1.3) <0.001 
Duration of Diabetes (years) 25.2 (9.1) 15.3 (7.0) <0.001 
LDL Cholesterol (mmol/l)   3.25 (1.09)   2.87 (0.90) <0.001 
HDL Cholesterol (mmol/l)   1.59 (0.42)   1.69 (0.45)   0.022 
Triglyceride (mmol/l) 1.14 [0.85-1.58] 0.85 [0.66-1.09] <0.001 
Smoking (Non/Moderate/Heavy smokers) (%) 39/27/34 51/31/18 <0.001 
Diastolic blood pressure (mmHg)   75 (12)   73 (11)   0.048 
Systolic blood pressure (mmHg) 127 (21) 114 (14) <0.001 
Serum Creatinine (µmol/l) 76 [68-90] 71 [64-78] <0.001 
eGFR (ml/min) 113.9 (17.4) 96.9 (27.5) <0.001 
Cardiovascular disease (%) 38.8 - - 
Albuminuria (Normo-/Micro-/Macro-) (%) 38.5/24.1/37.5 - - 
Retinopathy (No/Background/Proliferative) (%) 11.7/41.1/47.2 - - 
CRP (mg/l) 1.30 [0.46-2.80] 0.71 [0.35-1.82] <0.001 
IL-6 (pg/ml) 2.13 [1.35-3.94)] 1.55 [1.05-2.49] <0.001 
TNF-α (pg/ml) 3.17 [2.40-4.41] 2.23 [1.68-2.85] <0.001 
sE-selectin (ng/ml) 36 (17) 31 (11) <0.001 
sVCAM-1(ng/ml) 437 (147) 379 (104) <0.001 
CEL/Lysine (µmol l-1mmol-1) 0.030 (0.012) 0.031 (0.011)   0.896 
CML/Lysine (µmol l-1mmol-1) 0.058 (0.020) 0.055 (0.015)   0.097 
Pentosidine (nmol/l per mmol urinary creatinine) 0.46 [0.33-0.67] 0.43 [0.32-0.56]   0.003 
Data are means (standard deviation), median [inter-quartile range], or percentages, as appropriate.  
BMI, body mass index; HbA1c, glycated hemoglobin; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein; eGFR, estimated glomerular filtration rate by Cockcroft-Gault formula; CRP, C reactive protein; 
IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; sE-selectin, soluble E-selectin; sVCAM-1, soluble vascular 
cell adhesion molecule-1; CEL, N
ε
-(carboxyethyl)lysine; CML, N
ε
-(carboxymethyl)lysine; sRAGE, soluble 
receptor for advanced glycation end-products. 
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Associations between sRAGE and cardiovascular and microvascular disease  
Subjects with CVD had higher levels of sRAGE than those without CVD: β=0.16 ng/ml 
(95%CI: 0.05; 0.26) (Table 2.2, model 1; Figure 2.1). Adjustments for other risk factors 
did not change this difference (model 2).  
Soluble RAGE levels were also increased across the levels of severity of 
albuminuria: [β=0.04 (-0.08;0.16) and β=0.13 (0.01;0.25) in subjects with micro- and 
macroalbuminuria vs. normoalbuminuria, respectively (p-trend=0.031)] and similarly 
across the levels of severity of retinopathy [β=0.06 (-0.04;0.15) and β=0.12 (0.01;0.22) 
in those with non-proliferative and proliferative vs. without retinopathy, respectively 
(p-trend=0.037)] (Table 2.2; model 1; Figure 2.1). These differences were not 
markedly attenuated after further adjustments for other risk factors but were not 
longer statistically significant (model 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 sRAGE levels according to the presence of cardiovascular disease and the presence and 
severity of albuminuria and retinopathy. Bars are means adjusted for age, sex, duration of 
DM and HbA1c; error bars indicate SEs of the means. 
 
Association between sRAGE and markers of endothelial and renal dysfunction, low-
grade inflammation and advanced glycation endproducts  
Soluble RAGE was positively and significantly associated with endothelial dysfunction, 
low-grade inflammation and AGEs scores, and even more strongly so with levels of 
eGFR (Table 2.3; model 1). Adjustments for other cardiovascular risk factors did not 
materially change these associations (model 2). 
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Table 2.3 Associations between levels of sRAGE levels and markers of endothelial and renal 
dysfunction, low-grade inflammation and advanced glycation endproducts. 
Dependent Variables Model β 95% CI p-value 
Endothelial dysfunction z-score 1   0.18 0.12; 0.24 <0.001 
 2   0.17 0.11; 0.23 <0.001 
Estimated glomerular filtration rate 1 -0.32 -0.39; -0.25 <0.001 
 2 -0.28 -0.35; -0.21 <0.001 
 3 -0.28 -0.34; -0.21 <0.001 
Inflammation z-score  1   0.15 0.09; 0.21 <0.001 
 2   0.14 0.09; 0.20 <0.001 
Advanced glycation endproducts z-score 1   0.21 0.15; 0.27 <0.001 
 2   0.20 0.14; 0.25 <0.001 
β, standardised regression coefficient: indicates increase (in SDs) of the dependent variable per 1 SD 
increase in sRAGE levels; CI: confidence interval. Model 1, adjusted for age, sex, duration of diabetes and 
HbA1c; Model 2, model 1 + adjustments for other cardiovascular risk factors (i.e. body mass index, 
triglycerides HDL, LDL, smoking and systolic blood pressure); Model 3, model 2 + adjustment for the 
presence of vascular complications. 
 
Mediating effects of endothelial and renal dysfunction and low-grade inflammation in 
the associations between sRAGE and cardiovascular and microvascular complications  
The differences in sRAGE between subjects with vs. without CVD were attenuated 
after adjustments for markers of endothelial dysfunction and low-grade inflammation 
and more strongly so after adjustments for eGFR (Table 2.2, models 3 to 5 vs. model 
2). These variables explained about 13%, 20% and 33% of the association between 
sRAGE levels and the prevalence of CVD, respectively. All together, these potential 
mediators explained about 50% (change of β from 0.15 in model 2 to 0.08 in model 6) 
of the differences in sRAGE between subjects with vs. without CVD. Endothelial 
dysfunction, low-grade inflammation and particularly eGFR also attenuated the 
differences in sRAGE levels across the levels of severity of albuminuria and 
retinopathy (Table 2.2, models 3 to 6).  
Additional analyses  
In the analyses above (Table 2.2, models 4), we have considered eGFR (a marker of 
kidney dysfunction) as a potential mediator in the relationship between sRAGE and 
vascular complications. However, kidney dysfunction could also be a confounder in 
the association between sRAGE levels and vascular complications, and our analyses 
cannot distinguish between these possibilities. Finally, eGFR could also be a risk 
marker of vascular complications. When analysed as such, we observed that subjects 
with CVD had lower eGFR than those without CVD [β=–5.33 ml/min (95%CI: -10.49; 
-0.16), after adjustments for other cardiovascular risk factors and sRAGE levels]. 
However, the inverse associations reported between sRAGE and eGFR (Table 2.3, 
models 1 and 2), were not attenuated when further adjusted for the presence of 
 sRAGE and vascular complications 
37 
2 
vascular disease (Table 2.3, model 3), which argues against eGFR being a risk marker 
of vascular disease. 
We found significant effect modification by sex in the association between sRAGE 
and CVD (p-valuessex-interaction=0.008), indicating that the association between sRAGE 
and CVD was stronger in men [β=0.25 ng/ml (0.08;0.43)] than in women 
[β=0.07 ng/ml (-0.07;0.20)]. However, in both sexes the direction of the association 
was the same and the number of cases and controls did not differ markedly between 
the two sexes: 55:81 and 61:97 in men and women, respectively. 
Discussion 
The main finding of this study is that sRAGE levels are positively associated with 
cardiovascular disease in type 1 diabetes. This association was independent of other 
‘traditional’ cardiovascular risk factors, but could be partially explained by endothelial 
and renal dysfunction and low-grade inflammation. Although sRAGE has been 
investigated in several studies, findings have been scattered. This is the first study that 
has investigated the associations between sRAGE and macro- and microvascular 
complications, and has also addressed potential mechanisms that could explain the 
observed associations. 
The observed positive association between sRAGE and CVD reported herein is in 
line with some (16,17) but not all (19,22) previous studies. The reasons for these 
contradictory findings are not clear but may be explained by the fact that different 
variants of soluble RAGE were measured and investigated across studies. Human 
endothelial cells express at least three RAGE variants (6). The first one is the full-
length RAGE, the second, the amino-terminally truncated variant with still an 
unknown function, and the third, the carbonyl-terminally truncated soluble form. This 
naturally occurring form of soluble RAGE, as well as artificially produced sRAGE, can 
potentially bind to an AGE ligand thereby acting as a decoy, preventing AGE-RAGE 
interaction and activation (6). This could thus explain any inverse association observed 
between sRAGE and vascular complications. However, although sRAGE has been an 
interesting subject of investigation under this suspected decoy function, it is very 
unlikely that sRAGE can act as such (i.e. by capturing and eliminating AGEs) because 
the sRAGE concentrations found in plasma are approximately 1000 times lower than 
needed for efficient binding and elimination of AGEs (18). Although circulating RAGE 
can be measured, different pools of soluble forms of RAGE are detected by different 
assays, namely the total pool of sRAGE by the Quantikine sRAGE ELISA kit (R&D 
systems, Minneapolis, USA) (15-18,21-23) or specifically esRAGE  by the B-Bridge 
International esRAGE ELISA kit (Daiichi Fine Chemicals, Takaoka, Japan) (18-20). The 
conflicting findings from the studies so far may thus be due to differences in 
measured variants of soluble RAGE, each of which might have a different function. 
Recently, new splice variants have been discovered (8) and further studies are 
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necessary to establish which variants of sRAGE are measured by these assays. The 
differences in the study population (i.e. diabetes vs. no diabetes or differences in 
ethnicity) might also contribute to the discrepancies in previous studies.  
sRAGE levels were also positively associated with microvascular complications, 
although these were not independent of other risk factors in the present study. 
Positive associations between sRAGE levels and albuminuria have been reported 
previously, although these were not fully adjusted for conventional risk factors (i.e. 
dyslipidaemia, smoking and/or blood pressure) (15,18). In contradiction, subjects with 
diabetic retinopathy were characterised by lower levels of soluble RAGE compared to 
individuals without retinopathy, but again these differences did not account for 
confounding and selection bias may have influenced the association (20).  
We, as others, have found positive associations between sRAGE and markers of 
endothelial dysfunction and low-grade inflammation (38). The current view is that the 
activation of RAGE, a 55-kDa protein and member of the immunoglobulin superfamily 
of cell surface receptors, through ligand binding activates the endothelial cell and 
triggers multiple signalling cascades (10,11). This results in activation and 
translocation of nuclear transcription factors and transcription of the target genes, 
including VCAM-1 (11), E-selectin (12), and proinflammatory cytokines (13). AGEs are 
positive regulators of the cellular RAGE expression (39), and an increased formation of 
AGEs enhanced the expression and secretion of the soluble forms of RAGE (40,41). In 
addition, the association between sRAGE and AGEs observed in this study supports 
the view that sRAGE could be a reflection of RAGE, and that activation of the AGE-
RAGE axis can lead to increased endothelial dysfunction and low-grade inflammation, 
and subsequently to an increased risk of cardiovascular complications in type 1 
diabetes. 
We have shown that sRAGE is positively and independently associated with renal 
dysfunction, defined as eGFR. This is in line with a previous study, which has shown 
that the activation of the AGE-RAGE axis could lead to glomerulosclerosis and 
glomerular hyperpermeability through the upregulation of vascular endothelial 
growth factor and/or transforming growth factor-β (14). We have also shown that 
renal dysfunction mediated the associations between sRAGE levels on the one hand 
and CVD or microvascular complications on the other. Although there is some 
evidence to support the assumption of renal dysfunction being a mediator in the 
causal pathway between sRAGE levels (as a reflection of the activity of the AGE-RAGE 
axis) and vascular complications, we cannot neglect the possibility of renal 
dysfunction being a confounder in these associations.  
It is unclear why the relationship between sRAGE levels and CVD observed in the 
present study was stronger in men than in women. sRAGE levels did not differ 
between the two sexes. In this study cohort, associations between sialic acid and 
fibrinogen and coronary heart disease have also been found in men only (42). These 
findings suggest that different pathophysiological mechanisms may be involved in the 
two sexes with regard to CVD in type 1 diabetes. 
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There are limitations to our study. First, we cannot establish whether the 
associations are causal due to the cross-sectional design of the study, and our findings 
are limited to type 1 diabetic patients. However, no longitudinal data of this type exist 
in large groups of type 1 diabetes at the time, and therefore this cross-sectional study 
may serve as a reasonable starting point to further explore these associations. 
Second, although we minimised the influence of confounding in the associations 
observed by adjustments for many possible confounders, interference by factors we 
did not measure cannot be ruled out. Third, the levels of the mediators investigated 
were only measured once, which might have diluted the associations we found. 
However, we combined different markers of the potential mediators in Z-scores to 
yield more robust scores.  
In conclusion, in this study of patients with type 1 diabetes, sRAGE was found to be 
significantly associated with CVD and this was independent of other cardiovascular 
risk factors. Endothelial and renal dysfunction and low-grade inflammation explained 
about 50% of this association, suggesting that sRAGE levels as a reflection of RAGE 
lead to greater prevalence of CVD through increased endothelial and renal 
dysfunction and low-grade inflammation. Nevertheless, the precise role of sRAGE in 
the pathophysiology of diabetes mellitus and vascular complications need to be 
explored further in prospective studies. 
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Abstract 
Background and objective 
To investigate the associations of plasma levels of soluble receptor for advanced glycation endproducts 
(sRAGE) with incident cardiovascular disease (CVD) and all-cause mortality in type 1 diabetes, and the 
extent to which any such associations could be explained by endothelial and renal dysfunction, low-grade 
inflammation, arterial stiffness and advanced glycation endproducts (AGEs). 
 
Methods 
We prospectively followed 169 individuals with diabetic nephropathy and 170 individuals with persistent 
normoalbuminuria who were free of CVD at study entry and in whom levels of sRAGE and other biomarkers 
were measured at baseline. The median follow-up duration was 12.3 (7.6–12.5) years.  
 
Results 
The incidence of fatal and non-fatal CVD and of all-cause mortality increased with higher baseline levels of 
Ln-sRAGE independently of other CVD risk factors: hazard ratio (HR)=1.90 (95%CI=1.13 to 3.21) and HR=2.12 
(1.26 to 3.57) per 1 unit increase in Ln-sRAGE, respectively. Adjustments for estimated glomerular filtration 
rate (eGFRMDRD), but not or to a smaller extent for markers of endothelial dysfunction, low-grade 
inflammation, arterial stiffness and AGEs, attenuated these associations to HR=1.59 (0.91 to 2.77) for fatal 
and non-fatal CVD events, and to HR=1.90 (1.09 to 3.31) for all-cause mortality. In addition, in patients with 
nephropathy the rate of decline of GFR was 1.38 ml/min/1.73 m
2
 per year greater per 1 unit increase of 
Ln-sRAGE at baseline (p=0.036). 
 
Conclusions 
Higher levels of sRAGE are associated with incident fatal and non-fatal CVD, and all-cause mortality in 
individuals with type 1 diabetes. sRAGE-associated renal dysfunction may partially explain this association. 
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Introduction 
Recent studies have suggested a potential role of the receptor for advanced glycation 
endproducts (RAGE) in the development of vascular disease in individuals with 
diabetes mellitus (1). At the molecular level, RAGE is upregulated in atherosclerotic 
lesions in diabetes (2). RAGE-induced production of adhesion molecules (3-5) and 
inflammatory cytokines (4) could contribute to endothelial (4,5) and renal dysfunction 
(6), low-grade inflammation (4,5) and arterial stiffening, all of which may partially 
explain the increased CVD in diabetes.  
We have recently shown, in a large cross-sectional study of type 1 diabetes 
(EURODIAB), that plasma levels of sRAGE were positively associated with macro- and 
microvascular complications, and also with endothelial and renal dysfunction, and 
low-grade inflammation as pathophysiological mechanisms that explained, in part, the 
associations of sRAGE with vascular complications (7). Whether sRAGE is associated 
with incident fatal and non-fatal CVD as well as all-cause mortality in individuals with 
type 1 diabetes has never been investigated. In addition, the extent to which any such 
associations could be explained by markers of endothelial and renal dysfunction, low-
grade inflammation, arterial stiffness and AGEs, is also not known. We hereby address 
these questions in a 12-yr prospective follow-up study. 
Methods 
Study population and design 
In 1993, 199 of all 242 albuminuric patients older than 18 years attending the 
outpatient clinic at Steno Diabetes Centre agreed to participate and were enrolled in a 
prospective observational study. Diabetic nephropathy was diagnosed according to 
the following criteria: persistent macroalbuminuria (>300 mg/24 h) in at least two out 
of three previous consecutive 24-h urine collections, presence of retinopathy, and 
absence of other kidney or urinary tract disease. In addition, 192 patients with 
persistent normoalbuminuria [i.e. urinary albumin excretion rate (UAE) <30 mg/24 h] 
and matched for age, sex, and duration of diabetes were also enrolled as controls (8). 
The present study refers to 339 of the original 391 patients included in the cohort; 
details on inclusion/exclusion criteria and study main outcomes are depicted in a flow 
chart (Figure 3.1). The study was approved by the local ethics committee, in 
accordance with the Helsinki Declaration, and all patients gave their informed written 
consent.  
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Figure 3.1 Flow chart study population. 
 Note: some patients had a non-fatal and a fatal cardiovascular event, and some patients both 
suffered a stroke and had ischaemic heart disease (IHD), or peripheral arterial disease (PAD). 
Time to the event that occurred first was used in the analyses. 
Baseline investigations 
sRAGEs 
Plasma levels of sRAGE were measured using a commercially available ELISA kit 
(Quantikine; R&D systems, Minneapolis, MN, USA) according to the manufacturer’s 
protocol. Briefly, a monoclonal antibody generated against the N-terminal 
extracellular domain of human RAGE was used to capture sRAGE from plasma. 
Captured sRAGE was detected with a polyclonal anti-human sRAGE antibody. After 
washing, plates were incubated with streptavidin–horseradish peroxidase, developed 
with appropriate substrate, and OD450 was determined using an enzyme-linked 
immunosorbent assay plate reader. Measurements were performed in duplicate and 
the intra- and inter-assay CV values were 2% and 17.5%, respectively.  
All-cause mortality n=82
Nephropathy n=199 Normoalbuminuria n=192
n=1 Missing sRAGE
n=21 Prior CVD
n=7 ESRD at baseline
Missing sRAGE n=3
Prior CVD n=3
Study population n=339
n=1 Lost to follow up Lost to follow up n=16
CVD n=85
Non-fatal CVD n=53 Fatal CVD n=48
Eligible subjects n=356
Heart n=28
Stroke n=9
Non-specific n=11
IHD   n=35
Stroke n=23
PAD n=12
Diabetes     n=4
Infection n=13
Cancer n=6
Suicide n=4
Other n=7
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Other baseline measurements 
Measurements of other biomarkers and risk factors have been described in detail 
elsewhere (8,9). All investigations were performed in the morning after an overnight 
fast. No antihypertensive medication was ever prescribed in 24% of patients with 
nephropathy and 88% of the normoalbuminuric patients. All of the remaining patients 
were asked to stop their antihypertensive and diuretic treatment 8 days before the 
examination, but 15% of the 339 patients (27% in the nephropathy group) considered 
in our analyses did not comply with this recommendation. Arterial blood pressure was 
measured twice with an appropriate cuff size following at least 10 min rest in the 
supine position. Mean arterial pressure was calculated as [systolic blood pressure + 
(2*diastolic blood pressure)]/3. Pulse pressure was calculated by subtracting the 
diastolic from the systolic blood pressure, and used as a marker of arterial stiffness 
(21). Urinary albumin excretion was measured by an enzyme immunoassay from 24-h 
urine collections. Serum creatinine concentration was assessed by a kinetic Jaffé 
method. In all patients glomerular filtration rate (eGFR) was estimated according to 
the short Modification of Diet in Renal Disease equation (MDRD)=186 * [serum 
creatinine (mg/dl)]−1.154 * [age]−0.203 * [0.742 if paQent is female]. PaQents were 
interviewed using the WHO cardiovascular questionnaire. Individuals were 
categorised into three groups according to their smoking status as never, former or 
current smokers. 
High-sensitivity C-reactive protein and secreted phospholipase A2 were 
determined by ELISAs as described previously (9). Commercially available ELISA kits 
were used for measurements of plasma soluble vascular cell adhesion molecule-1, 
soluble intercellular adhesion molecule-1 and interleukin-6 (Quantikine High 
Sensitivity; R&D Systems, Oxon, U.K.). The intra- and inter-assay CVs of these 
immunoassays were <8%. Protein-bound pentosidine levels were determined in 
plasma by a single step reversed phase based high-performance liquid 
chromatography separation with fluorescent detection. Protein-bound Nε-
(carboxymethyl)lysine (CML) and Nε-(carboxyethyl)lysine (CEL) were determined in 
plasma by stable-isotope dilution tandem mass spectrometry. The intra- and inter-
assay CVs were 2.7% and 2.8% for pentosidine, 3.5% and 3.6% for CML, and 7.3% and 
2.0% for CEL, respectively. The laboratory analyses of these biomarkers were done on 
frozen (-80°C) samples. 
Follow-up and study end-points 
All patients were followed up to the last visit at Steno Diabetes Center, until 1 
September 2006 or until death (n=82) or emigration (n=3). All patients were traced 
through the national register during autumn 2006. If a patient had died before 1 
September 2006, the date of death was recorded and the primary cause of death was 
obtained from the death certificate, which was reviewed by two independent 
observers. Additional available information from necropsy reports was also included. 
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All deaths were classified as cardiovascular unless an unequivocal non-cardiovascular 
cause was established. In all patients alive at the end of follow-up non-fatal CVD were 
retrieved from their patient files at Steno Diabetes Center or other hospital records. 
The primary end-point was a combination of fatal and non-fatal CVD (i.e. myocardial 
infarction, percutaneous coronary intervention, coronary bypass grafting, amputation 
due to ischaemia, vascular surgery for peripheral atherosclerotic disease and stroke), 
and the secondary end-point was all-cause mortality.  
Statistical analyses 
All analyses were performed with SPSS version 15.0 for Windows (SPSS, Chicago, IL, 
USA).  
Variables with a skewed distribution were loge transformed prior to further 
analyses. Comparisons of baseline characteristics between groups were performed 
with Student’s t or χ
2
 tests, as appropriate. The associations between Ln-sRAGE and 
study end-points were investigated with Cox proportional hazards regression models 
adjusted, first, for sex, age, duration of diabetes, case-control status and HbA1c, 
second, for other traditional cardiovascular risk factors, and third, for the use of renin-
angiotensin-aldosterone system inhibitors and/or other antihypertensive treatment or 
whether subjects did or did not withheld their medication prior to baseline 
examinations. Further adjustments for markers of renal dysfunction, [i.e. estimated 
glomerular filtration rate (eGFRMDRD) or Ln-UAE], low-grade inflammation [average of 
the z scores of Ln-interleukin-6, Ln-C-reactive protein, soluble intracellular adhesion 
molecule-1 (sICAM-1) and Ln-secreted phospholipase-A2], endothelial dysfunction 
(average of the z scores of soluble vascular cell adhesion molecule-1 and sICAM-1), 
and arterial stiffness (i.e. pulse pressure), were added into this model to ascertain the 
extent these could explain (i.e. attenuate the strength of) the association between Ln-
sRAGE and study end-points. The cross-sectional associations between Ln-sRAGE and 
markers of these pathophysiological mechanisms and AGEs (average of the z scores of 
Ln-pentosidine, N
ε
-(carboxymethyl)lysine and N
ε
-(carboxyethyl)lysine), were 
examined with the use of linear regression analyses.  
Finally, we investigated whether the associations listed above differed between 
patients with normoalbuminuria vs. nephropathy by adding interaction terms 
between Ln-sRAGE and case-control status to our models; whenever the p-value of 
such interactions were <0.1, results were presented for the two groups separately. 
Results 
During the course of follow-up [median: 12.3 years (inter-quartile range 7.6-12.5)], 82 
individuals (24.2%) died; 85 (25.1%) suffered a fatal (n=48) and/or non-fatal (n=53) 
CVD event. Individuals with incident CVD events or who had died at follow-up had, at 
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baseline, higher levels of Ln-sRAGE and a more adverse atherosclerotic risk (Table 
3.1).  
After adjustments for age, sex, case-control status, HbA1c and duration of 
diabetes, the incidence of fatal and non-fatal CVD increased with a HR of 2.00 (95% CI: 
1.19-3.36), and the incidence of all-cause mortality increased with a HR of 2.44 
(1.46-4.07), per unit increase in baseline levels of Ln-sRAGE (Table 3.2, model 1, Figure 
3.2A and B, respectively). The associations between Ln-sRAGE and study end-points 
were attenuated, but remained significant after adjustments for other CVD risk factors 
and the use of medication: HR=1.90 (1.13-3.21) for fatal and non-fatal CVD events, 
and HR=2.12 (1.26-3.57) for all-cause mortality (Table 3.2, models 2-3).  
Further adjustment for eGFRMDRD attenuated the associations between Ln-sRAGE 
and incident fatal and non-fatal CVD as well as all-cause mortality by 28% and 14%, 
respectively (Table 3.2, model 4). Adjustments for Ln-UAE, pulse pressure and AGEs 
attenuated these associations to a smaller extent, whereas adjustments for markers 
of endothelial dysfunction and low-grade inflammation did not (Table 3.2, models 
5-9), despite the adverse associations between Ln-sRAGE and these variables (Table 
3.3).  
The adverse associations between Ln-sRAGE on the one hand, and baseline levels 
of eGFRMDRD, inflammation, endothelial dysfunction and AGEs on the other were 
stronger in individuals with nephropathy than in those with normoalbuminuria, 
however (Table 3.3).  
 
 
 
 
 
 
 
 
 
 
 
 
     A                                                                                                       B 
 
 
Figure 3.2 Cumulative hazard for fatal and non-fatal CVD (A) as well as all-cause mortality (B) across 
tertiles of plasma sRAGE. Data are adjusted for age, sex, case-control status, duration of 
diabetes and HbA1c. Compared with patients in the lowest tertile of sRAGE, those in the 
middle and highest tertiles had increased risk for non-fatal and fatal CVD [HR=1.33 (95%CI 
0.76 to 2.31) and 1.78 (1.03 to 3.06), respectively, p for trend=0.038] and all-cause mortality 
[HR=1.31 (95%CI 0.73 to 2.38) and 2.04 (1.17 to 3.55), respectively, p for trend=0.010]. 
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Additional analyses 
In all individuals, decline in eGFRMDRD per year (ΔeGFRMDRD) was estimated using the 
last eGFRMDRD measure at follow-up. During the course of follow-up, and in patients 
with diabetic nephropathy only, GFR was also measured yearly after a single injection 
of 3.7 MBq 51Cr-EDTA (GFREDTA) by determination of radioactivity in venous blood 
samples taken 180, 200, 220 and 240 minutes after the injection. With the use of 
these data we estimated a more valid and precise rate of decline in kidney function 
(ΔGFREDTA) over time in those patients with at least 3 follow-up measurements. 
In order to clarify further the role of eGFR in the associations between Ln-sRAGE 
and incident fatal and non-fatal cardiovascular disease, we also investigated the 
extent to which Ln-sRAGE levels at baseline were associated with changes in (e)GFR 
and the extent to which any such associations could explain the sRAGE-related 
increase risks. 
eGFRMDRD decreased over the course of follow-up [median decline of: 
-2.07 ml/min/1.73 m
2
 per year (inter-quartile range –2.90 to –1.19)]. After 
adjustments for baseline eGFRMDRD, age, sex, HbA1c, duration of diabetes, smoking 
status, MAP, total cholesterol and use of RAAS inhibitors or other antihypertensive 
treatment, higher levels of Ln-sRAGE at baseline were associated with an accelerated 
decline in eGFRMDRD [β=-0.34 ml/min/1.73 m
2
 per year, (95%CI: –0.90 to 0.21), 
p=0.227]. However, this association was present in individuals with nephropathy [β=-
0.71 ml/min/1.73 m
2
 per year (–1.70 to 0.29)], but not in those with 
normoalbuminuria [β=0.23 (–0.32 to 0.77)]. 
In patients with nephropathy we had data on ΔGFREDTA on 165 out of the 169 
patients in this group: median decline of -2.99 ml/min/1.73 m
2
 per year (inter-quartile 
range: -5.15 to -1.60). In these patients, and after adjustments for age, sex, HbA1c, 
duration of diabetes, MAP, smoking status, total cholesterol and use of RAAS 
inhibitors or other antihypertensive treatment, the rate of decline in ΔGFREDTA was 
1.38 ml/min/1.73 m
2
 per year (p=0.036) greater per each unit increase in Ln-sRAGE 
levels at baseline. This raises the possibility that sRAGE-associated impaired renal 
clearance could explain, at least in part, the positive association between Ln-sRAGE 
and incident fatal and non-fatal cardiovascular disease. In addition, in these patients, 
the associations between Ln-sRAGE and incident fatal and non-fatal CVD events as 
well as all-cause mortality (Table 3.4, models 4a and 5a) were further attenuated 
when adjusted for Δ(e)GFR (either as estimated by MDRD or EDTA, but more strongly 
so by the latter). 
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Discussion 
The main findings of this study were two-fold. First, in patients with type 1 diabetes, 
higher levels of plasma sRAGE are associated with incident fatal and non-fatal CVD as 
well as all-cause mortality, independently of other ‘traditional’ cardiovascular risk 
factors. Second, these associations could be partially explained by sRAGE-associated 
impairment in renal clearance, particularly in patients with nephropathy. Our findings 
are in agreement with studies that have examined the associations of sRAGE with 
CVD, but these were limited by cross-sectional designs (7,10-12). This is the first 
prospective study that has investigated the associations between plasma sRAGE and 
incident fatal and non-fatal CVD as well as all-cause mortality in a large sample of 
individuals with type 1 diabetes, and has also addressed potential mechanisms that 
could explain the associations observed. 
We hypothesised sRAGE to act as a putative marker of RAGE expression. The 
adverse associations found between sRAGE and CVD but also between sRAGE and 
markers of renal and endothelial dysfunction, low-grade inflammation, pulse pressure 
and AGEs reported herein, which are in agreement with others (7,10-15), supported 
this hypothesis. However, sRAGE reflects the total pool of soluble RAGE in plasma, and 
thus consists of different variants. These can result from alternative splicing (e.g. 
endogenous secretory RAGE, esRAGE) (16) or from proteolytical cleavage of the 
membrane-bound RAGE (17). The exact functions of sRAGE in plasma are unknown 
but these may differ across different variants. Indeed, several studies have reported 
inverse and thus ‘protective’ associations between esRAGE, and (surrogate markers 
of) CVD (11,18-23). We have measured the total pool of plasma sRAGE only and 
therefore cannot discern whether the different variants of sRAGE have specific and 
potentially opposite associations with study outcomes. In addition, the extent to 
which levels of (e)sRAGE in plasma reflect local concentrations and have the same 
effects as in tissues need to be further clarified.  
The associations of sRAGE with CVD and all-cause mortality were attenuated when 
further adjusted for baseline eGFR, the former association being no longer statistically 
significant. However, this adjustment explained only 28% of the increased CVD risk 
associated with higher sRAGE. In addition, independent associations of both sRAGE 
and creatinine with CVD have been reported in individuals with diabetes (10). 
Furthermore, we found that sRAGE contributed to an accelerated decline in GFR, as 
estimated by eGFRMDRD or by GFREDTA in subjects with diabetic nephropathy. This is in 
line with a recent study in which sRAGE was inversely associated with changes in eGFR 
in the course of 1-yr of follow-up in a large population of elderly women (24). These 
findings support the hypothesis of renal dysfunction being one of the intermediate 
factors linking sRAGE (as a reflection of RAGE expression) to vascular complications. 
However, we cannot discard the alternative (or concomitant) possibility, i.e. that 
baseline sRAGE levels may have been elevated as a consequence of impaired renal 
clearance. Indeed, our data also support this possibility; specifically, the association 
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between higher baseline eGFR (per 10 ml/min per 1.73 m
2
) and incident CVD [HR=0.89 
(95% CI 0.78-1.00)] was attenuated by ~24% when further adjusted for Ln-sRAGE: to 
HR=0.92 (95% CI 0.81-1.04). These observations reflect the interrelationships between 
sRAGE and eGFR at baseline, the exact directions of which we cannot fully unravel in 
the present study. Nevertheless, and altogether, these observations support the view 
that higher sRAGE, due to, but also to a great extent independent of, impaired GFR 
are positively associated with CVD and all-cause mortality. Further studies with 
repeated data on both sRAGE and GFR are needed to disentangle the temporal order 
of these associations.  
There are limitations to our study. Samples for analyses of sRAGE and other 
biomarkers were taken at baseline only, which impedes evaluation of the impact of 
changes in these variables on study outcomes. In addition, the relatively high inter-
assay CV in the measurement of plasma sRAGE, and the potential misclassification of 
non-specific mortality as CVD-related mortality may have introduced non-differential 
biases, in which case the estimates reported herein may have been underestimated. 
However, we cannot discard the possibility that possible underreporting of non-fatal 
CVD introduced some differential bias affecting our results. Finally, although our 
findings did not suggest strong mediating effects of endothelial dysfunction, low-
grade inflammation, arterial stiffness and AGEs in the associations between sRAGE 
and study outcomes, we cannot fully exclude their potential mediating role due to the 
use of a selection of markers representing these processes. 
In conclusion, higher plasma sRAGE levels, as a reflection of RAGE expression, are 
associated with incident fatal and non-fatal CVD as well as all-cause mortality in type 1 
diabetes, and this may partially be explained by sRAGE-associated renal dysfunction in 
patients with nephropathy. 
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Abstract 
Background and objective 
To investigate the associations of plasma levels of advanced glycation end products (AGEs) with incident 
cardiovascular disease (CVD) and all-cause mortality in type 1 diabetes, and the extent to which any such 
associations could be explained by endothelial and renal dysfunction, low-grade inflammation and arterial 
stiffness. 
 
Methods 
We prospectively followed 169 individuals with diabetic nephropathy and 170 individuals with persistent 
normoalbuminuria who were free of CVD at study entry and in whom levels of Nε-(carboxymethyl)lysine, 
Nε-(carboxyethyl)lysine, pentosidine and other biomarkers were measured at baseline. The median follow-
up duration was 12.3 (inter-quartile range: 7.6–12.5) years.  
 
Results 
During the course of follow-up, 82 individuals (24.2%) died; 85 (25.1%) suffered a fatal (n=48) and/or non-
fatal (n=53) CVD event. The incidence of fatal and non-fatal CVD, and of all-cause mortality increased with 
higher baseline levels of AGEs independently of traditional CVD risk factors: hazard ratio (HR)=1.30 
(95%CI=1.03 to 1.66) and HR=1.27 (1.00 to 1.62), respectively. These associations were not attenuated after 
further adjustments for markers of renal or endothelial dysfunction, low-grade inflammation or arterial 
stiffness. 
 
Conclusions 
Higher levels of AGEs are associated with incident fatal and non-fatal CVD as well as all-cause mortality in 
individuals with type 1 diabetes, independently of other risk factors and of several potential AGEs-related 
pathophysiological mechanisms. AGEs may thus explain, in part, the increased cardiovascular disease and 
mortality attributable to type 1 diabetes, and constitute a specific target for treatment in these patients. 
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Introduction 
Diabetes is characterised by hyperglycaemia and associated with increased 
cardiovascular disease (CVD) risk (1). Advanced glycation end products (AGEs) may 
link hyperglycaemia to the development of vascular complications in diabetes (2). 
AGEs affect cells in three general ways: 1) cellular functions can be altered when 
intracellular proteins are modified by AGEs, 2) modification of extracellular matrix 
proteins results in abnormal interactions betweens these proteins, and 3) circulating 
AGEs can bind to AGE receptors, which could induce receptor-mediated production of 
reactive oxygen species and activate transcription factor NF-κB, thereby leading to 
deleterious changes in cellular processes (2).  
Several studies so far have examined the associations between various plasma 
AGEs and microvascular and macrovascular complications in subjects with (3-12) or 
without (6-8,13-15) diabetes, most of which were confined to specific study 
populations (i.e. in elderly, patients with end stage renal failure, patients with heart 
failure or women only) (6,7,13,14) and/or had a cross-sectional design (3,5,10-12). 
Among the few prospective studies, most have reported positive associations 
between plasma AGEs and (CVD) mortality in patients with (8,9) or without (6,7,14,15) 
type 2 diabetes. However, so far, no prospective studies have investigated the 
associations between plasma AGEs and incident cardiovascular complications in 
patients with type 1 diabetes. In addition, the mechanisms through which AGEs could 
lead to the development of cardiovascular disease in these individuals are unclear. 
Endothelial (2) and renal dysfunction (16), low-grade inflammation (2,14) and arterial 
stiffness (2) could constitute such mechanisms.     
In view of these considerations, we have investigated, in a 12-yr prospective 
follow-up study; first, whether plasma levels of N
ε
-(carboxyethyl)lysine (CEL), 
N
ε
-(carboxymethyl)lysine (CML) and pentosidine were associated with incident fatal 
and non-fatal CVD as well as all-cause mortality in individuals with type 1 diabetes; 
and second, the extent to which any such associations were explained (i.e. mediated) 
by markers of endothelial and renal dysfunction, low-grade inflammation, and arterial 
stiffness. 
Methods 
Study population and design 
In 1993, 199 patients with type 1 diabetes and diabetic nephropathy defined 
according to clinical criteria [i.e. persistent macroalbuminuria (>300 mg/24 h) in at 
least two out of three previous consecutive 24-h urine collections, in the presence of 
diabetic retinopathy and the absence of other kidney or urinary tract disease] and 192 
with persistent normoalbuminuria (i.e. urinary excretion rate <30 mg/24 h) were 
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recruited from the outpatient clinic at Steno Diabetes Center for a prospective 
observational follow-up study. Details of the inclusion criteria and selection 
procedures have been described elsewhere (17). The study was approved by the local 
ethics committee, in accordance with the Helsinki Declaration, and all patients gave 
their informed written consent. 
Baseline investigations 
Biomarkers  
Analyses of the biomarkers were done on frozen (-80°C) samples and were performed 
at a central laboratory by C.G.S.  
The AGEs CML, CEL and pentosidine were measured as decribed (18,19) with 
minor modifications. Briefly, (to measure CEL, CML and pentosidine) 50 μl plasma was 
mixed with 100 μl water in a 10 ml glass tube with a Teflon-lined screw-cap. To 
prevent formation of AGEs from early glycation products during sample preparation, 
plasma samples were reduced by 500 μl sodium borohydride borate buffer (200 mM, 
pH 9.2) before precipitation. This mixture was allowed to stand for 2 h at room 
temperature. Proteins were then precipitated by addition of 2 ml 20% trichloroacetic 
acid and centrifuged for 10 min (4°C) at 4500 × g. The supernatant was carefully 
removed by aspiration with a Pasteur pipette. The protein pellet was washed once by 
adding 2 ml 5% trichloroacetic acid followed by centrifugation and removal of the 
supernatant. The samples were hydrolyzed by adding 1000 μl 6 N HCl and incubated 
for 18 h at 110°C.  
After hydrolysis, 100 μl of these samples were evaporated to dryness at 80°C 
under a stream of nitrogen gas and reconstituted in 200 μl 0.5 mM 
tridecafluoroheptanoic acid for the CEL and CML measurements. Five microliters of 
this solution was injected on the ultra-performance liquid chromatography tandem 
mass spectrometry. Liquid chromatography was performed at 30°C using an Acquity 
UPLC BEH C18, 1.7 µm, 2.1 × 100 mm column (Waters, Milford, MA) and the 
Micromass Quattro Premier XE Tandem Mass Spectrometer (Waters, Milford, MA) 
was used in the multiple reaction monitoring mode in the ESI-positive mode. The 
intra- and inter-assay CVs were 7.3% and 2.0% for CEL, and 3.5% and 3.6% for CML, 
respectively. 
For the pentosidine measurement 900 μl of the hydrolysed samples were 
evaporated to dryness at 80°C under a stream of nitrogen gas and reconstituted in 
200 μl 25 mM citric acid/l. This solution was centrifuged for 10 min (4°C) at 4500 × g 
and ten microliters of this solution was injected on the high-performance liquid 
chromatography system. Detection was carried out using a Jasco type 821-FP 
spectrofluorometer (Jasco Benelux, Maarssen, The Netherlands) set at an excitation 
and emission wavelength of 325 and 385 nm, respectively. The intra- and inter-assay 
CVs were 2.7% and 2.8% for pentosidine, respectively. 
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High-sensitivity C-reactive protein (hsCRP) and secreted phospholipase A2 (sPLA2) 
were determined by enzyme-linked immunosorbent assays (ELISA) as described 
previously (20). Commercially available ELISA kits were used for measurements of 
plasma soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular 
adhesion molecule-1 (sICAM-1) and interleukin-6 (IL-6) (Quantikine High Sensitivity; 
R&D Systems, Oxon, U.K.). The intra- and inter-assay CVs of these immunoassays were 
<8%.  
Other baseline assessments 
All investigations were performed in the morning after an overnight fast. No 
antihypertensive medication was ever prescribed in 24% of patients with nephropathy 
and 88% of the normoalbuminuric patients. All of the remaining patients were asked 
to stop their antihypertensive and diuretic treatment 8 days before the examination. 
Arterial blood pressure was measured twice with an appropriate cuff size following at 
least 10 minutes rest in the supine position. Mean arterial pressure (MAP) was 
calculated as [systolic blood pressure + (2*diastolic blood pressure)]/3. Pulse pressure 
was calculated by subtracting the diastolic from the systolic blood pressure, and used 
as a marker of arterial stiffness (21). Body mass index (BMI) was calculated by dividing 
weight by height squared. Urinary albumin excretion (UAE) was measured by an 
enzyme immunoassay from 24-h urine collections. Serum creatinine concentration 
was assessed by a kinetic Jaffé method. In all patients glomerular filtration rate (eGFR) 
was estimated according to the short Modification of Diet in Renal Disease equation 
(MDRD) = 186 * [serum creatinine (mg/dl)]−1.154 * [age]−0.203 * [0.742 if patient is 
female]. Patients were interviewed using the WHO cardiovascular questionnaire. 
Individuals were categorised into three groups according to their smoking status as 
never, former or current smokers. 
Follow-up and study end-points 
All patients were followed up to the last visit at Steno Diabetes Center, until 
1 September 2006 or until death (n=82) or emigration (n=3). All patients were traced 
through the national register during autumn 2006. If a patient had died before 
1 September 2006, the date of death was recorded and information on the primary 
cause of death was obtained from the death certificate, which was reviewed by two 
independent observers. Additional available information from necropsy reports was 
also included. All deaths were classified as cardiovascular unless an unequivocal non-
cardiovascular cause was established. In all patients alive at the end of follow-up non-
fatal cardiovascular events were retrieved from their patient files from Steno Diabetes 
Center and/or other hospital records. The primary study outcome was a combined 
end-point of fatal and non-fatal cardiovascular disease (i.e. myocardial infarction, 
percutaneous coronary intervention, coronary bypass grafting, amputation due to 
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ischaemia, vascular surgery for peripheral atherosclerotic disease and stroke), and the 
secondary outcome was all-cause mortality. 
Statistical analyses 
All analyses were performed with the Statistical Package for Social Sciences (SPSS) 
version 15.0 for Windows (SPSS, Chicago, IL, USA).  
Variables with a skewed distribution, i.e. triglycerides, CRP, IL-6, sPLA2, UAE and 
pentosidine, were loge transformed prior to further analyses. Comparisons of baseline 
characteristics between groups were performed with Student’s t or χ
2
 tests, as 
appropriate. To investigate the association between CEL, CML, Ln-pentosidine and an 
AGEs score (calculated by averaging the z scores of CEL, CML and Ln-pentosidine) on 
the one hand and incident CVD as well as all-cause mortality on the other, we used 
Cox proportional hazards regression models. These analyses were adjusted, first, for 
sex, age, duration of diabetes, case-control status and HbA1c; second, for other 
cardiovascular risk factors (i.e. BMI, smoking status, total cholesterol and MAP); and 
third, for the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and/or 
other antihypertensive treatment. This model was then further adjusted for markers 
of renal dysfunction, (i.e. eGFRMDRD and Ln-UAE), low-grade inflammation (expressed 
as a total score computed by averaging the z scores of Ln-IL-6, Ln-CRP, sICAM-1 and 
Ln-sPLA2), endothelial dysfunction (expressed as a total score computed by averaging 
the z scores of sVCAM-1 and sICAM-1), and arterial stiffness (i.e. pulse pressure); 
these markers were entered one at a time to ascertain the extent to which any such 
marker could attenuate (i.e. explain) the strength of the association between the 
AGEs and study end-points, which were given as hazard ratios (HR) with 95% 
confidence intervals (CIs).  
We used linear regression analyses to investigate the cross-sectional associations 
between CEL, CML, Ln-pentosidine and AGEs score on the one hand and markers of 
renal dysfunction, low-grade inflammation, endothelial dysfunction, and arterial 
stiffness on the other. Results of these analyses are expressed in standardised 
regression coefficients to allow comparison of the strength of the association 
between the AGEs and each of these variables.  
Finally, we investigated whether the associations listed above differed between 
patients with normoalbuminuria and those with nephropathy by adding interaction 
terms to our models, the significance of which was judged on the basis of a p-value 
<0.1 for the interaction term. We found no such interactions and therefore all results 
are presented for the two groups combined. 
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Results 
Of the 391 patients included in this study, we excluded 17 (1 with nephropathy and 16 
with normoalbuminuria) in whom follow-up data were not obtained, 4 with missing 
data on baseline biomarkers levels (1 patient with nephropathy and 3 patients with 
normoalbuminuria), 7 with end stage renal failure and 24 with prior CVD at baseline 
(21 patients with nephropathy and 3 with normoalbuminuria). Results reported herein 
thus refer to 339 patients (170 with persistent normoalbuminuria and 169 with 
nephropathy at baseline).   
During the course of follow-up [median: 12.3 years (inter-quartile range 7.6-12.5)], 
82 individuals (24.2%) died; 85 (25.1%) suffered a fatal (n=48) and/or non-fatal (n=53) 
CVD event. Individuals with incident CVD events or who had died at follow-up had, at 
baseline, higher levels of AGEs and a more adverse atherosclerotic risk profile as 
illustrated by the more unfavorable levels of traditional risk factors, markers of 
endothelial dysfunction, low-grade inflammation and pulse pressure (Table 4.1).  
After adjustments for age, sex, duration of diabetes, HbA1c, case-control status, 
other risk factors and the use of medication, the incidence of fatal and non-fatal CVD 
increased with a HR of 1.30 (1.03 to 1.66) per 1 SD increase in baseline levels of AGEs 
score (Table 4.2, model 3). The HRs for incident fatal and non-fatal CVD per 1 SD 
increase in baseline CEL, CML and Ln-pentosidine were comparable: HR=1.24 (1.01 to 
1.52), HR=1.22 (0.96 to 1.56) and HR=1.29 (1.03 to 1.60), respectively (Table 4.3, 
model 3). Similar results were found for the associations between the AGEs and 
incident all-cause mortality: HR=1.22 (1.00 to 1.49), HR=1.17 (0.91 to 1.50) and 
HR=1.28 (1.03 to 1.59), respectively (Table 4.2 and 4.4 for analyses for each AGE 
separately).  
If we excluded from the analyses the CVD cases to which an unequivocal CVD-
related cause of death could not be ascribed, our results did not change: HR=1.31 
(1.02 to 1.70) after adjustments for age, sex, duration of diabetes, HbA1c, case-
control status, other risk factors and the use of medication. 
The associations between AGEs and CVD and all-cause mortality were comparable 
between patients with normoalbuminuria and nephropathy at baseline: HR=1.60 
(95%CI: 0.68 to 3.80) and HR=1.35 (1.05 to 1.73) for CVD, and HR=1.32 (0.48 to 3.63) 
and 1.37 (1.06 to 1.77) for all-cause mortality, respectively. It should be noted that the 
wider confidence intervals around the estimates in the normoalbuminuria group were 
most likely due to the relatively low number of events (21 CVD and 18 deaths in this 
group). 
Adjustment for markers of renal dysfunction (model 4a), low-grade inflammation 
(model 4b), endothelial dysfunction (model 4c) and arterial stiffness (model 4d) did 
not attenuate the associations between the AGEs and the study end-points, despite 
the adverse associations between plasma AGEs and most of these pathophysiological 
mechanisms (Table 4.5 and 4.6 for the associations presented for each AGE 
separately).  
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Table 4.2 Associations between baseline plasma AGEs and incident primary and secondary end points 
(n=339). 
  Primary endpoint (85 events)    Secondary endpoint (82 events)  
Model HR 95% CI p-value  HR 95% CI p-value 
1 1.33 1.05; 1.69 0.018  1.34 1.06; 1.69 0.013 
2 1.36 1.08; 1.73 0.011  1.34 1.06; 1.69 0.013 
3a  1.35 1.07; 1.71 0.013  1.36 1.07; 1.72 0.011 
3b 1.31 1.03; 1.66 0.026  1.25 0.99; 1.59 0.060 
3 1.30 1.03; 1.66 0.029  1.27 1.00; 1.62 0.047 
4a 1.31 0.99; 1.73 0.057  1.27 0.95; 1.68 0.103 
4b  1.26 1.00; 1.61 0.055  1.24 0.98; 1.58 0.076 
4c  1.31 1.00; 1.62 0.028  1.26 1.00; 1.59 0.051 
4d 1.30 1.02; 1.66 0.036  1.28 1.01; 1.64 0.046 
Primary endpoint was a combined endpoint of fatal and non-fatal cardiovascular disease (CVD), and the 
secondary endpoint was all-cause mortality. During the course of follow-up, 82 individuals died; 85 suffered 
a fatal (n=48) and/or non-fatal (n=53) CVD event. HR, hazard ratio for primary or secondary endpoint per 
1 SD increase in baseline AGEs score; AGEs, advanced glycation end products; CI, confidence interval. Model 
1 is adjusted for age, sex, HbA1c, case-control status and duration of diabetes; Model 2: model 1 + body 
mass index, mean arterial pressure, smoking status and total cholesterol; Model 3a: model 2 + renin-
angiotensin-aldosterone system (RAAS) inhibitors; Model 3b: model 2 + other antihypertensive agents; 
Model 3: model 2 + RAAS inhibitors and other antihypertensive agents; Model 4a: model 3 + estimated 
glomerular filtration rate by abbreviated modification of diet in renal disease equation and Ln-urinary 
albumin excretion rate; Model 4b: model 3 + low-grade inflammation score; Model 4c: model 3 + 
endothelial dysfunction score; Model 4d: model 3 + pulse pressure. 
 
Table 4.3 Associations between baseline plasma AGEs and incident fatal and non-fatal cardiovascular 
disease (n=339/85 events). 
  CEL    CML    Ln-pentosidine  
Model HR 95% CI p-value  HR 95% CI p-value  HR 95% CI p-value 
1 1.31 1.07; 1.61 0.009  1.12 0.88; 1.43 0.347  1.35 1.09; 1.68 0.006 
2 1.29 1.05; 1.58 0.015  1.24 0.98; 1.57 0.078  1.35 1.09; 1.67 0.006 
3a  1.28 1.04; 1.57 0.020  1.24 0.98; 1.57 0.074  1.34 1.08; 1.66 0.008 
3b 1.25 1.01; 1.53 0.036  1.22 0.96; 1.56 0.100  1.29 1.04; 1.61 0.021 
3 1.24 1.01; 1.52 0.041  1.22 0.96; 1.56 0.098  1.29 1.03; 1.60 0.024 
4a 1.21 0.95; 1.53 0.118  1.23 0.96; 1.58 0.108  1.30 1.00; 1.70 0.048 
4b  1.21 0.98; 1.49 0.075  1.19 0.94; 1.51 0.152  1.25 1.01; 1.56 0.043 
4c  1.24 1.01; 1.52 0.041  1.23 0.97; 1.55 0.095  1.29 1.04; 1.60 0.023 
4d 1.24 1.00; 1.52 0.047  1.24 0.97; 1.58 0.088  1.27 1.01; 1.59 0.042 
5* 1.12 0.75; 1.65 0.587  0.93 0.60; 1.44 0.736  1.24 0.87; 1.76 0.237 
HR, hazard ratio for fatal and non-fatal cardiovascular disease per 1 SD increase in baseline CEL, CML or Ln-
pentosidine levels; AGEs, advanced glycation end products; CEL, N
ε
-(carboxyethyl)lysine; CML, 
N
ε
-(carboxymethyl)lysine; CI, confidence interval. Model 1 is adjusted for age, sex, HbA1c, case-control 
status and duration of diabetes; Model 2: model 1 + body mass index, mean arterial pressure, smoking 
status and total cholesterol; Model 3a: model 2 + renin-angiotensin-aldosterone system (RAAS) inhibitors; 
Model 3b: model 2 + other antihypertensive agents; Model 3: model 2 + RAAS inhibitors and other 
antihypertensive agents; Model 4a: model 3 + estimated glomerular filtration rate by abbreviated 
modification of diet in renal disease equation and Ln-urinary albumin excretion rate; Model 4b: model 3 + 
low-grade inflammation score; Model 4c: model 3 + endothelial dysfunction score; Model 4d: model 3 + 
pulse pressure; Model 5: model 3 + CEL, CML and Ln-pentosidine. *Due to the high correlations (r>0.7) 
between all three AGEs, this model may suffer from collinearity and may not be appropriate. 
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Table 4.4 Associations between baseline plasma AGEs and incident all-cause mortality (n=339/82 
events). 
  CEL    CML    Ln-pentosidine  
Model HR 95% CI p-value  HR 95% CI p-value  HR 95% CI p-value 
1 1.30 1.08; 1.58 0.006  1.09 0.85; 1.40 0.509  1.42 1.15; 1.76 0.001 
2 1.27 1.04; 1.55 0.017  1.21 0.95; 1.54 0.133  1.35 1.10; 1.67 0.005 
3a  1.29 1.05; 1.57 0.014  1.21 0.95; 1.54 0.128  1.37 1.11; 1.70 0.004 
3b 1.20 0.99; 1.47 0.067  1.16 0.91; 1.49 0.234  1.26 1.01; 1.56 0.037 
3 1.22 1.00; 1.49 0.051  1.17 0.91; 1.50 0.215  1.28 1.03; 1.59 0.027 
4a 1.19 0.94; 1.50 0.153  1.16 0.88; 1.51 0.297  1.30 1.00; 1.70 0.054 
4b 1.20 0.98; 1.48 0.076  1.14 0.89; 1.46 0.314  1.25 1.01; 1.56 0.043 
4c  1.21 0.99; 1.48 0.058  1.16 0.92; 1.48 0.213  1.27 1.03; 1.58 0.029 
4d  1.23 1.00; 1.51 0.049  1.19 0.92; 1.54 0.179  1.28 1.02; 1.60 0.032 
5* 1.18 0.79; 1.76 0.413  0.80 0.50; 1.28 0.346  1.29 0.91; 1.84 0.159 
HR, hazard ratio for all-cause mortality per 1 SD increase in baseline CEL, CML or Ln-pentosidine levels; 
AGEs, advanced glycation end products; CEL, N
ε
-(carboxyethyl)lysine; CML, N
ε
-(carboxymethyl)lysine; CI, 
confidence interval. Model 1 is adjusted for age, sex, HbA1c, case-control status and duration of diabetes; 
Model 2: model 1 + body mass index, mean arterial pressure, smoking status and total cholesterol; Model 
3a: model 2 + renin-angiotensin-aldosterone system (RAAS) inhibitors; Model 3b: model 2 + other 
antihypertensive agents; Model 3: model 2 + RAAS inhibitors and other antihypertensive agents; Model 4a: 
model 3 + estimated glomerular filtration rate by abbreviated modification of diet in renal disease equation 
and Ln-urinary albumin excretion rate; Model 4b: model 3 + low-grade inflammation score; Model 4c: 
model 3 + endothelial dysfunction score; Model 4d: model 3 + pulse pressure; Model 5: model 3 + CEL, CML, 
Ln-pentosidine. *Due to the high correlations (r>0.7) between all three AGEs, this model may suffer from 
collinearity and may not be appropriate. 
 
Table 4.5 Associations between plasma AGEs and potential mechanisms linking AGEs to incident CVD 
and all-cause mortality (n=339). 
Dependent variable    All n=339  
 Model  β 95% CI p-value 
Baseline eGFRMDRD  1  -0.32 -0.42; 0.23 <0.001 
 2  -0.29  -0.39; -0.20 <0.001 
Ln-urinary albumin excretion rate 1  -0.07  -0.12; -0.02   0.008 
 2  -0.04 -0.09; 0.00   0.071 
Inflammatory score  1  0.06 -0.02; 0.14   0.123 
 2  0.09  0.01; 0.17   0.036 
Endothelial dysfunction score  1  0.13  0.03; 0.22   0.008 
 2  0.13  0.03; 0.23   0.009 
Pulse pressure 1  0.03 -0.08; 0.14   0.591 
 2  0.03 -0.07; 0.12   0.615 
β, standardised regression coefficient: indicates change in dependent variable (in SD) per 1 SD increase in 
baseline AGEs score; AGEs, advanced glycation end products; CVD, cardiovascular disease; CI, confidence 
interval; eGFRMDRD, estimated glomerular filtration rate by abbreviated modification of diet in renal disease 
equation. Model 1, adjusted for age, sex, duration of diabetes, case-control status and HbA1c; Model 2, 
model 1 + body mass index, smoking status, mean arterial pressure, total cholesterol, use of renin-
angiotensin-aldosterone system inhibitors, other antihypertensive treatment and continuation of 
medication at baseline examination. 
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Because the two markers (Ln-UAE and eGFR) of renal dysfunction were 
interrelated (standardised β=-0.52, 95%CI:-0.61 to –0.43) and because both markers 
individually were inversely associated with AGEs (Table 4.5), while Ln-UAE was 
positively and eGFR was inversely associated with incident CVD, adjustments for renal 
dysfunction were performed by adjustments for both baseline Ln-UAE and eGFR to 
ensure the most appropriate correction for renal dysfunction (model 4a).  
Additional analyses 
Patients were asked to stop their antihypertensive and diuretic treatment 8 days 
before the examination. However, 27% and 4% of patients in the nephropathy and 
normoalbuminuria groups, respectively, had taken antihypertensive medication on 
the day of examination. The associations between AGEs and study outcomes did not 
appreciably differ between those who did or did not withhold their medication at 
baseline examination, nor did they change after additional adjustment for medication 
withdrawal status (data not shown).  
Discussion 
The main findings of this study were that in patients with type 1 diabetes higher 
baseline plasma levels of AGEs are associated with incident fatal and non-fatal 
cardiovascular disease as well as all-cause mortality, independently of ‘traditional’ 
cardiovascular risk factors, but also of markers of renal and endothelial dysfunction, 
low-grade inflammation and arterial stiffness. AGEs may thus constitute a specific 
target for treatment in order to prevent the excess cardiovascular disease and 
mortality observed in patients with type 1 diabetes.  
Our results are in agreement with studies that have shown positive associations 
between plasma levels of AGEs or Amadori products, specifically non-CML AGE (11), 
pentosidine (3) and Amadori-albumin (22), and microvascular complications, but 
these studies were limited by their cross-sectional designs (3,11,22) and/or were 
confined to small study populations (3,11). This is the first prospective study that has 
examined the associations between plasma CEL, CML and pentosidine and incident 
fatal and non-fatal cardiovascular disease as well as all-cause mortality in a large 
sample of patients with type 1 diabetes, and has also addressed the potential 
pathophysiological mechanisms that may explain the associations observed. Our 
findings are also in agreement with two previous studies which have related higher 
skin autofluorescence (23), as a potential marker for tissue AGEs accumulation, and 
AGEs levels in skin collagen (24) with incident coronary heart disease and 
microvascular complications in patients with type 1 diabetes, respectively. Whether 
and to what extent skin autofluorescence is associated with plasma AGEs levels still 
needs to be investigated.  
 AGEs and incident CVD as well as all-cause mortality 
71 
4 
We investigated three out of many different AGEs, all of which were associated 
with incident fatal and non-fatal CVD to a similar extent. Based on their molecular 
characteristics one could hypothesise that each AGE could exert unfavorable effects 
on cellular functions through (partially) different pathways. However, CEL (as a 
putative marker of intracellular glycation), CML (as a potential ligand of RAGE), and 
pentosidine (as one of the cross-linking AGEs) were highly correlated with each other 
(correlation coefficients all >0.7) and, therefore, in mutually adjusted analyses, none 
was independently associated with study outcomes (Table 4.3 and 4.4, model 5). 
These findings suggest that the adverse effects of CEL, CML and pentosidine on 
cardiovascular risk in type 1 diabetes largely overlap. Further studies may be needed 
to unravel the specific effects, if any, of intracellular protein glycation, formation of 
cross-links in the extracellular matrix, and the AGE-RAGE axis on increased CVD risk 
attributable to AGEs in type 1 diabetes.  
Although some minor differences were found in the adverse associations between 
each of the AGEs on the one hand and markers of renal and endothelial dysfunction, 
low-grade inflammation and pulse pressure on the other, overall, none of these 
pathophysiological mechanisms investigated explained the positive associations 
between the AGEs and incident fatal and non-fatal CVD as well as all-cause mortality. 
We cannot discard the possibility that the use of a selection of markers representing 
renal and endothelial dysfunction, low-grade inflammation and arterial stiffness may 
have led to an underestimation of their mediating effects in those associations, 
however. Furthermore, other mechanisms (e.g. oxidative stress) not investigated 
herein could also play a role in the link between AGEs and CVD. It is noteworthy that 
markers of renal dysfunction, specifically UAE (but not eGFR), and of arterial stiffness, 
i.e. pulse pressure, did not attenuate the associations between AGEs and incident 
fatal and non-fatal CVD as well as all-cause mortality, but were associated with 
incident fatal and non-fatal CVD independently of AGEs and other risk factors 
[HR=2.19 (1.17 to 4.10) and HR=1.53 (1.15 to 2.02), respectively]. These findings thus 
suggest that all these three mechanisms may need specific monitoring/treatment in 
order to decrease excess cardiovascular disease in diabetes.   
There are limitations to our study. First, samples for analyses of AGEs and other 
biomarkers were taken at baseline only, which impedes evaluation of the impact of 
changes in these variables on cardiovascular outcome. Second, potential 
misclassification of non-specific mortality as CVD-related mortality may have 
introduced non-differential biases, in which case the estimates reported herein may 
have been underestimated. However, we cannot discard the possibility that our 
results may have been affected by possible differential underreporting of non-fatal 
CVD. Third, we measured plasma levels of three specific AGEs and it is not clear 
whether these are representative of the total pool of AGEs. In addition, AGEs 
accumulate in tissue and cellular concentrations of AGEs are higher than plasma AGEs 
levels (25). Further studies in which both plasma and tissue levels of AGEs are 
measured are needed to clarify the relation between the AGEs levels in these two 
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compartments and their specific association to CVD. Fourth, we as most of other 
studies conducted in humans (4-9,11-13) did not normalise the plasma AGEs levels for 
an amino acid concentration, which may not enable direct comparison (of absolute 
values) with some other studies (3,5,10,12,14,15). Nevertheless, we do not think 
normalization for an amino acid concentration is likely to affect the associations 
between plasma AGEs and study endpoints in our present study, because in 
preliminary analyses (in a different cohort) we observed very strong correlations 
(r>0.9) between normalised and non-normalised values of AGEs, and comparable 
associations of normalised and non-normalised plasma AGEs levels with outcome 
(data not shown). 
In conclusion, higher plasma levels of AGEs at baseline are associated with incident 
fatal and non-fatal CVD as well as all-cause mortality in type 1 diabetes independent 
of other risk factors and may thus constitute a pathway which explains, at least in 
part, the increased CVD risk attributable to type I diabetes in these patients. 
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Abstract 
Background and objective  
High-mobility group box-1 (HMGB1) is a pro-inflammatory cytokine that may contribute to the pathogenesis 
of micro- and macrovascular complications commonly observed in diabetes. We investigated whether 
HMGB1 is associated with: (1) markers of low-grade inflammation (LGI) and endothelial dysfunction (ED), 
and pulse pressure (PP, a marker of arterial stiffness); (2) prevalent nephropathy, retinopathy, and 
cardiovascular disease (CVD) in type 1 diabetes; and (3) the potential mediating roles of LGI, ED, and PP 
therein.  
 
Methods  
Cross-sectional nested case-control study of 463 patients (226 women; mean age 40±10 yrs) with type 1 
diabetes from the EURODIAB Prospective Complications Study (PCS). We used linear and binary or 
multinomial logistic regression analyses adjusted for traditional risk factors.  
 
Results  
Serum Ln-HMGB1 levels were positively associated with LGI and ED [standardised β=0.11 (95% CI: 0.03; 
0.19) and β=0.11 (0.03; 0.20), respectively], but not with PP. Higher Ln-HMGB1 (per unit) was associated 
with greater odds of micro- and macroalbuminuria: OR=1.24 (0.90; 1.71) and OR=1.61 (1.15; 2.25), p for 
trend=0.004, respectively, Further adjustments for LGI or ED did not attenuate these associations. No such 
associations were found between Ln-HMGB1 and estimated glomerular filtration rate (eGFR), retinopathy 
or CVD, however.  
 
Conclusions  
In type 1 diabetes higher serum HMGB1 levels are associated with greater prevalence and severity of 
albuminuria, though not with eGFR, retinopathy, and CVD. Prospective studies are needed to clarify the 
causal role of HMGB1, if any, in the pathogenesis of vascular complications in type 1 diabetes. 
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Introduction 
The pathophysiological mechanisms that could link hyperglycaemia to the 
development of micro- and macrovascular complications in patients with diabetes 
mellitus are still unclear. One of the proposed mechanisms involves advanced 
glycation end products (AGEs) and the receptor for advanced glycation end products 
(RAGE) (1-4). Besides AGEs, RAGE can also be activated by other ligands, such as high-
mobility group box-1 (HMGB1) (5).  
HMGB1 is a multifunctional nuclear DNA-binding protein that facilitates gene 
transcription (6). Extracellular HMGB1 released from necrotic cells (7) as well as from 
immune cells upon inflammatory stimuli (8) functions as a pro-inflammatory cytokine, 
which elicits pro-inflammatory responses from macrophages (9) and endothelial cells 
(10). Extracellular HMGB1, however, can also initiate tissue repair (11) and promote 
angiogenesis in animal models (12). In addition, HMGB1 functions as a chemotactic 
agent for endothelial precursor cells (13) and smooth muscle cells (14). Extracellular 
effects of HMGB1 are mediated by its binding to RAGE, but also, at least in part, by its 
binding to the receptors of the toll like receptors family (15). The mechanisms behind 
the balance between the detrimental and the beneficial actions of HMGB1, and 
whether these actions might be receptor-specific are still unclear.  
Owing mainly to its pro-inflammatory function, it has been suggested that HMGB1 
may be involved in the development of vascular disease (16). In this line, higher serum 
HMGB1 levels have been reported in individuals with coronary heart disease (17,18) 
or heart failure (19) compared with those without these diseases. Inflammation is 
involved in the development of diabetic nephropathy (20), and in this line, a recent 
study showed that HMGB1 may play a role in the development of diabetic 
nephropathy in rats (21).  
Whether HMGB1 levels are associated with the presence and severity of 
nephropathy, retinopathy and cardiovascular disease (CVD) in patients with type 1 
diabetes, and the potential roles of low-grade inflammation (LGI), endothelial 
dysfunction (ED), and arterial stiffness therein have never been investigated, however. 
We have therefore addressed these issues in a large group of patients with type 1 
diabetes in the EURODIAB PCS. 
Methods 
Subjects and study design 
We used data from the EURODIAB PCS, which is a follow-up of the EURODIAB IDDM 
complications study that has been described in detail elsewhere (22-24). Briefly, 
baseline investigations were performed between 1989 and 1991 on 3,250 patients 
with type 1 diabetes. All patients gave informed consent and the study was approved 
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by the local Ethics Committees. Of the 3,250 included patients, 1,880 (57.8%) returned 
for follow-up examination on average 7-9 years after the baseline examinations. At 
follow-up, a cross-sectional nested case-control study of markers of LGI and ED, and 
their associations with complications was performed in a subset of patients (n=543). 
Cases were selected as those with greatest vascular complication burden as possible 
(n=348) and controls were selected as those who were completely free of any 
complications (i.e. with no evidence of CVD, albuminuria and retinopathy) (n=195). 
The present cross-sectional nested case-control study (2,25-31) includes 463 of the 
subjects in whom complete data on serum levels of HMGB1 and other covariates of 
interest were available.  
Biomarkers 
Serum HMGB1 levels were measured in duplicate with a commercially available ELISA 
kit (Shino-Test Corporation, Tokyo, Japan) and the intra- and inter-assay coefficients 
of variation were 2.7 and 7.6%, respectively. 
Soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble E-selectin 
(sE-selectin) were measured in duplicate by sandwich enzyme immunoassays (R&D 
Systems, Oxon, U.K.). The intra- and inter-assay coefficients of variation for sVCAM-1 
were 4.0% and 9.1%, respectively, and for sE-selectin, 2.1% and 3.1%, respectively 
(2,26).  
Total transforming growth factor β1 (TGF-β1) was measured by an ELISA 
development system (R&D Systems, Oxon, U.K.) and the intra- and inter-assay 
coefficients of variations were 5.0 and 7.0%, respectively (27). Plasma levels of 
C-reactive protein (CRP) were measured with a highly sensitive in-house ELISA and 
plasma levels of interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α) were 
measured using commercially available ELISA kits (R&D Systems, Oxon, U.K.). Intra- 
and inter-assay coefficients of variation were 3.9 and 8.7%, 4.5 and 9.0%, 7.3 and 
8.5%, respectively (2,26).  
Other risk factors  
Blood pressure was measured twice in a seated position with a random zero 
sphygmomanometer (Hawskley, Lancing, UK) and appropriate cuff size, after patients 
had rested for five minutes, and the mean of the two readings was used in the 
analyses (32). Mean arterial pressure (MAP) was calculated as [systolic blood pressure 
+ (2*diastolic blood pressure)]/3. PP was calculated by subtracting the diastolic from 
the systolic blood pressure, and used as a marker of arterial stiffness (32,33). Smoking 
habits were ascertained by questionnaire and subjects were categorised into 
categories: ‘non-‘, ‘moderate’, and ‘heavy smokers’, according to their levels of pack 
years smoked (none, and below or above the sex-specific median, respectively) (2). 
Weight and height were measured with indoor clothing without shoes and body mass 
index (BMI) was calculated. Fasting cholesterol and triglyceride levels were measured 
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by enzymatic colorimetric tests (34). Glycated haemoglobin (HbA1c) was measured by 
a latex enhanced turbidimetric immunoassay (Roche Products, Welwyn Garden City, 
UK). The reference range for this assay was 4.2–6.2%.  
Main outcomes 
Albumin excretion rates were measured from duplicate 24-h urine collections and 
micro- and macroalbuminuria were defined as an albumin excretion rate between 20 
and 200, and above 200 μg/min, respectively (22). GFR was estimated with the 
Cockcroft–Gault formula (35) and with the short modified diet in renal disease 
equation (36). Retinopathy was assessed from retinal photographs according to the 
EURODIAB protocol. Accordingly, non-proliferative retinopathy was defined as the 
presence of one or more microaneurysms, haemorrhages, and/or hard exudates. 
Proliferative retinopathy was defined as any new vessels, fibrous proliferations, pre-
retinal haemorrhage, vitreous haemorrhage, or photocoagulation scars (37). CVD was 
defined as a positive medical history of a cardiovascular event, including myocardial 
infarction, angina, coronary artery bypass graft and/or stroke, and/or ischaemic 
changes on a centrally Minnesota coded ECG (38). 
Statistical analyses  
All analyses were performed with the Statistical Package for Social Sciences (SPSS) 
version 15.0 for Windows (SPSS Inc, Chicago, Illinois, USA). Variables with a skewed 
distribution (i.e. HMGB1, triglycerides, CRP, IL-6, TNF-α, and TGF-β1) were loge 
transformed prior to further analyses. Comparisons of characteristics between 
subjects with vs. without vascular complications were performed with Student’s t- or 
Chi-Square tests, as appropriate. In these analyses, cases were all those subjects with 
any vascular complication (n=289); controls were all those without any vascular 
complication (n=174). 
Markers of low-grade inflammation (LGI) were comprised into an overall LGI score 
by averaging the z-scores of LnCRP, LnIL-6, LnTNF-α and LnTGF-β1; likewise, markers 
of endothelial dysfunction (ED) were comprised into an overall ED score by averaging 
the z-scores of sVCAM-1 and sE-selectin (2-4,26). A z-score represents the distance 
between an individual’s biomarker score from the population’s total mean in units of 
the population’s standard deviation, and is thus a common transformation that 
enables the combination of several markers originally expressed in different units. The 
two scores thus obtained represent a more robust measure of the individuals’ levels 
of LGI and ED and have the advantage of reducing the influence of the biological 
variability expected when LGI or ED is characterised based on the levels of each 
biomarker separately, since these were only measured once. 
Linear regression analyses were used to examine the extent to which Ln-HMGB1 
was associated with each of the biomarkers of LGI and ED, as well as their overall 
scores, and PP. We reported standardised regression coefficients (95% confidence 
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interval) to allow comparison of the strength of the associations. These analyses were 
first adjusted for age, sex, HbA1c, duration of DM, case-control status, BMI, total 
cholesterol, MAP and smoking; second, for the use of antihypertensive medication; 
and third for eGFR estimated with Cockcroft-Gault formula. 
We used multinomial logistic regression analyses to examine the associations 
between Ln-HMGB1 and the presence and severity of albuminuria as well as 
retinopathy, and binary logistic regression analyses to investigate the associations 
between Ln-HMGB1 and prevalent CVD. These analyses were adjusted for 
conventional CVD risk factors, use of antihypertensive medication and eGFR as 
described above, to ascertain independence from these factors. We further adjusted 
these associations for LGI and ED scores, and PP to ascertain the extent to which these 
mechanisms could explain (i.e. mediate) a portion of the associations found, in which 
case the effect sizes (OR) would be appreciably attenuated. 
Results 
Table 5.1 shows the characteristics of the patients with any vascular complications vs. 
those without. Overall, individuals with vascular complications had a more adverse 
atherosclerotic risk profile as illustrated by more unfavourable levels of conventional 
risk factors, LGI, ED, PP, and eGFR,. 
After adjustments for age, sex, HbA1c, duration of diabetes, case-control status, 
BMI, total cholesterol, MAP, and smoking, serum Ln-HMGB1 levels were positively 
associated with LGI and ED scores (standardised regression coefficient β=0.11 [95%CI: 
0.03 to 0.19] and β=0.11 [0.03 to 0.20], respectively), but not PP (Table 5.2, Model 1). 
Further adjustments for antihypertensive medication and eGFR did not attenuate 
these positive associations (Table 5.2, models 2-3). Serum Ln-HMGB1 levels were not 
associated with eGFR however. 
After adjustments for conventional risk factors, Ln-HMGB1 levels were associated 
with greater odds for micro- and macroalbuminuria: OR=1.23 (0.90 to 1.70) and 
OR=1.61 (1.15 to 2.26), p for trend=0.004, per unit higher Ln-HMGB1, respectively 
(Table 5.3, model 3; Figure 5.1). When albuminuria was analysed as a continuous 
outcome, each unit increase in Ln-MHGB1 was associated with 3.9 μg/min (95%CI: 0.3 
to 7.9) in albuminuria (p=0.030). No such associations were found between Ln-
HMGB1 levels and prevalent CVD [OR=0.86 (0.66 to 1.12)] or retinopathy [OR=0.94 
(0.70 to 1.26) and OR=0.90 (0.64 to 1.26) for prevalent non-proliferative and 
proliferative retinopathy, respectively], however.  
Despite the positive associations between Ln-HMGB1 and LGI as well as ED, the 
associations between HMGB1 and micro- and macroalbuminuria were not appreciably 
attenuated when these were further adjusted for the LGI score (model 4 vs. model 3) 
or the ED score (model 5 vs. model 3). 
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Table 5.1 Clinical characteristics of the study population. 
 All (n=463) 
 
Vascular complications 
(n=289) 
No vascular complications 
(n=174) 
p-value 
Age (years) 41.8 (10.4) 35.9 (8.1) <0.001 
Sex (m/f, %) 55/45 45/55   0.056 
BMI (kg/m
2
) 24.9 (3.5) 23.8 (2.6) <0.001 
HbA1c (%)   9.0 (1.5)   7.8 (1.3) <0.001 
Duration of diabetes (years) 25.2 (9.1) 15.3 (7.0) <0.001 
Total cholesterol (mmol/l)   5.49 (1.12)   5.00 (1.09) <0.001 
Triglycerides (mmol/l) 1.14 [0.85-1.58] 0.86 [0.67-1.10] <0.001 
Smoking (non/moderate/heavy) (%) 38.8/27.3/33.9 51.2/31.0/17.8   0.001 
Diastolic blood pressure (mmHg)   75 (12)   73 (11)   0.060 
Systolic blood pressure (mmHg) 126 (22) 114 (14) <0.001 
Mean arterial pressure (mmHg)   92 (13)   87 (11) <0.001 
Pulse pressure (mmHg)   51 (19)   41 (11) <0.001 
Antihypertensive medication (%) 45.3 6.3 <0.001 
eGFRGC (ml min
-1
 1.73m
-2
) 96.9 (27.7) 114.0 (17.5) <0.001 
eGFRMDRD (ml min
-1
 1.73m
-2
) 86.6 (25.4) 101.5 (16.0) <0.001 
Albuminuria (normo-/micro-/macro-) (%) 38.1/23.5/38.4 - - 
Retinopathy (no/background/proliferative) (%) 12.1/41.5/46.4 - - 
Cardiovascular disease (%) 38.1 - - 
High-mobility group box-1 (ng/ml) 1.26 [0.78-2.57] 1.45 [0.89-2.75]   0.406 
CRP (mg/l) 1.29 [0.46-2.75] 0.71 [0.35-1.88] <0.001 
IL-6 (pg/ml)   2.12 [1.34-3.94)] 1.57 [1.06-2.50] <0.001 
TNF-α (pg/ml) 3.18 [2.39-4.47] 2.22 [1.68-2.85] <0.001 
TGF-β1 (ng/ml) 5.55 [3.70-8.90] 5.25 [3.28-8.03]   0.132 
Inflammation score 0.17 (0.62) -0.28 (0.54) <0.001 
sE-selectin (ng/ml) 36 (17)   31 (11) <0.001 
sVCAM-1(ng/ml) 437 (149)   380 (104) <0.001 
Endothelial dysfunction score 0.14 (0.80)   -0.24 (0.49) <0.001 
Data are means (standard deviation), median [inter-quartile range], or percentages, as appropriate.  
BMI, body mass index; HbA1c, glycated haemoglobin; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein; eGFRCG, estimated glomerular filtration rate by Cockcroft-Gault formula; eGFRMDRD, estimated 
glomerular filtration rate by short modification of diet in renal disease equation; CRP, C reactive protein; 
IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; TGF-β1, transforming growth factor β1; sE-selectin, 
soluble E-selectin; sVCAM-1, soluble vascular cell adhesion molecule-1. 
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Figure 5.1 Serum high-mobility group box-1 levels according to the presence and severity of 
albuminuria and retinopathy, and the presence of cardiovascular disease. 
 Bars indicate geometric means + SE, which were adjusted for age, sex, HbA1c, duration of 
diabetes, case-control status, body mass index, total cholesterol, triglycerides, smoking, mean 
arterial pressure, antihypertensive medication, estimated glomerular filtration rate by 
Cockcroft-Gault formula, and presence of CVD, albuminuria and/or retinopathy as 
appropriate. 
Discussion 
The main finding of this study is that, among individuals with type 1 diabetes, serum 
HMGB1 levels are positively associated with the presence and severity of albuminuria, 
though not with eGFR, retinopathy, and CVD. In addition, HMGB1 levels were 
positively associated with markers of LGI and ED, but these did not explain the 
association of HMGB1 with albuminuria. This is the first study to investigate the 
associations between HMGB1 and micro- and macrovascular complications as well as 
markers of LGI and ED in patients with type 1 diabetes.  
The positive association between HMGB1 and albuminuria observed in the present 
study is supported by the findings in previous studies in rats, in which higher kidney 
HMGB1 levels were associated with the presence and severity of diabetic 
nephropathy (39). In addition, it has been reported that higher HMGB1 expression 
was found in the cytoplasm than in the nuclei of renal tissues in diabetic rats 
compared to mainly nucleic HMGB1 expression in renal tissues in control rats (21). 
The latter study has also reported higher RAGE expression and nucleic factor κB 
(NF-κB) activity suggesting a pathogenic role of HMGB1 in the development of renal 
injury in diabetic rats through RAGE and activation of NF-κB (21). However, we have 
measured serum HMGB1 only and it is unknown how serum levels relate to tissue 
levels. Extracellular HMGB1 may activate NF-κB and initiate and amplify the 
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upregulation of pro-inflammatory cytokines and adhesion molecules by binding to 
RAGE (5) or toll-like receptors (15,16), and subsequently lead to increased risk for 
albuminuria.  
Both HMGB1 (5) and AGEs (40) are shown to be ligands of RAGE. Ligation of RAGE 
leads via various intracellular signaling pathways to the activation of transcription 
factor nuclear factor κB, which may alter the gene transcription and could lead to the 
upregulation of proinflammatory cytokines and adhesion molecules. These processes 
may underlie the pathogenesis of vascular complications in type 1 diabetes. Both 
serum HMGB1 and sRAGE (2) levels were positively associated with the presence and 
severity of albuminuria in patients with type 1 diabetes. However, in the present 
study we could not find an association between serum HMGB1 levels and the 
presence of CVD, while in our previous studies we have shown that both sRAGE (3), as 
a reflection of RAGE, and AGEs (4) were positively associated with incident CVD. This 
suggests that although HMGB1, AGEs, and (s)RAGE are interrelated they may not 
contribute to the same pathways that underlie the pathogenesis of micro- and 
macrovascular complications. This may, at least in part, be explained by the various 
different receptors for both HMGB1 (15) and AGEs (41), and by the fact that beside 
HMGB1 and AGEs, many other ligands exist for RAGE (42). 
The adverse association between higher levels of HMGB1 and the presence and 
severity of albuminuria could not be explained by HMGB1-related low-grade 
inflammation and/or endothelial dysfunction. No association was found between 
HMGB1 and PP, and therefore, this marker of arterial stiffness could also not explain 
any association between HMGB1 and albuminuria. These findings suggest that 
HMGB1, LGI, ED and PP may all constitute different and independent pathways 
leading to albuminuria in type 1 diabetes. Indeed, this is supported by the 
observations that both higher LGI and ED scores were independently of serum HMGB1 
levels associated with greater odds for micro- and macroalbuminuria: OR=1.51 (0.88 
to 2.59) and OR=1.86 (1.10 to 3.18) per unit higher LGI score, and OR=1.56 (95% CI: 
0.97 to 2.49) and OR=2.08 (1.33 to 3.27) per unit higher ED score, respectively. 
Although to a smaller extent, PP (per 10mmHg) was also associated with greater odds 
for micro- [OR=1.09 (0.86 to 1.38) ] and macroalbuminuria [OR=1.20 (0.97 to 1.49)], 
independently of HMGB1 levels. 
The lack of an association between serum levels of HMGB1 and CVD observed in 
the present study is in contrast to the positive associations that have been reported 
between serum levels of HMGB1 and coronary artery disease as well as heart failure 
in three previous studies, all of which were conducted among in patients with type 2 
diabetes (17-19). In view of the strong associations observed between HMGB1 and 
LGI, ED as well as albuminuria, all of which are strong correlates of CVD, the lack of 
associations between HMGB1 and CVD as well as retinopathy are difficult to 
conciliate. We cannot discard the possibility that a type II error may have occurred 
and that we thus did not find an association between HMGB1 and prevalent CVD due 
to the play of chance. Further, preferably prospective, studies are needed to establish 
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these associations more definitely. Indeed, the fact that we examined the associations 
in the context of a cross-sectional nested case-control study also is a limitation to our 
study, and any inferences about causality should thus be made with caution. Since 
there are no longitudinal data of this type in large groups of type 1 diabetes at this 
time, the present cross-sectional study may serve as a reasonable starting point to 
further explore these associations. In addition, we defined presence of CVD as a 
positive medical history of a cardiovascular event. We may have missed subclinical 
cardiovascular complications, which may lead to a dilution of the associations 
observed. 
In conclusion, higher serum levels of HMGB1 are cross-sectionally associated with 
a higher prevalence of micro- and macroalbuminuria, but seemingly not with eGFR, 
retinopathy, and CVD, in patients with type 1 diabetes. Further prospective studies 
are needed to further clarify the causal role of HMGB1, if any, in the pathophysiology 
of micro- and macrovascular complications in type 1 diabetes. 
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Abstract 
Background and objective  
To investigate the associations of plasma levels of pro-inflammatory cytokine high-mobility group box 1 
(HMGB1) with incident cardiovascular disease (CVD) and all-cause mortality in type 1 diabetes, and the 
extent to which any such associations could be explained by low-grade inflammation (LGI), endothelial and 
renal dysfunction, or pulse pressure (PP, a marker of arterial stiffness). 
 
Methods  
We prospectively followed 165 individuals with diabetic nephropathy and 168 individuals with persistent 
normoalbuminuria who were free of CVD at study entry and in whom levels of HMGB1 and other 
biomarkers were measured at baseline. 
 
Results  
Plasma levels of Ln-HMGB1 were not associated with markers of LGI, endothelial and renal dysfunction, and 
PP. During the course of follow-up [median: 12.3 years (7.8-12.5)], 80 individuals died; 82 suffered a fatal 
(n=46) and/or nonfatal (n=53) CVD event. Incident fatal and nonfatal CVD and all-cause mortality increased 
with higher baseline plasma levels of Ln-HMGB1 independently of other CVD risk factors: HR=1.55 (95%CI: 
0.94;2.48) and HR=1.86 (1.18;2.93), respectively. Further adjustments for LGI, endothelial and renal 
dysfunction, and PP did not attenuate these associations. 
 
Conclusions  
Plasma HMGB1 levels are positively associated with incident all-cause mortality in type 1 diabetes, 
independently of conventional cardiovascular risk factors and markers of several potential HMGB1-related 
pathophysiological mechanisms. To a lesser extent, higher plasma HMGB1 levels are also associated with 
incident fatal and nonfatal CVD in these patients. Thus, HMGB1 may explain, in part, the increased risk of 
CVD and mortality in type 1 diabetes. 
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Introduction 
The pathophysiological mechanisms that could link hyperglycaemia to the 
development of cardiovascular complications in patients with diabetes mellitus are 
still unclear. One of the proposed mechanisms involves advanced glycation end 
products (AGEs) and the receptor for advanced glycation end products (RAGE) (1). 
Besides AGEs, RAGE can also be activated by other ligands, which include high-
mobility group box 1 (HMGB1) (2). 
HMGB1 is a multifunctional nuclear DNA-binding protein that facilitates gene 
transcription (3). Extracellular HMGB1 released from necrotic cells (4) as well as from 
immune cells upon inflammatory stimuli (5) functions as a pro-inflammatory cytokine, 
which elicits pro-inflammatory responses from macrophages and endothelial cells 
(6,7). Extracellular effects of HMGB1 are mediated by its binding to RAGE, but also, at 
least in part, by its binding to the receptors of the toll-like receptors family (8). 
HMGB1-induced production of adhesion molecules and inflammatory cytokines could 
contribute to low-grade inflammation, endothelial and renal dysfunction, and arterial 
aging, all of which may partially explain the increased CVD in diabetes. 
So far, three cross-sectional studies have investigated the associations between 
HMGB1 and cardiovascular outcomes in humans. These have reported higher levels of 
HMGB1 in patients with stable or unstable angina pectoris (9), with type 2 diabetes 
and coronary artery disease (10), and with heart failure (11) as compared with 
controls. In addition, one of these studies has also shown that individuals with heart 
failure at study entry who died during the follow-up of two years had higher levels of 
HMGB1 at baseline compared with the survivors (11).  
Whether HMGB1 levels are associated with incident fatal and nonfatal CVD as well 
as all-cause mortality in individuals with type 1 diabetes, and the potential mediating 
roles of low-grade inflammation, endothelial and renal dysfunction, and pulse 
pressure (PP, as a marker of arterial stiffness) herein have never been investigated. 
We addressed these questions in a 12-year prospective follow-up study. 
Methods 
Study population and design 
In 1993, 199 patients with type 1 diabetes and diabetic nephropathy defined 
according to clinical criteria [i.e. persistent macroalbuminuria (>300 mg/24 h) in at 
least two out of three previous consecutive 24-h urine collections, in the presence of 
diabetic retinopathy and the absence of other kidney or urinary tract disease] and 192 
with persistent normoalbuminuria (i.e. urinary excretion rate <30 mg/24 h) were 
recruited from the outpatient clinic at Steno Diabetes Center for a prospective 
observational follow-up study. Details of the inclusion criteria and selection 
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procedures have been described elsewhere (12). The study was approved by the local 
ethics committee, in accordance with the Helsinki Declaration, and all patients gave 
their informed written consent.  
Baseline investigations 
Biomarkers  
Analyses of the biomarkers were done on frozen (-80°C) samples and were performed 
at a central laboratory by C.G.S.  
Plasma HMGB1 levels were measured in duplicate with a commercially available 
ELISA kit (Shino-Test Corporation, Tokyo, Japan) and the intra- and inter-assay 
coefficients of variation were 4.0% and 11.0%, respectively. 
High-sensitivity C-reactive protein (hsCRP) and secreted phospholipase A2 (sPLA2) 
were determined by enzyme-linked immunosorbent assays (ELISA) as described 
previously (13). Commercially available ELISA kits were used for measurements of 
plasma soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular 
adhesion molecule-1 (sICAM-1) and interleukin-6 (IL-6) (Quantikine High Sensitivity; 
R&D Systems, Oxon, U.K.). The intra- and inter-assay CVs of these immunoassays were 
<8%.  
Protein-bound N
ε
-(carboxyethyl)lysine (CEL) and N
ε
-(carboxymethyl)lysine (CML) 
were determined in plasma by stable-isotope dilution tandem mass spectrometry 
(14). Protein-bound pentosidine levels were determined in plasma by a single step 
reversed phase based high-performance liquid chromatography separation with 
fluorescent detection. The intra- and inter-assay CVs were 7.3% and 2.0% for CEL, 
3.5% and 3.6% for CML, and 2.7% and 2.8% for pentosidine, respectively. 
Other baseline assessments  
All investigations were performed in the morning after an overnight fast. No 
antihypertensive medication was ever prescribed in 24% of patients with nephropathy 
and 88% of the normoalbuminuric patients. All of the remaining patients were asked 
to stop their antihypertensive and diuretic treatment 8 days before the examination. 
Arterial blood pressure was measured twice with an appropriate cuff size following at 
least 10 minutes rest in the supine position. Mean arterial pressure (MAP) was 
calculated as [systolic blood pressure + (2*diastolic blood pressure)]/3. PP was 
calculated by subtracting the diastolic from the systolic blood pressure, and used as a 
marker of arterial stiffness (15). Body mass index (BMI) was calculated by dividing 
weight by height squared. Urinary albumin excretion (UAE) was measured by an 
enzyme immunoassay from 24-h urine collections. Serum creatinine concentration 
was assessed by a kinetic Jaffé method. In all patients glomerular filtration rate (eGFR) 
was estimated according to the short Modification of Diet in Renal Disease equation 
(MDRD) (16). Patients were interviewed using the WHO cardiovascular questionnaire. 
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Individuals were categorised into three groups according to their smoking status as 
never, former or current smokers. 
Follow-up and study endpoints 
All patients were followed up to the last visit at Steno Diabetes Center, until 
1 September 2006 or until death (n=82) or emigration (n=3). All patients were traced 
through the national register during autumn 2006. If a patient had died before 
1 September 2006, the date of death was recorded and information on the primary 
cause of death was obtained from the death certificate, which was reviewed by two 
independent observers. Additional available information from necropsy reports was 
also included. All deaths were classified as cardiovascular unless an unequivocal non-
cardiovascular cause was established. In all patients alive at the end of follow-up, non-
fatal cardiovascular events were retrieved from their patient files from Steno Diabetes 
Center and/or other hospital records. The primary study outcome was a combined 
endpoint of fatal and non-fatal cardiovascular disease (i.e. myocardial infarction, 
percutaneous coronary intervention, coronary bypass grafting, amputation due to 
ischaemia, vascular surgery for peripheral atherosclerotic disease and stroke), and the 
secondary outcome was all-cause mortality. 
Statistical analyses 
All analyses were performed with the Statistical Package for Social Sciences (SPSS) 
version 15.0 for Windows (SPSS, Chicago, IL, USA).  
Variables with a skewed distribution, i.e. HMGB1, triglycerides, CRP, IL-6, sPLA2, 
UAE and pentosidine, were loge transformed prior to further analyses. Comparisons of 
baseline characteristics between groups were performed with Student’s t or χ
2
 tests, 
as appropriate.  
We used linear regression analyses to investigate the cross-sectional associations 
between HMGB1 and markers of low-grade inflammation, endothelial and renal 
dysfunction, and arterial stiffness. Results of these analyses are expressed as 
standardised regression coefficients to allow comparison of the strength of the 
association between HMGB1 and each of these variables.  
To investigate the associations between plasma HMGB1 and incident CVD as well 
as all-cause mortality, we used Cox proportional hazards regression models. These 
analyses were adjusted, first, for sex, age, duration of diabetes, case-control status 
and HbA1c; second, for other cardiovascular risk factors (i.e. BMI, smoking status, 
total cholesterol and MAP); and third, for the use of renin-angiotensin-aldosterone 
system (RAAS) inhibitors, other antihypertensive treatment, and/or whether subjects 
did or did not withhold their medication prior to baseline examinations. This model 
was then further adjusted for markers of low-grade inflammation (expressed as a total 
score computed by averaging the z scores of Ln-IL-6, Ln-CRP, sICAM-1 and Ln-sPLA2), 
endothelial dysfunction (expressed as a total score computed by averaging the 
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z scores of sVCAM-1 and sICAM-1), renal dysfunction (i.e. eGFRMDRD and Ln-UAE), and 
arterial stiffness (i.e. PP); these markers were entered one at a time to ascertain the 
extent to which any such marker could attenuate (i.e. explain) the strength of the 
association between HMGB1 and study endpoints, which were given as hazard ratios 
(HR) with 95% confidence intervals (CIs).  
Finally, we investigated whether the associations listed above differed between 
patients with normoalbuminuria and those with nephropathy by adding interaction 
terms to our models, the significance of which was judged on the basis of a p-value 
<0.1 for the interaction term. We found no such interactions and therefore all results 
are presented for the two groups combined. 
Results 
Of the 391 patients included in this study, we excluded 17 (1 with nephropathy and 16 
with normoalbuminura) in whom follow-up data were not obtained, 10 with missing 
data on baseline biomarkers levels (5 patients with nephropathy and 5 with 
normoalbuminuria), 7 with end stage renal failure and 24 with prior CVD at baseline 
(21 patients with nephropathy and 3 with normoalbuminuria). Results reported herein 
thus refer to 333 patients (165 with nephropathy and 168 with persistent 
normoalbuminuria at baseline).   
During the course of follow-up [median: 12.3 years (inter-quartile range 7.8-12.5)], 
80 individuals (24.0%) died; 82 (24.6%) suffered a fatal (n=46) and/or non-fatal (n=53) 
CVD event. Individuals with incident CVD events or who had died at follow-up had, at 
baseline, a more adverse atherosclerotic risk (Table 6.1).  
Plasma Ln-HMGB1 levels were not associated with markers of low-grade 
inflammation, endothelial and renal dysfunction, advanced glycation endproducts, 
and arterial stiffness (Table 6.2). 
After adjustment for age, sex, duration of diabetes, case-control status, HbA1c, 
BMI, smoking status, total cholesterol, MAP, and the use of antihypertensive 
medication, the incidence of fatal and nonfatal CVD as well as all-cause mortality 
increased with higher baseline levels of HMGB1: HR= 1.55 (95% CI: 0.96 to 2.51) and 
HR= 1.86 (1.18 to 2.93) per unit increase in Ln-HMGB1, respectively (Table 6.3, model 
3; Figure 6.1 A-B).  
Further adjustments for markers of low-grade inflammation (model 4), endothelial 
and renal dysfunction (models 5-6), and PP (model 7) did not appreciably attenuate 
the positive associations between Ln-HMGB1 and study endpoints (Table 6.3, models 
4-7 vs. model 3). 
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Table 6.2 Associations between plasma Ln-HMGB1 and markers of low-grade inflammation, 
endothelial and renal dysfunction, advanced glycation endproducts, and pulse pressure 
(n=333). 
  Model 1    Model 2  
Dependent variable β 95% CI p-value  β 95% CI p-value 
Ln C-reactive protein   0.05 -0.06; 0.16 0.354    0.06 -0.05; 0.17 0.266 
Ln interleukin-6   0.11 0.00; 0.21 0.049    0.08 -0.03; 0.19 0.141 
Ln secreted phospholipase A2   0.04 -0.06; 0.14 0.422    0.02 -0.08; 0.13 0.668 
Low-grade inflammation score
 
  0.07 -0.01; 0.14 0.097    0.05 -0.02; 0.13 0.173 
        
Soluble vascular cell adhesion molecule-1 -0.02 -0.13; 0.08 0.677  -0.02 -0.12; 0.09 0.735 
Soluble intercellular adhesion molecule-1   0.15   0.04; 0.26 0.007    0.10 -0.01; 0.20 0.071 
Endothelial dysfunction score    0.06 -0.02; 0.15 0.134    0.04 -0.05; 0.12 0.371 
        
N
ε
-(carboxyethyl)lysine   0.08 -0.03; 0.18 0.158    0.08   0.03; 0.18 0.148 
N
ε
-(carboxymethyl)lysine   0.08 -0.03; 0.18 0.138    0.08 -0.03; 0.18 0.135 
Ln pentosidine   0.00 -0.11; 0.10 0.946   0.01 -0.09; 0.11 0.878 
Advanced glycation endproducts score   0.05 -0.05; 0.15 0.300    0.05 -0.04; 0.15 0.252 
        
Baseline eGFRMDRD   0.03 -0.06; 0.12 0.487    0.00 -0.08; 0.09 0.938 
Ln urinary albumin excretion rate   0.01 -0.03; 0.05 0.668    0.02 -0.03; 0.06 0.434 
Pulse pressure   0.03 -0.06; 0.13 0.485    0.03 -0.05; 0.12 0.442 
β, standardised regression coefficient: indicates change in dependent variable (in SD) per 1 SD increase in 
Ln-HMGB1. Model 1, adjusted for age, sex, duration of diabetes, case-control status and HbA1c; Model 2, 
model 1 plus additional adjustments for smoking status, mean arterial pressure, body mass index, total 
cholesterol, use of renin-angiotensin-aldosterone system inhibitors, other antihypertensive treatment, and 
continuation of medication at baseline examination. 
 
 
Table 6.3 Associations between plasma Ln-HMGB1 and incident CVD events as well as all-cause 
mortality (n=333). 
 Fatal and nonfatal CVD  All-cause mortality 
Model: adjustments HR 95% CI p-value  HR 95% CI p-value 
1: age, sex, HbA1c, case-control status and 
duration of diabetes 
1.37 0.86; 2.20 0.186  1.65 1.06; 2.57 0.028 
2: model 1 + MAP, BMI, smoking status and 
total cholesterol 
1.47 0.91; 2.36 0.113  1.72 1.08; 2.74 0.022 
3a: model 2 + RAAS inhibitors agents 1.49 0.93; 2.39 0.098  1.73 1.08; 2.75 0.021 
3b: model 2 + other antihypertensive agents 1.53 0.96; 2.43 0.075  1.85 1.18; 2.91 0.007 
3c: model 2 + continuation of medication 
use at baseline examination 
1.53 0.94; 2.48 0.087  1.69 1.07; 2.69 0.026 
3: model 3a, 3b and 3c 1.55 0.96; 2.51 0.073  1.86 1.18; 2.93 0.008 
4: model 3 + inflammatory score  1.50 0.93; 2.43 0.095  1.81 1.15; 2.87 0.011 
5: model 3 + endothelial dysfunction score 1.55 0.96; 2.51 0.073  1.81 1.14; 2.87 0.012 
6: model 3 + eGFRMDRD and Ln-UAE  1.54 0.96; 2.45 0.071  1.80 1.14; 2.84 0.011 
7: model 3 + pulse pressure 1.49 0.92; 2.42 0.105  1.80 1.14; 2.85 0.012 
HR, hazard ratio for fatal and non-fatal CVD or all-cause mortality per each unit increase in Ln-HMGB1 levels 
at baseline; CI, confidence interval; CVD, cardiovascular disease; MAP, mean arterial pressure; BMI, body 
mass index; RAAS inhibitors, renin-angiotensin-aldosterone system inhibitors; eGFR, estimated glomerular 
filtration rate; UAE, urinary albumin excretion rate. 
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Figure 6.1 Cumulative hazard for fatal and non-fatal CVD (A) as well as all-cause mortality (B) across 
tertiles of plasma HMGB1. Data are adjusted for age, sex, case-control status, duration of 
diabetes, HbA1c, smoking status, mean arterial pressure, body mass index, total cholesterol, 
use of renin-angiotensin-aldosterone system inhibitors, other antihypertensive treatment, 
and continuation of medication at baseline examination. Compared with patients in the 
lowest tertile of HMGB1, those in the middle and highest tertiles had increased risk for fatal 
and nonfatal CVD [HR=1.18 (95%CI 0.68 to 2.05) and 1.29 (0.73 to 2.28), respectively, p for 
trend=0.337] and all-cause mortality [HR=1.28 (95%CI 0.70 to 2.33) and 2.05 (1.14 to 3.67), 
respectively, P for trend=0.018]. 
 
Discussion 
The main finding of this study was that, in patients with type 1 diabetes, higher 
levels of plasma HMGB1 are associated with all-cause mortality, independently of 
conventional cardiovascular risk factors, and markers of low-grade inflammation, 
endothelial and renal dysfunction, and pulse pressure. To a lesser extent, higher 
plasma HMGB1 levels were also positively associated with incident fatal and nonfatal 
CVD in these patients. This is the first prospective study that has investigated the 
associations between plasma HMGB1 and incident fatal and nonfatal CVD as well as 
all-cause mortality in a large sample of individuals with type 1 diabetes, and has also 
addressed potential mechanisms that could explain the associations observed. 
Our findings are in agreement with three studies that have reported positive 
associations of HMGB1 with coronary artery disease (9,10), heart failure (11), and 
mortality related to heart diseases (11) in patients with and without type 2 diabetes, 
though these were limited by their cross-sectional study design (9-11) or a short 
follow-up period (11). In addition, at the molecular level, fatty streaks and fibrofatty 
lesions contain more macrophages with cytoplasmic and nucleic HMGB1 compared 
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with normal intima (17), and HMGB1 is also expressed by activated vascular smooth 
muscle cells in more advanced atherosclerotic lesions (18). Furthermore, neutralising 
HMGB1 attenuated the development of atherosclerosis in an animal model (19). 
Interestingly, in that same study neutralizing HMGB1 had only small effects on the 
expression of proinflammatory cytokines, which suggests that HMGB1 in 
atherosclerotic lesions may affect immune cell function rather than the expression of 
proinflammatory cytokines (19). In the present study, we did not find strong 
associations between HMGB1 and markers of low-grade inflammation, endothelial 
and renal dysfunction, and pulse pressure, although we cannot fully discard these 
potential associations due to the use of a selection of markers representing these 
processes.  
Further adjustments for the markers of these pathophysiological mechanisms (i.e. 
low-grade inflammation, endothelial and renal dysfunction, and arterial stiffness) did 
not attenuate the positive associations observed between HMGB1 and outcomes. 
These findings suggest that these different pathophysiological mechanisms and 
HMGB1 may constitute distinct pathways leading to increased risk of CVD and 
mortality in these patients. Indeed, this is supported by the associations of eGFRMDRD, 
Ln-UAE, and pulse pressure with incident fatal and nonfatal CVD [HR=1.15 (95% CI: 
1.02 to 1.29) per 10 ml/min/1.73m
2 
decrease in eGFRMDRD, HR=1.37 (1.06 to 1.77) per 
1 unit increase in Ln-UAE, and HR=1.24 (1.05 to 1.45) per 10mmHg increase, 
respectively], independently of HMGB1. 
Plasma levels of HMGB1 were not associated with plasma levels of CML, while 
both HMGB1 (2) and CML (20) are ligands for RAGE, and both plasma levels of HMGB1 
and CML were positively associated with incident CVD and all-cause mortality in 
patients with type 1 diabetes as shown in the present and in a previous study (14), 
respectively. Mutual adjustment for each other did not appreciably attenuate these 
positive associations (data not shown). These findings suggest that HMGB1-related 
and CML-related pathways leading to increased risk for CVD morbidity and mortality 
in type 1 diabetes do not overlap to an important extent, and may form specific 
targets for treatment in these patients. 
The positive association between HMGB1 and incident all-cause mortality was 
stronger than that between HMGB1 and incident fatal and nonfatal CVD. In addition 
to diabetes (10,21) and CVD (9-11), HMGB1 is also associated with various diseases 
(e.g. inflammatory diseases and cancer) (22) commonly related with increased risk for 
mortality. This may explain, at least in part, the stronger association with incident all-
cause mortality than with incident fatal and nonfatal CVD. In addition, compared to 
fatal endpoints, nonfatal endpoints may have been more susceptible to 
misclassification bias, because of their dependency on the completeness and accuracy 
of patients’ records and/or discharge letters. Most likely, if any misclassification 
occurred, we may have missed some cases (i.e. patients who were possibly considered 
as ‘free from CVD’ when in fact they were not), and in this case, such misclassification 
was likely to be random, because CVD status was ascribed without previous 
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knowledge of subjects’ plasma HMGB1 levels. These misclassifications, if present, 
may, if anything, lead to an underestimation of the strength of the association 
between HMGB1 and the combined study endpoint (incident fatal and nonfatal CVD).  
There are limitations to our study. Samples for analyses of HMGB1 and other 
biomarkers were taken at baseline only, which impedes evaluation of the impact of 
changes in these variables on study outcomes. In addition, we measured plasma 
HMGB1 only and it is unknown how plasma levels relate to intracellular levels. 
Therefore, further studies are needed to elucidate both the interrelationship between 
extracellular and intracellular HMGB1 levels, and their associations with 
cardiovascular disease. Furthermore, in a recent study in patients with type 1 diabetes 
(EURODIAB nested case-control study) preliminary data showed that serum HMGB1 
was not associated with prevalent CVD (23). The apparent discrepancy with the 
positive association between plasma HMGB1 and incident CVD observed in the 
present study suggests that measures obtained in serum and plasma may not 
represent the same pool of HMGB1. Further studies are needed to clarify both the 
interrelationship between serum and plasma levels of HMGB1, and their associations 
with cardiovascular disease. 
In conclusion, higher plasma HMGB1 levels are associated with incident all-cause 
mortality in type 1 diabetes, independently of other conventional cardiovascular risk 
factors and markers of low-grade inflammation, endothelial and renal dysfunction, 
and arterial stiffness. To a lesser extent, higher plasma HMGB1 levels were also 
associated with higher incident fatal and nonfatal CVD in these patients. Altogether, 
HMGB1 may explain, in part, the risk of CVD and mortality in type 1 diabetes and may 
constitute a specific target for treatment in these patients. 
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Abstract 
Background and objective  
Accelerated arterial ageing, characterised by steeper increases in pulse pressure (PP) with age, increases 
cardiovascular disease (CVD) risk in type 1 diabetes. Advanced glycation endproducts (AGEs) and low-grade 
inflammation (LGI) may underlie these increases in PP and CVD risk. We have therefore investigated the 
extent to which PP mediates the associations of AGEs and LGI with incident CVD in 339 patients with type 1 
diabetes.  
 
Methods  
Brachial PP, AGEs (e.g. pentosidine), and LGI markers (e.g. C-reactive protein, CRP) were measured at 
baseline. Incident CVD (n=85) was ascertained over a median of 12.3 years. We used multivariable linear 
and Cox-regression models, and the αβ product-of-coefficients method to ascertain the mediated effect.  
 
Results  
Both Ln-pentosidine and Ln-CRP (per SD) were independently associated with higher PP [2.4 mmHg (95%CI: 
0.6-4.2) and 2.6 mmHg (1.1-4.2)] and incident CVD [HR=1.32 (1.01-1.72) and HR=1.40 (1.08-1.82), 
respectively]. Further adjustment for PP significantly attenuated the associations of the cross-link AGE, 
pentosidine, and CRP, a marker of LGI, with CVD by 18% and 14%, respectively, and may, thus, partially 
explain these associations. In addition, we categorised individuals into 4 groups: low-CRP/low-PP (n=93/10 
events, referent), high-CRP/low-PP (n=76/12 events), low-CRP/high-PP (n=77/23 events) and high-CRP/high-
PP (n=93/40 events). Compared with the reference group, the risk factor-adjusted risk estimates were 
higher for both patients with high-CRP/low-PP [HR=1.18 (0.50-2.80)] and low-CRP/high-PP [HR=1.48 (0.63-
3.50)], but considerably higher for those with high-CRP/high-PP [HR=2.63 (1.17-5.91)]. 
 
Conclusions  
In type 1 diabetes, arterial stiffness, as expressed by PP, may explain a portion, albeit small, of the higher 
CVD risk associated with pentosidine. Cross-link breakers may, thus, offer a means to reduce arterial 
stiffening and related CVD in these patients. In addition, PP and CRP were interrelated and explained a 
portion of the associations with incident CVD in a mutual fashion. Notably, both CRP and PP remained 
independently associated with higher incidence of CVD, and in combination may increase even further the 
risk of CVD. This suggests that both LGI and arterial stiffness may need to be monitored and targeted 
separately in order to interrupt this vicious cycle and thereby deter the related cardiovascular sequelae 
often affecting these patients. 
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Introduction 
Patients with type 1 diabetes are characterised by accelerated arterial ageing, as 
illustrated by steeper increases in pulse pressure (PP) with age as compared with their 
peers without diabetes (1). Such increases in PP reflect arterial stiffening (2) and are 
associated with higher incident CVD in these patients (3,4). The mechanisms 
underlying the increases in PP in diabetes are not clear, but advanced glycation 
endproducts (AGEs) (5) and low-grade inflammation (LGI) may play a role (2).  
AGEs are formed by a nonenzymatic reaction between reducing sugars and 
proteins. These stable compounds accumulate with ageing and may contribute to age- 
and diabetes-associated arterial stiffening through the formation of collagen cross-
linking, which alters the structure and function of the extracellular matrix (5). A causal 
underlying role of LGI in the development of arterial stiffness has been suggested by 
studies linking higher levels of C-reactive protein (CRP) (6) and inflammation-sensitive 
proteins in plasma (7) to the incidence of isolated systolic hypertension (6) or 
subsequent increases in PP (7). The premise of elevated CRP antedating the onset of 
hypertension has also been confirmed by prospective studies among initially 
normotensive individuals (8-11). Indeed, inflammation may influence arterial 
stiffening by affecting vascular smooth muscle cell tone due to reduced availability of 
nitric oxide and increased activity of vasoconstrictors such as endothelin-1, and by 
affecting the composition of the extracellular matrix (12). In addition, inflammation 
may increase the production of reactive oxygen species (13), which in turn triggers 
inflammatory processes leading to the proliferation of smooth muscle cells, the influx 
of leucocytes, and the production of pro-inflammatory cytokines (14). However, 
others have suggested that increases in PP per se may be a driving force behind 
increases in inflammation (reverse causation), and thereby in CVD risk (15-17). It is 
thus not clear whether elevated LGI leads to increases in PP or whether elevated PP 
imposes biomechanical stimuli to endothelial cells promoting a cascade of 
mechanisms associated with inflammation that then lead to higher levels of CRP 
(reverse causation) (12,14,18,19). Another possibility is that CRP and PP act in concert 
and further boost each other’s deleterious impact on CVD (self-enforcing/bidirectional 
causation).  
We have recently shown that AGEs (20) and LGI (21) were associated with higher 
incident fatal and non-fatal CVD in type 1 diabetes. Given that both these mechanisms 
may enhance PP, and thereby increase CVD risk, elevated PP may thus constitute a 
mechanism through which LGI and AGEs are associated with increased CVD risk in 
these patients (Hypothesis one, Figure 7.1A – PP as a mediator). Alternatively (reverse 
causation), or in addition (bi-directional causation), LGI may (also) be consequent to 
increased PP and thus mediate the association between PP and incident CVD 
(Hypothesis 2, Figure 7.1B). In the present study we investigated these hypotheses in 
a 12-yr prospective cohort study of type 1 diabetes and incident CVD and all-cause 
mortality. The hypotheses were tested with the use of Mediation Analyses, a data 
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analysis technique that helps identify whether a variable is likely to be in the causal 
pathway relating determinant to outcome variables, by quantifying and ascertaining 
the significance of any such mediation effect (22,23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Hypotheses tested in the present study. Panel A) Hypothesis 1 - the associations of low-grade 
inflammation (LGI) and advanced glycation endproducts (AGEs) with incident cardiovascular 
disease (CVD) are, in part, mediated by arterial stiffness (as expressed by pulse pressure – PP); 
Panel B) Hypothesis 2 – LGI (also) mediates the association between PP and incident CVD, and 
in combination, LGI and PP may self-enforce their impact on CVD risk; Dotted and dashed 
lines indicate indirect/mediated ‘effects’ and the uninterrupted lines indicate direct or 
independent ‘effects’. 
Methods 
Study population and design 
In 1993, 391 patients with type 1 diabetes were enrolled in this 12-yr prospective 
observational study on CVD and mortality, as described in detail elsewhere 
(20,21,24,25). Briefly, 199 patients with type 1 diabetes and nephropathy and 192 
with normoalbuminuria were recruited from the outpatient clinic at the Steno 
↑ Arterial
stiffness
(Pulse pressure)
↑ Advanced
glycation
endproducts
↑ Cardiovascular
disease
↑ Low -grade
inflammation
A
B
↑ Arterial
stiffness
(Pulse pressure)
↑ Advanced
glycation
endproducts
↑ Cardiovascular
disease
↑ Low -grade
inflammation
 PP, AGEs, low-grade inflammation and incident CVD 
109 
7 
Diabetes Center. Normoalbuminuria was defined as urinary excretion rate (UAE) 
<30 mg/24 h, and diabetic nephropathy was defined according to the following clinical 
criteria: UAE >300 mg/24 h in at least two out of three previous consecutive 24-h 
urine collections, presence of diabetic retinopathy (assessed by fundus photography 
after pupillary dilatation), and no clinical or laboratory evidence of kidney or renal 
tract disease other than diabetic glomerulosclerosis. The study was approved by the 
local ethics committee and all patients gave their informed written consent.  
Baseline investigations 
All investigations were performed in the morning after an overnight fast. No 
antihypertensive medication was ever prescribed in 24% of patients with nephropathy 
and 88% of the normoalbuminuric patients. All of the remaining patients were asked 
to stop their antihypertensive treatment 8 days before the examination, but 27% and 
4% of patients in, respectively, the nephropathy and normoalbuminuria groups, did 
not comply with this recommendation.  
Blood pressure  
Systolic (SBP) and diastolic blood pressure (DBP) were measured twice and averaged, 
on the right arm, after at least 10 minutes of rest in the supine position. The 
measurements were performed with a Hawksley random zero sphygmomanometer 
(Hawksley & Sons Ltd, lancing, Sussex, UK) and appropriate cuff size. DBP was 
recorded at the disappearance of Korotkoff sounds (phase V). MAP was calculated as 
[(2*DBP)+SP)]/3. PP was calculated by subtracting DBP from SBP. 
Biomarkers of AGEs, LGI, and endothelial dysfunction  
Analyses of the biomarkers were done on frozen (-80°C) samples in our central 
laboratory (by C.G.S).  
Plasma levels of protein-bound N
ε
-(carboxyethyl)lysine (CEL) and N
ε
-
(carboxymethyl)lysine (CML) were determined, as markers of non-crosslinking AGEs, 
by stable-isotope dilution tandem mass spectrometry, and of protein-bound 
pentosidine, as a marker of cross-linking AGEs, were determined by a single step 
reversed phase based high-performance liquid chromatography (HPLC) separation 
with fluorescent detection (20). The intra- and inter-assay coefficients of variation 
(CVs) were 7.3% and 2.0% for CEL, 3.5% and 3.6% for CML, and 2.7% and 2.8% for 
pentosidine, respectively. 
We measured CRP, interleukin-6 (IL-6), and secreted phospholipase A2 (sPLA2) as 
markers of low-grade inflammation, soluble vascular cell adhesion molecule-1 
(sVCAM-1) as a marker of endothelial dysfunction, and soluble intercellular adhesion 
molecule-1 (sICAM-1) as a marker of both LGI and endothelial dysfunction. High-
sensitivity CRP was determined by in house enzyme-linked immunosorbent assays 
(ELISA) (26). Commercially available ELISA kits were used for the measurement of IL-6, 
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sPLA2, sICAM-1, and sVCAM-1 (Quantikine High Sensitivity; R&D Systems, Oxon, U.K.) 
(21). The intra- and inter-assay CVs of these immunoassays were all <8%.  
Other risk factors  
Measures of body mass index (BMI), glycated haemoglobin (HbA1c), total cholesterol, 
24-h UAE rate, estimated glomerular filtration rate (eGFR) and smoking status (never, 
former or current) were described in detail before (20,21,25).  
Follow-up and study end-points 
All patients were followed up to the last visit at Steno Diabetes Center, until 
1 September 2006 or until death (n=82) or emigration (n=3). All patients were traced 
through the national register during autumn 2006. If a patient had died before 
1 September 2006, the date of death was recorded and information on the primary 
cause of death was obtained from the death certificate, which was reviewed by two 
independent observers. Additional information available from necropsy reports was 
also included. All deaths were classified as cardiovascular unless an unequivocal non-
cardiovascular cause was established. In all patients alive at the end of follow-up, non-
fatal cardiovascular events were retrieved from their patient files at the Steno 
Diabetes Center and/or other hospitals.  
The primary study outcome was a combined end-point of fatal and non-fatal CVD 
(i.e. myocardial infarction, percutaneous coronary intervention, coronary bypass 
grafting, amputation due to ischaemia, vascular surgery for peripheral atherosclerotic 
disease and stroke). The study’s secondary end-point was all-cause mortality. 
Statistical analyses 
All analyses were performed with the Statistical Package for Social Sciences (SPSS) 
version 15.0 for Windows (SPSS, Chicago, IL, USA) or R version 2.13.0 (The R 
Foundation for Statistical Computing 2011). Variables with a skewed distribution, i.e. 
CRP, IL-6, sPLA2, pentosidine, and UAE, were loge transformed (Ln) prior to further 
analyses. Comparisons of baseline characteristics between groups were performed 
with Student’s t or χ
2
 tests, as appropriate.   
Mediation analyses  
The mediating role (i.e. extent and significance) of a variable/pathobiological 
mechanism hypothesised to be in the pathway between a given determinant and 
outcome was ascertained by quantitative appreciation of the attenuation in the 
strength of the association between determinant and outcome after adjustment for 
the potential mediator (22,23).  
Accordingly, we used ‘αβ product of coefficients’ method to investigate the 
mediating role of PP in the associations of AGEs and markers of LGI (main 
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determinants) with incident CVD or all-cause mortality (outcomes) (23). These 
analyses entail a series of steps to retrieve four coefficients (i.e. α, β, τ, and τ’) 
reflecting the associations of interest (Figure 7.2). First, we used multivariable linear 
regression analyses to ascertain which of the AGEs and markers of LGI considered 
were associated with PP (α paths). Second, we used Cox proportional hazards analyses 
to investigate the associations between PP (the potential mediator) and incident CVD 
or all-cause mortality, when adjusted for the AGEs and markers of LGI identified in the 
previous step (β path). Finally, Cox proportional hazards analyses were used to 
ascertain the relationships between AGEs or markers of LGI and incident CVD or 
mortality before (τ1 and τ2, respectively) and after adjustment for PP (i.e. τ1’ and τ2’, 
respectively). Given that the α and the β (as well as τ and τ’) coefficients and 
respective standard errors (SEs) were obtained by, respectively, ordinary least squares 
regression and maximum likelihood, they were first scaled to enable comparability 
across different estimation models, as described in detail elsewhere (23,27). The 
scaled coefficients and SEs were then entered into the RMediation package written 
for use in the R statistical software to calculate the αβ product and respective 95% 
confidence interval (CI) (28). The αβ product indicates the magnitude of attenuation 
from τ (Figure 7.2A) to τ’ (Figure 7.2B, i.e. the mediated effect, which is significant if 0 
is not included in the CI. Note that this specific software uses bootstrapping 
procedures to estimate asymmetric CIs to properly reflect the distribution of the αβ 
product, which is often skewed (22,29). The proportion mediated (in %) was 
estimated by dividing the mediated effect (αβ) by the total relationship of AGEs or 
markers of LGI with incident CVD (or all-cause mortality) as α1β /α1β+τ1’ or α2β 
/α2β+τ2’, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Illustration of the steps involved in mediation analyses models applied to the present study.   
 X, study main determinants; M, potential mediator; Y, study outcome; LGI, low-grade 
inflammation; AGEs, advanced glycation endproducts. 
 
B 
A 
τ1’ 
τ2 
τ2’ 
α2 Covariates 
α1 β 
M = Arterial stiffness 
(Pulse pressure) 
X1 = AGEs  
X2 = LGI  
Y = Cardiovascular 
disease 
X1 = AGEs  
X2 = LGI 
Y = Cardiovascular 
disease 
τ1 
Chapter 7 
112 
All analyses described above were adjusted for sex, age, duration of diabetes, 
HbA1c, presence of nephropathy, BMI, smoking status, total cholesterol, use of 
antihypertensive medication, whether or not patients withheld medication at the 
baseline examination, endothelial dysfunction markers (sVCAM-1 and sICAM-1, if 
appropriate), eGFR, and Ln-UAE (models 1). We also included: mutual adjustment for 
AGEs or markers of LGI to ascertain independence of these two mechanisms (models 
2); and adjustment for MAP (steady load) to establish that associations could be 
attributed to arterial stiffness (PP) independently of residual contribution from 
peripheral resistance (models 3) (30). All effect estimates were expressed per SD of 
the main determinants to enable comparisons of the strength of associations between 
them. To investigate whether the associations listed above differed between patients 
with normoalbuminuria vs. with nephropathy, or between individuals who did vs. did 
not withhold medication at the baseline examination, we added interaction terms to 
our models. We did not find any significant interactions (p-values for interaction terms 
all>0.1). All results were therefore presented for the whole study population. 
Joint effects of CRP and PP on incident CVD  
To evaluate whether CRP and PP exerted synergistic effects on incident CVD, we 
constructed cumulative hazard curves after categorizing individuals into 4 groups: 
low-CRP/low-PP, high-CRP/low-PP, low-CRP/high-PP and high-CRP/high-PP, with high 
and low defined as ≥ or < the median levels of CRP and PP. The observed effect 
estimates (HR) for the high-CRP-high-PP group were then compared with those that 
could be expected by combination of the independent effects of high-CRP with high-
PP, assuming either an additive or a multiplicative interaction between CRP and PP 
(31). 
Results 
Of the 391 patients included in this study, we excluded 17 in whom it was not possible 
to obtain sufficient follow-up data, 4 with missing data on baseline biomarkers levels, 
7 with end stage renal failure and 24 with prior CVD. Results reported herein thus 
refer to 339 patients.   
During the course of follow-up (median: 12.3 years [inter-quartile range 7.6-12.5]), 
82 individuals (24.2%) died; 85 (25.1%) suffered a fatal (n=48) and/or non-fatal (n=53) 
CVD event. Comparisons of the baseline characteristics between individuals with vs. 
without incident CVD events are shown in Table 7.1. 
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Table 7.1 Baseline characteristics according to the occurrence of cardiovascular disease events during 
follow-up. 
 Fatal or non-fatal CVD 
(n=85) 
No CVD 
(n=254) 
P-value 
Sex: male/female (%) 61/39 60/40   0.901 
Age (yrs) 44.7 (9.0) 40.3 (9.6) <0.001 
Duration of diabetes (yrs) 30.7 (8.8) 26.8 (7.5) <0.001 
Nephropathy: yes (%) 75 41 <0.001 
Retinopathy: no/simplex/proliferative (%) 8/37/55 21/45/34 <0.001 
HbA1c (%)   9.5 (1.5)   8.9 (1.4) <0.001 
Body mass index (kg/m
2
) 23.9 (3.3) 23.9 (2.8)   0.991 
Total cholesterol (mmol/l)   5.70 (1.10)   4.99 (1.12) <0.001 
Urinary albumin excretion rate (mg/24h) 644 [33-1940] 17 [7-525] <0.001 
eGFRMDRD (ml min
-1
 1.73m
-2
) 65.5 (29.1) 86.8 (21.1) <0.001 
Antihypertensive medication (%) 66 31 <0.001 
Smoking: never/former/current (%) 28/19/53 37/17/46   0.513 
Pentosidine (pmol/mg) 49.3 [35.7-71.8] 40.8 [34.0-49.0]   0.001 
Nε-(carboxyethyl)lysine (μmol/l) 1.02 (0.28) 0.92 (0.19)   0.004 
Nε-(carboxymethyl)lysine (μmol/l) 3.60 (1.12) 3.54 (0.84)   0.634 
C-reactive protein (mg/l) 1.59 [0.64-3.22] 0.96 [0.41-2.09]   0.008 
Interleukin-6 (pg/ml) 2.18 [1.52-3.45] 1.49 [0.99-2.35] <0.001 
Secreted phospholipase A2 (μg/ml) 4.40 [2.80-7.00] 4.00 [2.70-6.23]   0.329 
Soluble intercellular adhesion molecule-1 (ng/ml)    771 (258)   726 (272)   0.182 
Soluble vascular cell adhesion molecule-1 (ng/ml) 1045 (269)   984 (346)   0.141 
Systolic blood pressure (mmHg) 157 (24) 136 (20) <0.001 
Diastolic blood pressure (mmHg)   85 (13)   79 (12)   0.001 
Mean arterial pressure (mmHg) 109 (15)   98 (13) <0.001 
Pulse pressure (mmHg)   73 (21)   57 (15) <0.001 
Data are means (SD), median [inter-quartile range] or percentages, as appropriate. eGFRMDRD, estimated 
glomerular filtration rate by short modification of diet in renal disease equation. 
 
Associations of AGEs and markers of LGI with PP (α1 and α2 paths)  
In analyses adjusted for age, sex, duration of diabetes, use of antihypertensive 
medication, and other risk factors, pentosidine and CRP, but not the other AGEs or 
markers of LGI were significantly associated with PP (Table 7.2, model 1). These 
associations did not materially change when we included mutual adjustments 
between CRP and pentosidine (model 2) and further adjustment for MAP (model 3). In 
this fully adjusted model, PP was 2.6 mmHg (equivalent to 0.15 SD) and 2.4 mmHg 
(equivalent to 0.13 SD) higher per each SD increase in Ln-pentosidine and Ln-CRP, 
respectively. 
Associations of PP  with incident CVD and all-cause mortality (β path)  
After adjustments for conventional risk factors (Table 7.3, model 1), both pentosidine 
and CRP (model 2), and MAP (model 3), PP (per SD) was independently associated 
with higher incident CVD: HR=1.40 (95%CI: 1.04-1.88). The association of PP with all-
cause mortality was weaker [HR=1.36 (1.00-1.85)] and borderline not significant. 
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Associations between pentosidine and CRP with incident CVD and mortality (τ1 and τ2 
paths) and the mediating role of PP herein (τ1’ and τ2’ paths)  
In analyses adjusted for conventional risk factors (Table 7.3, model 1), one another 
(model 2), and MAP (model 3), pentosidine and CRP were both independently and 
significantly associated with higher incident CVD: HR=1.32 (1.01-1.72) and HR=1.40 
(1.08-1.82) per SD higher Ln-pentosidine and Ln-CRP, respectively. After further 
adjustment for PP the association between pentosidine and incident CVD was 
attenuated to HR=1.23 (0.93-1.63) and was no longer statistically significant; the 
association between CRP and incident CVD was attenuated to HR=1.35 (1.08-1.82), 
but remained statistically significant (model 4).  
Mediation analyses showed that the magnitude of the mediated effects by PP 
amounted to ~18% in the pentosidine→CVD association and to ~14% in the 
CRP→CVD association, and both were statistically significant (Table 7.4).  
In analyses with the study’s secondary end-point, adjustment for PP attenuated 
the increased risk for all-cause mortality associated with pentosidine from HR=1.31 
(1.00-1.71) to 1.26 (0.96-1.66) and the increased risk associated with CRP from 
HR=1.31 (0.99-1.73) to 1.26 (0.95-1.67) (Table 7.3). The magnitude of these 
attenuations was similar to those observed in analyses with incident CVD and 
amounted to ~15% and ~16%, respectively, but did not reach statistical significance 
(Table 7.4).  
Joint effects of CRP and PP on incident CVD   
The cumulative hazard curves after categorizing individuals into 4 groups: low-
CRP/low-PP (n=93/10 events, referent), high-CRP/low-PP (n=76/12 events), low-
CRP/high-PP (n=77/23 events) and high-CRP/high-PP (n=93/40 events), with high and 
low defined as ≥ or < the median levels of CRP (1.06 mg/l) and PP (58 mm Hg) are 
shown in Figure 7.3. Compared with the reference group, the risk factor-adjusted risk 
estimates were higher for both patients with high-CRP/low-PP [HR=1.18 (0.50-2.80)] 
and low-CRP/high-PP [HR=1.48 (0.63-3.50)], but considerably higher for those with 
high-CRP/high-PP [HR=2.63 (1.17-5.91)]. Albeit possibly underpowered due to 
stratification (see wider CIs around risk estimates), these analyses showed that the 
observed CVD risk for having both elevated CRP and elevated PP (2.63) was higher 
than could be expected from their independent effects considering either an additive 
[i.e. 1.18+1.48-1=1.66] or a multiplicative model [i.e. 1.18*1.48=1.75]. For the 
secondary end-point all-cause mortality, the risk factor-adjusted risk estimates were 
higher for patients with high-CRP/low-PP [HR=1.93 (0.74-5.07)] and low-CRP/high-PP 
[HR=1.59 (0.63-4.07)]. The risk for all-cause mortality when having both higher CRP 
and higher PP [HR=2.83 (1.14-7.05)] was higher than could be expected from their 
independent effects considered in an additive [i.e. 1.93+1.59-1=2.52], but not in a 
multiplicative model [i.e. 1.93*1.59=3.07]. 
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Figure 7.3 Cumulative hazard rates of fatal and non-fatal CVD in patients with type 1 diabetes 
according to their levels of C-reactive protein and pulse pressure. Data are adjusted for age, 
sex, duration of diabetes, Hb1Ac, presence of nephropathy, body mass index, total 
cholesterol, smoking, antihypertensive medication, withholding medication at the baseline 
examination, estimated glomerular filtration rate, Ln-urinary albumin excretion rate, 
endothelial dysfunction markers and pentosidine. 
 
Discussion 
Our study has three main findings. First, higher levels of plasma pentosidine and CRP 
were independently associated with higher PP as well as higher incident fatal and non-
fatal CVD among patients with type 1 diabetes. Second, PP significantly explained a 
portion of the higher fatal CVD risk associated with elevated pentosidine and CRP. This 
does not exclude the possibility of reverse causation, as indeed CRP also explained a 
similar and significant portion of the higher incidence of CVD associated with PP. 
However, and as third main finding, the combination of elevated CRP with elevated PP 
increased CVD risk beyond what could be expected by their independent effects, 
suggesting that LGI and arterial stiffness are causally interrelated and self-enforcing 
features involved in the development of CVD in type 1 diabetes. This is the first study 
that has examined the interrelationships of AGEs, LGI, and arterial stiffness and their 
impact on CVD by testing, with empirical data and mediation analytical techniques, 
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operative or mediating pathways. All in all, our findings support more closely our 2
nd
 
initial hypothesis (Figure 7.1B).  
We found a positive association between pentosidine, but not CEL nor CML, and 
PP. Pentosidine possibly contributes more directly to arterial stiffening by forming 
cross-links between molecules in the arterial wall.(5,32) Reductions in arterial stiffness 
in animals treated with aminoguanidine, a potent inhibitor of AGEs formation and 
protein-to-protein cross-linking (33), or 4,5-dimethyl-3-phenacylthiazolium chloride 
(DPTC or ALT-711), an AGE cross-link breaker compound (34), have substantiated the 
concept of AGE cross-link-mediated increase in arterial stiffness. The beneficial effects 
of ALT-11 were also confirmed in a proof-of principle randomised controlled trial 
showing ~15% improvements in arterial compliance accompanied by steeper 
decreases in PP in older individuals treated with ALT-711 as compared with placebo-
treated individuals (35). Our study extend these earlier findings and emphasise the 
clinical relevance of arterial stiffness resulting from cross-linking AGEs, by showing 
that pentosidine-related increases in PP may explain ~18% of the increased CVD risk 
associated with this AGE in type 1 diabetes.  
The lack of associations with the non-cross-linking AGEs examined in our study (i.e. 
CEL and CML) seem to emphasise further a predominant role of cross-linking AGEs in 
the process of accelerated arterial stiffening in diabetes. CEL, a putative marker for 
intracellular glycation, could alter cellular properties and lead to disturbances in 
vascular homeostatis (36,37). CML, a potential ligand for the receptor for AGE (RAGE) 
(38), could induce receptor-mediated activation of transcription factor NF-κB, thereby 
leading to formation of endothelial adhesion molecules (36). In this line, we have 
previously shown, in this cohort, that higher plasma soluble RAGE (sRAGE) levels were 
positively associated with both PP and incident CVD [HR=1.90 (1.13-3.21)], and that a 
portion of the latter could indeed be due to sRAGE-related increases in PP [HR 
attenuated to 1.67 (0.98-2.87)] (25). Therefore, CEL and CML may affect arterial 
stiffness through indirect effects on vascular cell function, whereas pentosidine may 
have a more direct impact on arterial stiffness (5,32). However, we have previously 
observed positive associations of CEL and CML with PP in another cohort of individuals 
with type 1 diabetes (EURODIAB) (39). The reasons for the discrepancy with the 
present study are not completely clear, but could in part be attributed to a relatively 
high portion of individuals with prevalent CVD in that study, whereas the present one 
excluded individuals with prior CVD. Indeed, in that study CEL and CML were positively 
associated with PP mainly in the individuals with prevalent vascular complications 
(39).  
The association observed between CRP and PP is in line with previous studies (15-
17), as well as with studies showing significant associations of predominantly CRP (and 
less so, if anything, of other LGI markers, e.g. IL-6) with more direct estimates of 
arterial stiffness (e.g. carotid distensibility and central pulse wave velocity) (40,41). 
We now extend these findings by showing that the mediating effects by PP in the 
CRP→CVD association (or, conversely, the mediating effects by CRP in the PP→CVD 
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association) were significant (albeit small in magnitude). We do not think that the 
mediation effects simply reflect confounding between CRP and PP given the abundant 
mechanistic evidence linking the two (either way) provided by prospective (6,7,17,40) 
and experimental studies [reviewed in (12,14)]. Instead, the association between CRP 
and PP may be causal and bidirectional and thus conciliate previous evidence focusing 
exclusively on one of the possible directions. Indeed, and in support of this, when in 
combination, higher levels of CRP and PP increased CVD risk to a greater extent than 
could be expected by their independent joint effects (Figure 3). Notably, self-enforcing 
effects of CRP and BP on incident CVD have been reported before (42). Altogether, the 
findings suggest a biological interaction (31) between inflammation and arterial 
stiffness underlying cardiovascular sequelae in type 1 diabetes.  
Both upregulation of sPLA2 (43) and of CRP (44) are downstream effects of IL-6. 
The lack of associations of IL-6 and sPLA2 with PP may be explained by the fact that 
IL-6 has many downstream effects, including anti-inflammatory effects (45), and these 
may not all be specifically associated with arterial stiffening. sPLA2 is an enzyme that 
catalyzes the hydrolysis of glycerophospholipids at the sn-2 position, which generates 
pro-atherogenic oxidised lipids (46) that are more specifically related to 
atherosclerosis than arterial stiffening. In addition, the diurnal variation of IL-6 and 
sICAM-1 may be greater than that of CRP (47), which may partially explain the lack of 
associations with PP. 
Despite being statistically significant, the magnitude of the mediation effects by PP 
(i.e. arterial stiffening) in the associations between pentosidine and CRP with incident 
CVD was small, which leaves much room for other mechanisms (e.g. atherosclerosis) 
to explain these associations. However, we may have underestimated the ‘true’ 
magnitude of mediation by PP. First, PP was calculated on the basis of two BP 
readings, which could be affected by measurement error. In addition, we used 
brachial, not central, PP as an estimate of arterial stiffness. In a recent meta-analysis, 
both central and brachial PP (10 mmHg) were significantly associated with incident 
CVD and mortality [HR=1.32 (1.22-1.42) and HR=1.19 (1.10-1.28), respectively] (48). 
Although central PP had only marginal added value in CVD risk prediction (48), the 
magnitude of the risk estimates was higher for the central than the brachial PP. A 
recent study in type 1 diabetes (the FinnDiane Study) (4) has shown that both brachial 
(10 mmHg) [risk-factors adjusted HR=1.22 (1.10-1.34) as estimated in the whole study 
population: events/n=178/4,321] and central PP [risk-factors adjusted HR=1.29 (1.02-
1.62), but estimated in a sub-population only: events/n=35/408], were associated 
with incident CVD, though the latter association was no longer significant after 
adjustment for previous CVD. Nevertheless, and despite the need to move beyond 
brachial PP to better understand etiology and fine tune stiffness-related risk 
estimation, it remains that brachial PP is an easily accessible measure and current 
clinical practice and decision making still relies on brachial BP recordings (2,49). 
Furthermore, given the evidence for an accelerated increase in brachial PP in type 1 
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diabetes (1), the central-to-brachial PP amplification phenomenon may be less 
influential in these individuals.  
Other limitations to our study are that AGEs, markers of LGI, and PP were only 
measured at baseline, impeding evaluation of the impact of changes in these variables 
on each other and on CVD. Therefore, although our data supports the view of a 
bidirectional and self-enforcing association between CRP and PP, we cannot establish 
definite causation between the two. Also, although we adjusted our analyses for a 
large set of covariates, we cannot fully exclude the possibility of residual confounding 
(50). Finally, this study was confined to individuals with type 1 diabetes and, 
therefore, extrapolations of its key findings to the general and/or other at-risk 
populations need caution. 
In conclusion, in type 1 diabetes, arterial stiffness, as expressed by PP, may explain 
a portion, albeit small, of the higher CVD risk associated with pentosidine. Cross-link 
breakers may, thus, offer a means to reduce arterial stiffening and related CVD in 
these patients. In addition, PP and CRP were interrelated and explained a portion of 
the associations with incident CVD in a mutual fashion. Notably, both CRP and PP 
remained independently associated with higher incidence of CVD, and in combination 
may increase even further the risk of CVD. This suggests that both LGI and arterial 
stiffness may need to be monitored and targeted separately in order to interrupt this 
vicious cycle and thereby deter the related cardiovascular sequelae often affecting 
these patients. 
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Summary  
The increasing prevalence of type 1 diabetes and its related vascular complications 
pose a tremendous burden for patients and our society (1), but the cellular and 
molecular mechanisms underlying the development of these vascular complications 
are still not fully elucidated. For the prevention and/or treatment of these diabetes-
related complications, we need a better understanding of these underlying 
mechanisms. Several potential mechanisms have been proposed to unravel the link 
between diabetes and the increased risk of cardiovascular disease (CVD) in these 
patients. We focused on the potential roles of advanced glycation endproducts (AGEs) 
and their receptor (RAGE), high-mobility group box-1 (HMGB1), endothelial and renal 
dysfunction, low-grade inflammation (LGI), and arterial stiffness (i.e. pulse pressure, 
PP).  
Present findings 
In the EURODIAB PCS nested case-control study we showed that higher levels of 
sRAGE, as a reflection of higher levels of RAGE, are cross-sectionally associated with 
greater prevalence of CVD in patients with type 1 diabetes (Chapter 2). This positive 
association could be attenuated by ~50% by endothelial and renal dysfunction and 
LGI, which suggests that these mechanisms may constitute pathways that link sRAGE, 
as a reflection of RAGE, to greater prevalence of CVD in type 1 diabetes. Positive 
trends were found between higher levels of sRAGE and the presence and across the 
levels of severity of albuminuria and retinopathy, though these were not independent 
of traditional risk factors. To gain more insight into the temporal relationship between 
sRAGE and vascular complications in type 1 diabetes, we investigated the associations 
between plasma sRAGE and incident fatal and non-fatal CVD as well as all-cause 
mortality in a 12 year follow-up study (Chapter 3). Incident fatal and non-fatal CVD as 
well as all-cause mortality doubled per unit higher Ln-sRAGE at baseline. Renal 
dysfunction, estimated by glomerular filtration rate, could explain in part (up to ~25%) 
the positive association between plasma sRAGE and incident fatal and non-fatal CVD. 
In addition, we showed that higher levels of sRAGE at baseline were associated with 
steeper decline in glomerular filtration rate in the course of follow-up (Chapter 3), 
which supports the hypothesis that renal dysfunction is an intermediate in the 
association between sRAGE and cardiovascular disease in these patients. 
We measured three AGEs (i.e. CEL, CML, and pentosidine) that could exert 
unfavourable effects on cellular functions through (partially) different pathways, and 
together, these may thus reflect a wide range of the potential adverse effects of AGEs. 
In a 12 year follow-up study in patients with type 1 diabetes, we observed ~30% 
increase in incident fatal and non-fatal CVD as well as all-cause mortality per 1 unit 
higher AGEs score (calculated by averaging the z-scores of CEL, CML, and pentosidine) 
independently of other risk factors (Chapter 4). 
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To further explore the ligand-RAGE axis, we also investigated the associations 
between HMGB1, a pro-inflammatory cytokine but also a ligand of RAGE, and the 
prevalence and incidence of vascular complications in type 1 diabetes. We showed 
positive cross-sectional associations between serum levels of HMGB1 and the 
presence and severity of albuminuria, but not with prevalent retinopathy and CVD 
(Chapter 5). This suggests that serum HMGB1 is involved differently in pathways that 
lead to micro- and macrovascular complications, which could, at least in part, be 
explained by the fact that HMGB1 is a ligand for different receptors with distinct 
functions. However, we cannot neglect the possibility that the lack of association 
between serum HMGB1 and prevalent CVD was due to the play of chance. In addition, 
in a prospective study in patients with type 1 diabetes we observed that higher levels 
of plasma HMGB1 are associated with higher incidence of all-cause mortality (Chapter 
6), and, to a lesser extent, also with higher incident fatal and non-fatal CVD. These 
associations were independent of conventional cardiovascular risk factors and of 
several potential HMGB1 related pathophysiological mechanisms.   
In an attempt to disentangle the associations between LGI (i.e. C-reactive protein, 
CRP), cross-linking AGEs (i.e. pentosidine), and arterial stiffness as well as their 
associations with incident fatal and non-fatal CVD (Chapter 7), we showed that in type 
1 diabetes, arterial stiffness, as expressed by PP, partially explains the higher risk for 
CVD associated with higher levels of pentosidine (marker of cross-linking AGEs). Cross-
link breakers may, thus, offer a means to reduce arterial stiffening and related CVD in 
these patients. In addition, PP and CRP were interrelated and explained a portion of 
the associations with incident CVD in a mutual fashion. Notably, both CRP and PP 
remained independently associated with higher incidence of CVD, and the 
combination of elevated CRP with elevated PP increased CVD risk beyond what could 
be expected from their independent effects, suggesting that LGI and arterial stiffness 
are causally interrelated and self-enforcing features involved in the development of 
CVD in type 1 diabetes. Both LGI and arterial stiffness may thus need to be monitored 
and targeted separately in order to interrupt this vicious cycle and thereby deter the 
related cardiovascular sequelae often affecting these patients. 
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General discussion 
Study population 
We used a European multi-centre nested case-control study and a Danish prospective 
cohort study in individuals with type 1 diabetes. In the cross-sectional nested case-
control study cases were selected as those with the greatest vascular complication 
burden as possible and controls were selected as those who were completely free of 
any vascular complication. This selection allowed us to compare individuals with single 
or multiple complications with individuals free of complications as efficiently as 
possible. Cases and controls were unmatched, so that the impact of variables of 
interest could still be assessed and analyses were performed with adjustments for 
potential confounders.  
The Danish prospective cohort study with a 12 year follow-up gave us the 
opportunity to look at the temporal relationships between determinants of interest 
and clinical outcomes. This study consisted of 391 patients with type 1 diabetes who 
were enrolled in a prospective observational study on cardiovascular complications 
and mortality. In 1993, 199 patients with type 1 diabetes and nephropathy and 192 
with normoalbuminuria (i.e. urinary excretion rate <30 mg/24 h) were recruited from 
the outpatient clinic at Steno Diabetes Center (Gentofte, Denmark). Diabetic 
nephropathy was defined according to the following clinical criteria: persistent 
macroalbuminuria >300 mg/24 h in at least two out of three previous consecutive 24-
h urine collections, presence of diabetic retinopathy (assessed by fundus photography 
after pupillary dilatation), and no clinical or laboratory evidence of kidney or renal 
tract disease other than diabetic glomerulosclerosis.  
Both studies included patients with type 1 diabetes only. Therefore, extrapolations 
to other populations (e.g. patients with type 2 diabetes) need some caution. In 
addition, because we did not include a control group in our studies, we cannot 
address the question as to whether the AGE-RAGE axis-related higher prevalence and 
incidence of vascular complications could explain the excess risk for cardiovascular 
complications observed in type 1 diabetes. 
In aetiological research we try to investigate (confirm or exclude) the relation 
between a determinant and a certain disease outcome, in which the effects of factors 
that may obscure such relationship are taken into account. Although the individuals 
included in our studies were well characterised and we minimised the influence of 
confounding in the associations observed by adjustments for many possible 
confounders, interference by factors we did not measure cannot be ruled out. In 
addition, in all our studies we included individuals in whom full data on variables of 
interest were available. Selection bias may occur if individuals included in the analyses 
would differ considerably from the ones excluded from the analyses. However, no 
such differences with regard to our main determinants or our main outcome 
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measures were observed between individuals excluded and those included in our 
studies.  
Main determinants 
Soluble receptor for advanced glycation endproducts (RAGE)  
Different cell types including human endothelial cells express RAGE. In addition to cell-
bound RAGE, soluble forms of RAGE (sRAGE) appear extracellularly. These soluble 
forms result from alternative splicing (2) or from proteolytical cleavage of the 
membrane-bound RAGE (Figure 1.3), which is most probably shed into the circulation 
by the sheddase, a disintegrin and metalloprotease 10 (3). The functional role of these 
soluble forms of RAGE in the circulation remains unclear, but they may reflect the 
activity of the ligand-RAGE axis. The positive associations observed between sRAGE 
and prevalence and incidence of CVD reported in Chapter 2 and 3, respectively, are in 
line with a large Finnish cohort study (4), but not all previous studies (5-7), among 
patients with type 1 diabetes. The reasons for these contradictory findings are not 
clear, but may be explained by the fact that different pools of soluble RAGE were 
measured and investigated across studies, namely, the total pool of sRAGE by the 
Quantikine sRAGE ELISA kit (R&D systems, Minneapolis, USA) in the Finnish (4) and in 
our studies, or specifically the splice variant esRAGE by the B-Bridge International 
esRAGE ELISA kit (Daiichi Fine Chemicals, Takaoka, Japan) in the others (5-7). The 
inconclusive findings from the studies so far may thus be due to differences in 
measured variants of soluble RAGE, each of which might have a different function. 
The differences in the clinical settings or ethnicity might also contribute to the 
discrepancies in these studies.  
The naturally occurring form of sRAGE, as well as artificially produced sRAGE, can 
potentially bind to a ligand thereby acting as a decoy, which prevents ligand-RAGE 
interaction and activation (8,9). This could thus explain any inverse association 
observed between sRAGE/esRAGE and vascular complications. However, although 
sRAGE has been an interesting subject of investigation under this suspected decoy 
function, it is very unlikely that sRAGE can act as such (i.e. by capturing and 
eliminating AGEs and/or other ligands) because the levels of circulating sRAGE are at 
least 1000 times lower than needed for efficient binding and elimination of AGEs and 
other ligands. In addition, a recent 4-year prospective multi-centre study in patients 
with type 2 diabetes has reported both sRAGE and esRAGE to be positively associated 
with higher risk of coronary heart disease (10). 
Advanced glycation endproducts (AGEs) 
We included three different AGEs in our analyses. Based on their characteristics each 
of them may represent a different part of the mechanisms through which AGEs could 
exert their potential adverse effects in the development of vascular complications in 
 General discussion 
131 
8 
type 1 diabetes. CEL (as a putative marker of intracellular glycation), CML (as a 
potential ligand of RAGE), and pentosidine (as one of the cross-linking AGEs), 
together, may thus reflect a wide range of the potential unfavourable effects of AGEs.  
In our study (Chapter 4) we did not normalise CEL, CML and pentosidine for an 
amino acid, e.g. lysine, and this may not enable direct comparison (of absolute values) 
with other studies that have done so (and did not report the values for the AGEs and 
the amino acid, separately). This would be an important limitation if such lack of 
normalisation would affect our findings. In order to address this, we have examined 
data from the EURODIAB study, in which plasma CML, CEL, and lysine concentrations 
were available (11). When we examine the correlations between CEL and CML with or 
without normalisation for lysine (39.7 ± 4.4 mM), we found that CEL (1.21 ± 0.47 μM) 
and CEL/lysine (31 ± 11 μM/M) as well as CML (2.26 ± 0.79 μM) and CML/Lysine 
(57 ± 18 μM/M) were highly correlated: correlation coefficients were 0.95 and 0.94, 
respectively. Moreover, in the EURODIAB study the associations between plasma CEL 
as well as CML and the presence of CVD did not differ between normalised and non-
normalised values. Given these strong correlations between normalised and non-
normalised values of AGEs, and their comparable associations with the presence of 
CVD, normalisation for an amino acid concentration is unlikely to affect the 
associations between plasma AGEs and study endpoints in our prospective study 
(Chapter 4).     
High-mobility group box-1 (HMGB1) 
HMGB1 was discovered as an intranuclear protein involved in the DNA organisation 
and regulation of transcription (12). Recently, extracellular HMGB1, released by 
necrotic cells (13) and inflammatory cells upon activation (14), has been suggested to 
function as a pro-inflammatory cytokine (15), at least in part, through ligation of RAGE 
(16) or toll-like receptors (17).  
We have measured HMGB1 levels in serum in the cross-sectional study and in 
plasma in the prospective study. In the cross-sectional study we did not find a positive 
association between serum HMGB1 and prevalent CVD (Chapter 5) in contrary to the 
positive association observed in the prospective study between plasma HMGB1 levels 
and incident CVD (Chapter 6). The lack of association between serum HMGB1 and 
prevalent CVD may be due to the play of chance or residual confounding by, for 
example, lipid lowering drugs. However, the apparent discrepancy could also imply 
that serum HMGB1 and plasma HMGB1 do not represent the same pool of HMGB1 in 
these patients. This might be explained by the platelet activation and coagulation 
cascade initiated in the vacuum container during the usual process to obtain serum 
samples from the blood samples. Activated platelets release several pro-inflammatory 
cytokines, and platelet activation markers are positively associated with serum HMGB-
1 levels in patients with disseminated intravascular coagulation associated with 
haematologic malignancies (18). In addition, it has been reported that part of the 
HMGB-1 present in the cytoplasma of resting platelets could be transported to the 
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platelet surface upon platelet activation (19). This process may vary per blood sample 
according to the platelet count and, therefore, serum HMGB-1 levels may not reflect 
adequately the extracellular HMGB-1 levels in the subjects. 
Circulating levels vs. tissue levels of biomarkers  
In our studies we have measured circulating levels of sRAGE, AGEs, and HMGB1 only, 
and it is not clear whether these are representative of the total pool of these 
biomarkers. Indeed, AGEs accumulate in tissue and cellular concentrations of AGEs 
are higher than plasma AGEs levels (23). The extents to which the circulating levels of 
RAGE and HMGB1 relate to their tissue levels are unknown. Further studies in which 
both circulating and tissue levels of these biomarkers are measured are needed to 
clarify the relation between the biomarkers levels in the two compartments and their 
specific associations to vascular complications.  
Low-grade inflammation and endothelial dysfunction 
We used biomarkers to represent LGI and endothelial dysfunction, though we do not 
exactly know whether this is the most adequate method to represent these 
pathophysiological mechanisms, because both mechanisms comprise many aspects.  
In addition, the levels of the markers of LGI and endothelial dysfunction 
investigated were only measured once, which might have diluted the associations we 
found. However, we combined the z-scores of the different markers of LGI and 
endothelial dysfunction into averaged scores to overcome biological variability of a 
single biomarker. A z-score represents the distance between an individual’s biomarker 
score from the population’s total mean in units of the population’s standard 
deviation, and is thus a common transformation that enables the combination of 
several markers originally expressed in different units. We assumed that every 
biomarker measured reflects (part of) the process of LGI or endothelial dysfunction. 
We have weighted them equally, however, it is unclear which marker may be more 
important than the others.  
Arterial stiffness (i.e. pulse pressure) 
Brachial PP was calculated on the basis of two blood pressure readings, which could 
be affected by measurement error. In addition, we used brachial, not central, PP as an 
estimate of arterial stiffness. In a recent meta-analysis, both central and brachial PP 
(10 mmHg) were significantly associated with incident CVD and mortality [HR=1.32 
(1.22-1.42) and HR=1.19 (1.10-1.28), respectively] (20). Although central PP had only 
marginal added value in CVD risk prediction, the magnitude of the risk estimates was 
higher for the central than the brachial PP. A recent study in type 1 diabetes (the 
FinnDiane Study) has shown that both brachial (10 mmHg) [risk-factors adjusted 
HR=1.22 (1.10-1.34) as estimated in the whole study population: events/n=178/4,321] 
and central PP [risk-factors adjusted HR=1.29 (1.02-1.62), but estimated in a sub-
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population only: events/n=35/408], were associated with incident CVD, though the 
latter association was no longer significant after adjustment for previous CVD (21). 
Nevertheless, and despite the need to move beyond brachial PP to better understand 
aetiology and fine tune stiffness-related risk estimation, it remains that brachial PP is 
an easily accessible measure and current clinical practice and decision making still 
relies on brachial blood pressure recordings. Furthermore, given the evidence for 
accelerated arterial aging in type 1 diabetes (22), the central-to-brachial PP 
amplification phenomenon may be less influential in these individuals. 
Outcomes  
In the EURODIAB study prevalent CVD was defined as a positive medical history of a 
cardiovascular event including myocardial infarction, angina, coronary artery bypass 
graft and/or stroke, and/or ischaemic changes on a centrally Minnesota-coded ECG. 
This non-fatal outcome may be susceptible to misclassifications, because of its 
dependency on the completeness and accuracy of patients’ records and/or discharge 
letters. Albumin excretion rates (UAEs) were measured from duplicate 24 h urine 
collections, which are considered the gold standard for measuring albuminuria. 
However, these collections are cumbersome and inadequate collections may impair 
its reliability. Retinopathy was assessed from retinal photo-graphs according to the 
EURODIAB protocol (2-field 45° retinal photography) (24). This method compared 
favourably with the gold standard 7-field 30° retinal photography. The 2-field 45° 
proved to be acceptably repeatable and accurate (24). 
In the Danish prospective cohort study all patients were traced through the 
national register, which is a reliable source for mortality dates. The date of death was 
recorded and information on the primary cause of death was obtained from the death 
certificate, which was reviewed by two independent observers. Additional available 
information from necropsy reports was also included. In all patients alive at the end of 
follow-up non-fatal cardiovascular events were retrieved from their patient files from 
Steno Diabetes Center and/or other hospital records. The primary study outcome was 
a combined end-point of fatal and non-fatal CVD (i.e. myocardial infarction, 
percutaneous coronary intervention, coronary bypass grafting, amputation due to 
ischaemia, vascular surgery for peripheral atherosclerotic disease and stroke), and the 
secondary outcome was all-cause mortality. All deaths were classified as 
cardiovascular unless an unequivocal non-cardiovascular cause was established. 
Potential misclassification of non-specific mortality as CVD-related mortality may have 
introduced non-differential biases, in which case the estimates reported herein may 
have been underestimated.  
Although the secondary end-point in this study (all-cause mortality) was quite 
valid, our primary end-point including non-fatal end-points may have been more 
susceptible to misclassification bias, because of its dependency on the completeness 
and accuracy of patients’ records and/or discharge letters. Most likely, we may have 
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missed some cases (i.e. patients who were possibly considered as ‘free from CVD’ 
when in fact they were not), but then such misclassification was likely to be random 
because CVD status was ascribed without prior knowledge of subjects’ biomarkers 
levels. Again, these misclassifications, if present, may, if anything, have led to an 
underestimation of the strength of the associations between our main determinants 
and the combined main study end-point (fatal and non-fatal CVD). 
Clinical relevance  
The increasing prevalence of type 1 diabetes and its related vascular complications 
pose a tremendous burden for patients and our society, while the pathophysiological 
mechanisms underlying the development of these vascular complications are still to 
be elucidated. Results from animal studies suggested that the AGE-RAGE axis 
(9,23,25,26) and HMGB-1 (27) may play a role in the development of vascular 
complications in diabetes. Whether these animal models could adequately reflect the 
human clinical situation is unclear. Beside the differences between species, we also 
cannot neglect the differences in settings (28). Namely, in experimental animal studies 
the animal model is carefully selected to investigate one specific determinant, while in 
a human clinical setting we are confronted with patients with several comorbidities 
and various circumstances. Translational observational/descriptive studies in humans 
are often limited by ethical and financial issues. Ideally, we would like to test our 
hypotheses at relevant sites where the pathophysiological processes take place. 
However, mostly we are restricted to investigate markers, such as circulating levels, of 
the determinants of interest. Despite of this limitation, the findings observed in our 
studies have additional value to the existing knowledge from animal studies and bring 
us a step closer to revealing the relevance of the pathophysiological mechanisms 
investigated to the higher risk for vascular complications in type 1 diabetes. In 
addition, we have tried not to look only for putative associations between 
determinants and outcomes, but also to provide insights into the underlying 
pathways. Furthermore, though the intention of our studies was to investigate 
aetiological hypotheses, circulating levels of biomarkers investigated may have 
predictive qualities and could form easy accessible clinical tools, in contrast to the 
more difficultly obtainable tissue levels of these biomarkers. 
We showed that sRAGE, AGEs, HMGB1, and markers of LGI and arterial stiffness 
were, independently of traditional risk factors, associated with greater prevalence 
and/or higher incidence of vascular complications in patients with type 1 diabetes. 
These risk factors could constitute new targets in the prevention and/or treatment of 
vascular complications in type 1 diabetes. In addition, we showed that the individual 
mechanisms are related to each other, as illustrated in Figure 8.1. Higher incident CVD 
associated with higher levels of plasma sRAGE may, in part, be explained by sRAGE-
associated renal dysfunction. In addition, increased arterial stiffness may constitute a 
mechanism through which cross-linking AGEs could lead to higher risk for CVD, and 
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therefore, targeting cross-linking AGEs may offer a means to reduce related arterial 
stiffening and CVD in type 1 diabetes. Furthermore, both CRP and PP were 
independently associated with higher incidence of CVD, and the combination of 
elevated CRP with elevated PP increased CVD risk beyond what could be expected by 
their independent effects, suggesting that LGI and arterial stiffness exert self-
enforcing effects on CVD in type 1 diabetes. This suggests that both LGI and arterial 
stiffness may need to be monitored and targeted separately in order to interrupt this 
vicious cycle and thereby deter the related cardiovascular sequelae often affecting 
these patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1. Present findings. 
 
 
Future research 
Although markers of the AGE-RAGE axis, LGI and arterial stiffness were associated 
with greater prevalence and/or higher incidence of vascular complications in patients 
with type 1 diabetes, longitudinal studies are needed to elucidate further the 
temporal relationship between these risk factors and clinical outcome. In addition, for 
our mediation analyses we had data at one time point only on the determinants and 
potential mediators and, thus, we cannot exclude the possibility of reverse causation 
as illustrated by the bi-directional arrows in Figure 8.1 between our main 
determinants (i.e. AGEs, sRAGE, and HMGB1) and our potential mediators (i.e. LGI, 
endothelial and renal dysfunction, and arterial stiffness). For more sophisticated 
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mediation analyses, in which potential reverse causation analyses could be better 
addressed we would need data on both determinants and potential mediators at 
different time points during follow-up. No longitudinal data of the associations 
observed exist in large groups of type 1 diabetes at the time, thus these studies may 
serve as a reasonable starting point to further explore these associations.  
In addition, studies in which both circulating and tissue levels of these biomarkers 
are measured are needed to clarify the relation between the biomarkers levels in the 
two compartments and their specific relevance to vascular complications.  
Furthermore, it remains to be proven whether targeting and lowering the levels of 
these risk factors could also result in a more favourable clinical outcome. To enable 
such intervention studies we would also need drugs that are able to decrease levels 
and/or activity of the AGE-RAGE axis, LGI, and arterial stiffness. 
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Samenvatting  
Type 1-diabetes is een chronische ziekte, die zich gewoonlijk presenteert in de 
kindertijd of in de adolescentie. Type 1-diabetes wordt gekenmerkt door hoge 
glucosewaardes (hyperglykemie) en ontstaat door (auto-immuun) vernietiging van de 
insuline-producerende beta-cellen geclusterd in de eilandjes van Langerhans van de 
alvleesklier, wat resulteert in veelal een absoluut tekort aan insuline die dagelijkse 
insuline toediening noodzaakt. Symptomen veroorzaakt door hyperglykemie zijn 
onder meer polyurie, polydipsie, gewichtsverlies, verandering van gezichtsvermogen 
en vermoeidheid. Het aantal nieuwe ziektegevallen (incidentie) van type 1-diabetes bij 
kinderen varieert wereldwijd van 0,1/100.000 per jaar in Zunyi, China tot 
36,8/100.000 per jaar in Sardinië, Italië. In Nederland wordt de incidentie van type 
1-diabetes geschat op 13/100.000 per jaar bij kinderen ≤14 jaar. De incidentie van 
type 1-diabetes lijkt toe te nemen in alle leeftijdsgroepen, met name bij jongere 
kinderen, met een totale jaarlijkse stijging van ~3,9% geschat op basis van 20 
populatie-gebaseerde registers in 17 Europese landen in de periode 1989-2003. De 
redenen voor deze toenemende incidentie zijn onbekend, maar waarschijnlijk spelen 
omgevingsfactoren een rol hierin. Ondanks uitgebreid wetenschappelijk onderzoek, 
kan type 1-diabetes niet worden voorkomen of genezen met de huidige beschikbare 
behandelingen, zoals immunotherapie, stamceltherapie of transplantatie van 
eilandjes van Langerhans. 
Wereldwijd zijn er ~22 miljoen patiënten met type 1-diabetes en dit zal naar 
verwachting verdubbelen in de komende 20-30 jaar. In Nederland wordt het huidige 
voorkomen (prevalentie) van type 1-diabetes geschat op 100.000. De last van diabetes 
voor zowel patiënten als voor onze maatschappij wordt voornamelijk veroorzaakt 
door diabetes-gerelateerde korte en lange termijn complicaties, geïllustreerd door 
een ~4-voudige toename in het risico op hart- en vaatziekten (HVZ) bij type 
1-diabetes, en een ~7-voudige en ~17-voudige toename van het risico op sterfte aan 
HVZ bij respectievelijk mannen en vrouwen, die type 1-diabetes hadden en jonger dan 
40 jaar waren, vergeleken met mensen zonder diabetes. Daarnaast leiden diabetes-
gerelateerde microvasculaire complicaties (bijvoorbeeld diabetische retinopathie en 
nefropathie) tot een vermindering van visus en nierfunctie, die een hogere morbiditeit 
met zich meebrengen bij patiënten met type 1-diabetes.  
De toenemende prevalentie van type 1-diabetes en de bijbehorende vasculaire 
complicaties vormen een enorme last voor de patiënten en voor onze samenleving, 
maar de cellulaire en moleculaire mechanismen die ten grondslag liggen aan het 
ontstaan van deze vasculaire complicaties zijn nog steeds niet volledig opgehelderd. 
Voor de preventie en/of de behandeling van deze diabetes-gerelateerde complicaties, 
moeten we een beter begrip verkrijgen van de mogelijk onderliggende mechanismen. 
Verschillende mechanismen zijn geopperd om de link tussen diabetes en het 
verhoogde risico op HVZ bij deze patiënten te verklaren. We hebben ons gericht op de 
potentiële rol van geavanceerde glycerings eindproducten (AGEs) en hun receptor 
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(RAGE), high-mobility group box-1 (HMGB1), endotheel- en nierfunctiestoornissen, 
laaggradige ontsteking, en arteriële stijfheid (gemeten als verhoogde polsdruk).  
Resultaten 
In de EURODIAB nested case-control studie hebben we geobserveerd dat hogere 
waardes van het in plasma circulerende RAGE (sRAGE), als een weerspiegeling van 
hogere waardes van RAGE, cross-sectioneel geassocieerd zijn met een hogere 
prevalentie van HVZ in patiënten met type 1-diabetes (hoofdstuk 2). De sterkte van 
deze associatie neemt met ~50% af wanneer wij de rol van endotheel- en 
nierdisfunctie en laaggradige ontsteking in het model opnemen, hetgeen suggereert 
dat deze mechanismen mogelijk de link kunnen vormen tussen hogere waardes van 
sRAGE, als een reflectie van RAGE, en de hogere prevalentie van HVZ in patiënten met 
type 1-diabetes. Positieve trends werden ook gevonden tussen hogere waardes van 
sRAGE en de aanwezigheid als ook de mate van ernst van albuminurie en 
retinopathie, maar deze waren niet onafhankelijk van de traditionele risicofactoren 
van HVZ. Om meer inzicht te krijgen in de temporele relatie tussen sRAGE en 
vasculaire complicaties bij type 1-diabetes, onderzochten we de associatie tussen 
plasma sRAGE waardes en de incidentie van fatale en niet-fatale gevallen van HVZ 
evenals de totale sterftegevallen in een studie waarin we de patiënten 12 jaar hebben 
gevolgd (hoofdstuk 3). Incidentie van fatale en niet-fatale HVZ alsook totale 
mortaliteit verdubbelde ongeveer per eenheid hogere waarde van plasma sRAGE, 
welke is gemeten aan het begin van de studie. Nierdisfunctie, geschat door 
glomerulaire filtratiesnelheid, zou hierbij voor een deel (tot ~25%) de positieve 
associatie tussen plasma sRAGE en incidentie van fatale en niet-fatale HVZ kunnen 
verklaren. Daarnaast toonden we aan dat hogere waardes van plasma sRAGE gemeten 
bij aanvang van de studie geassocieerd waren met sterkere daling van de glomerulaire 
filtratiesnelheid gemeten in de loop van de studie (hoofdstuk 3), welke de hypothese 
ondersteunt dat nierfunctiestoornis een intermediaire rol kan spelen in de associatie 
tussen sRAGE en HVZ in deze patiënten. 
We hebben drie AGEs (CEL, CML, en pentosidine) gemeten, die ongunstige 
effecten op de celfuncties zouden kunnen uitoefenen door (gedeeltelijk) verschillende 
mechanismen, en samen, zouden deze drie dus een breed scala van de mogelijke 
schadelijke effecten van AGEs kunnen weerspiegelen. In een 12 jaar follow-up studie 
in patiënten met type 1-diabetes, observeerden we een ~30% toename in incidentie 
van fatale en niet-fatale HVZ alsook totale mortaliteit per 1 eenheid hogere AGEs 
score (berekend als het gemiddelde van de z-scores van CEL, CML, en pentosidine) en 
deze associatie was onafhankelijk van andere HVZ risicofactoren (hoofdstuk 4). 
Om verder de rol van de RAGE-as te verhelderen, hebben we ook onderzoek 
gedaan naar HMGB1, een pro-inflammatoir cytokine die een rol speelt bij ontsteking 
als deel van ons afweersysteem, maar ook een substraat die zich aan RAGE kan binden 
en kan activeren. We onderzochten de associaties tussen HMGB1 en de prevalentie 
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en incidentie van vasculaire complicaties bij type 1-diabetes. We observeerden een 
cross-sectionele associatie tussen hogere serumspiegels van HMGB1 en de 
aanwezigheid en de ernst van albuminurie, maar niet met retinopathie of HVZ 
(hoofdstuk 5). Dit suggereert dat serum HMGB1 op andere manieren betrokken kan 
zijn in de mechanismen die leiden tot micro- en macrovasculaire complicaties, welke 
ten dele verklaard zouden kunnen worden door het feit dat HMGB1 kan binden aan 
verschillende receptoren met verschillende functies. We kunnen echter niet 
voorbijgaan aan de mogelijkheid dat het ontbreken van een associatie tussen serum 
HMGB1 en prevalentie van HVZ te wijten was aan toeval. Aangezien wij in de 
prospectieve studie in patiënten met type 1-diabetes wel een associatie 
observeerden, waarbij hogere waardes van plasma HMGB1 geassocieerd waren met 
een hogere incidentie van totale mortaliteit (hoofdstuk 6) en, in een minder sterke 
mate, ook met hogere incidentie van fatale en niet-fatale HVZ. Deze associaties waren 
onafhankelijk van conventionele HVZ risicofactoren en verschillende potentiële 
HMGB1 gerelateerde pathofysiologische mechanismen. 
In een poging om de associaties tussen laaggradige ontsteking (gerepresenteerd 
door C-reactive protein, CRP), cross-linking AGEs (gerepresenteerd door pentosidine), 
en arteriële stijfheid onderling alsmede hun associaties met de incidentie van fatale 
en niet-fatale HVZ op te helderen (hoofdstuk 7), observeerden we in patiënten met 
type 1-diabetes, dat arteriële stijfheid, gerepresenteerd door polsdruk, gedeeltelijk 
het hogere risico op HVZ gerelateerd aan hogere pentosidinewaardes (marker van 
cross-linking AGEs) kon verklaren. Cross-link brekers kunnen daardoor een middel 
vormen om arteriële verstijving en de daaraan gerelateerde HVZ in deze patiënten 
verminderen. Daarnaast gingen hogere polsdrukwaardes samen met hogere CRP 
waardes, waarbij ze wederzijds hun associatie met een hogere incidentie van HVZ 
deels konden verklaren. Belangrijk daarbij is dat zowel hogere waardes van polsdruk 
als CRP onafhankelijk van elkaar geassocieerd bleven met hogere incidentie van HVZ 
en de combinatie van hoge polsdruk met hoog CRP het risico op HVZ vergrootte boven 
het te verwachten risico van wanneer men hun afzonderlijk effecten bijelkaar zou 
optellen. Dit suggereert dat arteriële stijfheid en laaggradige ontsteking causaal 
samenhangen en tevens dat er elkaar onderling versterkende mechanismen 
betrokken zijn bij het ontstaan van HVZ in type 1-diabetes. Zowel arteriële stijfheid als 
laaggradige ontsteking dienen dus afzonderlijk gemonitord en behandeld te worden 
om deze vicieuze cirkel te onderbreken en daarmee de cardiovasculaire complicaties 
die vaak in deze patiënten optreden te verminderen. 
In hoofdstuk 8 worden de belangrijkste bevindingen van dit proefschrift 
samengevat en bediscussieerd. Ondanks meerdere beperkingen, zijn de bevindingen 
in onze studies van additionele waarde boven de bestaande kennis vanuit 
voornamelijk dierproeven en brengen deze observaties ons een stap dichter bij het 
ophelderen van de relevantie van de onderzochte pathofysiologische mechanismen 
ter verklaring van het hogere risico op vasculaire complicaties geassocieerd met type 
1-diabetes. Daarnaast hebben we geprobeerd niet uitsluitend de mogelijke associaties 
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tussen determinanten en uitkomsten te benoemen, maar ook om inzicht te 
verschaffen in de potentiële onderliggende mechanismen als link tussen determinant 
en uitkomst. 
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Dankwoord  
En nu dan het allerlaatste stuk tekst van mijn boekje en tevens waarschijnlijk ook het 
meest gelezen stuk. Het begin van mijn promotietraject viel me zwaar, vooral door de 
sterke verandering in werkstructuur van patiëntenzorg naar computerwerk. Maar 
geleidelijk kon ik de nieuwe werksfeer waarderen en uiteindelijk heb ik een hele 
gezellige, maar vooral ook leerzame tijd gehad. Nu is dan het moment gekomen om 
de vele mensen die hieraan hebben bijgedragen te bedanken. 
 
Dear Isabel, thank you for all your efforts taken to guide me through the 
wilderness of epidemiology and statistics. Without being corny, I have to say that I 
have learned a lot from you and without you this thesis would have been impossible 
for me to finish (at least not in time). In the past four years there have been hard 
times, times when I was close to tears, and for those moments I am grateful for your 
listening ear and your mental support. Hopefully there will be more opportunities in 
the future to work with/learn from you. 
 
Uiteraard wil ik ook mijn promotores, Prof. dr. CDA Stehouwer en Prof. dr. CG 
Schalkwijk, bedanken voor hun bijdrage en steun. Beste Coen, ten eerste moet ik je 
bedanken voor de kans die je me hebt gegeven om meer inzicht te krijgen in 
wetenschappelijk onderzoek en vooral in epidemiologie. Zonder jouw overtuigende 
woorden was ik nooit aan epidemiologisch onderzoek begonnen. Na de afgelopen 
jaren kan ik zelfs zeggen dat ik epidemiologie best leuk ben gaan vinden. Daarnaast wil 
ik je graag bedanken voor alle nuttige opmerkingen die hebben geleid tot verdere 
diepgang van de papers.  Als laatste wil ik ook mijn dank uiten voor je snelle reacties. 
Beste Casper, om te beginnen bedankt voor de mogelijkheid om in deze leuke 
onderzoeksgroep te mogen werken. Daarnaast bedankt voor je laagdrempeligheid 
voor vragen stellen, je ontvangst in de vorm van een glimlach, je enthousiaste 
opstelling én de geweldige BBQs. 
 
Prof. dr. MH Prins. Beste Martin, helaas dat je uiteindelijk niet mijn promotor kon 
zijn. We hebben elkaar niet veel gesproken, maar ik ben je dankbaar voor je positieve 
houding en al je geboden hulp. 
 
De beoordelingscommissie Prof. dr. CP van Schayck, Prof. dr. JM Dekker, Prof. dr. 
Buurman en Prof. dr. NC Schaper wil ik graag bedanken voor de tijd die jullie hebben 
besteed aan het beoordelen van mijn proefschrift. Dear Prof. dr. A. Bierhaus, thank 
you very much for willing to be a member of the committee. 
 
Dear Prof. dr. Chaturvedi and Prof. dr. Fuller, thank you very much for the 
opportunity to use the data from the EURODIAB prospective complication study. I 
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would also like to thank you for your support and thoughtful comments when 
reviewing the manuscripts that led to chapters 2 and 5.  
 
Dear Prof. dr. P Rossing, Prof. dr. L Tarnow, Prof. dr. H-H Parving and Anders Jorsal, 
I am very pleased that I could use the data from the LEACE study. I would like to thank 
you for the fruitful collaboration between our departments. I would also like to thank 
you for your support and valuable comments during the review processes of the 
manuscripts that led to chapters 3, 4, 6 and 7. 
 
Mijn paranimfen, mijn kamergenootjes en mijn collega’s. Beste Lian en Roel, een 
groot deel van de gezelligheid is zeker aan jullie te danken! Maar de wederzijdse 
aanmoedigingen, steun en hulp hebben zeker ook bijgedragen aan het succesvolle 
wetenschappelijke deel van mijn promotietraject. Helemaal geweldig dat jullie ook 
tijdens de verdediging achter me willen staan! Toch wel een beetje jammer, dat we 
niet alledrie tegelijkertijd op één dag kunnen promoveren, maar ach… nu hebben we 
drie afzonderlijke gelegenheden om te feesten. Lieve Lian, nog even de laatste loodjes 
(en ja, die zijn behoorlijk zwaar), maar dat gaat jou zeker lukken! En misschien heb jij 
inmiddels ook een datum geprikt als dit boekje is gedrukt. Wie weet kunnen we in de 
toekomst weer samenwerken (danwel dat ik bij je aanklop om raad, denk je aan die 
chaise longue… ^_^). Beste Roel, bij jou komt het vast en zeker allemaal wel goed. 
Jouw gedrevenheid en doorzettingsvermogen zullen jou nog ver brengen. Uiteraard 
hartstikke leuk dat we nog wel even collega’s zullen blijven.  
 
Beste mede-AIOs (en ex-AIOs). Elisabeth, Hanneke, José, Katrien, Marcelle, 
Marjon, Rianne, Bas, Barry, Dennis, Martijn, Nick, Nordin, Olaf, Steven, Thomas en 
Yvo. Bedankt voor de nuttige discussies, alle gezelligheid en gekheid. Ik wens jullie 
allen nog veel succes met jullie verdere (wetenschappelijke) carrière. 
 
Katrien, Petra, Olaf en Ronald, graag wil ik jullie ook uitdrukkelijk bedanken voor 
de geboden hulp bij de administratieve zaken rondom het boekje. Als ik het zelf 
allemaal had moeten uitzoeken in die laaste weken waren allerlei brieven en 
bestanden nooit op tijd op hun bestemming aangekomen. 
 
En niet te vergeten, Jean, Marjo en Vicky, bedankt voor de vele metingen die jullie 
voor me hebben gedaan en de uitleg die jullie me hebben gegeven. Beste Jean, ik wil 
je ook graag bedanken voor de computer-technische ondersteuning van de afgelopen 
jaren en voor de mooie foto’s van de bruiloft.  
 
Ook alle andere collega’s en ex-collega’s Carla, Dany, Joséphine, Margee en 
Marleen wil ik graag bedanken voor hun bijdrage en prettige samenwerking.  
 
 Dankwoord 
149 
D 
Verder wil ik ook familie, vrienden en kennissen bedanken, die hun interesse en 
belangstelling hebben getoond in mijn promotie-onderzoek.  
 
Lieve papa en mama, ondanks dat jullie nooit hebben begrepen waarom ik 
promotie-onderzoek ben gaan doen of überhaupt waar het onderzoek over ging, 
hebben jullie me gesteund in mijn beslissing. En ja, nu is het boekje af, maar ben ik 
weer aan een andere opleiding begonnen. Het is altijd erg verwarrend voor jullie 
geweest, omdat ik altijd ‘student’ ben gebleven voor jullie opvattingen. Maar wees 
gerust, eens zal ik écht gaan werken ^_^ Beste Jan, bedankt voor je belangstelling in 
de afgelopen jaren en al die lekkere chocolaatjes. En voor ‘de andere eeuwige student 
in onze familie’, alles komt goed ^_^ 
 
En dan… als laatste… Lieve Paul, bedankt voor al je begrip die je hebt getoond voor 
mijn drukke leven, voor het niet beschikbaar zijn op minstens één dag van het 
weekeinde, voor het niet meegaan naar (familie)feestjes, voor het ‘moeten’ werken 
tijdens vakanties en zelfs tijdens onze huwelijksreis, voor het geen tijd hebben voor 
huishoudelijk werk en nog voor zo veel andere zaken. Nooit heb je geklaagd over mijn 
eeuwige excuus van werken. Je bent zelfs voor mij en mijn werk naar Roermond 
verhuisd en gelukkig heb jij je draai uiteindelijk kunnen vinden hier in Limburg. Naast 
alle leuke momenten hebben we ook moeilijke momenten samen gehad. Ik ben blij 
dat we elkaar hebben kunnen steunen tijdens die zwaardere tijden en dat we elkaar 
daardoor nog meer zijn gaan waarderen. Hopelijk gaat het me lukken in de toekomst 
wel meer tijd voor je vrij te maken. 
 
Johanna    
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Abbreviations  
ADAM10  A disintegrin and metalloprotease 10 
AGEs  Advanced glycation endproducts 
β  Regression coefficient 
BMI  Body mass index 
CEL  Nε-(carboxyethyl)lysine 
CI  Confidence interval 
CML  Nε-(carboxymethyl)lysine 
CRP  C-reactive protein 
CV  Coefficient of variation 
CVD  Cardiovascular disease 
DBP  Diastolic blood pressure 
ED  Endothelial dysfunction 
eGFR  Estimated glomerular filtration rate 
ELISA  Enzyme-linked immunosorbent assays 
esRAGE  Endogenous secretory RAGE 
ESRD  End-stage renal disease 
HDL  High density lipoprotein 
HMGB-1  High mobility group box 1 
HPLC  High performance liquid chromatography 
HR  Hazard ratio 
IHD  Ischaemic heart disease 
IL-6  Interleukin 6 
LDL  Low density lipoprotein 
LGI  Low-grade inflammation 
MAP  Mean arterial pressure 
MDRD  Modification of Diet in Renal Disease 
MS  Mass spectrometry 
NFkB  Nuclear factor-kB 
PAD  Peripheral arterial disease 
PP  Pulse pressure 
RAAS  Renin-angiotensin-aldosterone system 
RAGE  Receptor for AGEs 
SBP  Systolic blood pressure 
SD  Standard deviation 
SE  Standard error 
sICAM-1  Soluble intercellular adhesion molecule-1 
sPLA2  Secreted phospholipase A2 
sRAGE  Soluble RAGE 
sVCAM-1 Soluble vascular cell adhesion molecule 
TGF-β  Transforming growth factor-β 
TLR  Toll-like receptor 
TNF-a  Tumour necrosis factor-a 
UAE  urinary albumin excretion 
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